WO2021102197A1 - Anti-alpha-synuclein monoclonal antibodies, and methods using same - Google Patents

Anti-alpha-synuclein monoclonal antibodies, and methods using same Download PDF

Info

Publication number
WO2021102197A1
WO2021102197A1 PCT/US2020/061376 US2020061376W WO2021102197A1 WO 2021102197 A1 WO2021102197 A1 WO 2021102197A1 US 2020061376 W US2020061376 W US 2020061376W WO 2021102197 A1 WO2021102197 A1 WO 2021102197A1
Authority
WO
WIPO (PCT)
Prior art keywords
seq
acid sequence
amino acid
region
cdr2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2020/061376
Other languages
French (fr)
Inventor
Kelvin C. Luk
Virginia M.Y. Lee
John Q. Trojanowski
Kurt R. Brunden
Dustin COVELL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pennsylvania Penn
Original Assignee
University of Pennsylvania Penn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pennsylvania Penn filed Critical University of Pennsylvania Penn
Priority to CN202080092715.8A priority Critical patent/CN114945592B/en
Priority to AU2020386061A priority patent/AU2020386061A1/en
Priority to CA3158364A priority patent/CA3158364A1/en
Priority to JP2022528957A priority patent/JP7777071B2/en
Priority to US17/778,061 priority patent/US20230025707A1/en
Priority to IL293108A priority patent/IL293108A/en
Priority to EP20889174.7A priority patent/EP4061840A4/en
Priority to MX2022006026A priority patent/MX2022006026A/en
Publication of WO2021102197A1 publication Critical patent/WO2021102197A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette

Definitions

  • Parkinson's disease is a progressive neurodegenerative disease that affects 1% of the worldwide population but has no disease-modifying treatments. Even the most efficacious dopamine replacement therapy does not prevent disease progression, including the development of dementia which occurs in up to 80 percent of cases. Motor symptoms that are characteristic of the disease are often preceded by non-motor symptoms, including constipation, sleep disturbances, and olfactory dysfunction, and are often followed by cognitive decline, which can lead to a diagnosis of PD dementia (PDD).
  • PDD PD dementia
  • ⁇ -synucleinopathies due to the abnormal accumulation of normally synaptic ⁇ -Synuclein protein into neuronal Lewy bodies (LBs) and axonal Lewy neurites (LNs).
  • LBs neuronal Lewy bodies
  • LNs axonal Lewy neurites
  • ⁇ -Synuclein is not merely a bystander in these diseases since rare mutations, duplications, and triplications of ⁇ - Synuclein lead to familial PD.
  • ⁇ -Synuclein is primarily localized in the neuronal cytoplasm, it has been assumed that therapeutic molecules would need to cross not only the blood-brain-barrier (BBB), but also the neuronal plasma membrane, to interact with ⁇ -Synuclein.
  • BBB blood-brain-barrier
  • ⁇ -Synuclein a number of recent in vitro and in vivo studies suggest that misfolded ⁇ -Synuclein species are released by neurons and can be taken up by nearby neurons, inducing the transcellular transmission of pathogenic ⁇ -Synuclein.
  • extracellular ⁇ -Synuclein could be targeted for vascular or glymphatic clearance, its uptake could be blocked, or glial cells could be modified to promote clearance of extracellular ⁇ -Synuclein.
  • glial cells could be modified to promote clearance of extracellular ⁇ -Synuclein.
  • antibodies might block neuronal ⁇ -Synuclein uptake while also promoting glymphatic clearance to the periphery or glial clearance through binding to surface Fc receptors.
  • Passive immunotherapy treatment directly with antibodies, instead of injection of an immunogen
  • therapeutic antibodies have been demonstrated to be relatively safe and immunotherapy has been shown to promote clearance of extracellular targets.
  • Sufficient brain levels of the administered antibody have to be achieved to affect disease biology, but antibodies are known to have poor BBB penetration.
  • the present disclosure provides certain monoclonal antibodies comprising a light chain variable region (VL) and a heavy chain variable region (VH), as defined elsewhere herein.
  • the present disclosure further provides pharmaceutical compositions comprising at least one monoclonal antibody contemplated herein and at least one pharmaceutical excipient.
  • the present disclosure further provides certain isolated polynucleotides comprising at least one of the nucleic acid sequences contemplated herein.
  • the present disclosure further provides autonomously replicating or integrative mammalian cell vectors comprising at least one recombinant nucleic acid encoding at least one antibody comprising a light chain variable region (VL) and a heavy chain variable region (VH), as defined elsewhere herein.
  • the present disclosure further provides isolated host cells comprising any of the vectors contemplated herein.
  • the present disclosure further provides methods of treating, ameliorating, and/or preventing a synucleopathic disease in a subject.
  • the method comprises administering to the subject a therapeutically effective amount of at least one isolated monoclonal antibody contemplated herein.
  • the present disclosure further provides methods of detecting a synucleopathic disease in a subject.
  • the method comprises administering to the subject at least one labeled isolated monoclonal antibody contemplated herein.
  • the method comprises detecting presence or absence of a complex of the labeled isolated monoclonal antibody with any ⁇ -Syn fibrils, oligomers, and/or other misfolded ⁇ -Syn species present in the subject.
  • the subject if the complex is detected, the subject has a synucleopathic disease.
  • the present disclosure further provides methods of detecting total ⁇ -Syn, ⁇ -Syn fibrils, and/or ⁇ -Syn oligomeric species in a sample.
  • the method comprises contacting the sample with at least one labeled isolated monoclonal antibody contemplated herein.
  • the method comprises detecting presence or absence of a complex of the labeled isolated monoclonal antibody with total ⁇ -Syn, ⁇ -Syn monomer, ⁇ -Syn fibrils, and/or ⁇ -Syn oligomeric species present in the sample.
  • the complex if the complex is detected, total ⁇ -Syn, ⁇ -Syn monomers, ⁇ -Syn fibrils, and/or ⁇ -Syn oligomeric species are present in the sample.
  • FIGs. 1A-1F comprise a passive immunotherapy screen schematic.
  • FIG. 1A Mice were immunized with ⁇ -Synuclein pre-formed fibrils (PFFs) to induce an immune response and production of antibodies against pathogenic ⁇ -Synuclein.
  • FIG. IB Antibody producing B cells were subsequently harvested from the spleen of immunized mice and fused with myeloma cells to produce hybridoma clonal cell lines expressing antibodies against ⁇ - Synuclein.
  • FIG. 1C Hybridomas were separated into individual clonal populations and the antibody-containing supernatant from each clone was passed through a primary screen to identify candidates with preferred properties.
  • candidate antibodies also have a preference for fibrillar ⁇ -Synuclein, so they were screened in an indirect ELISA format for monomeric and fibrillar ⁇ -Synuclein.
  • Each antibody was epitope mapped and tested for immunogenicity against mouse and human ⁇ -Synuclein so it could be utilized in a mouse disease model.
  • antibodies were screened in a primary neuron immunotherapy assay for their ability to reduce ⁇ -Synuclein pathology in cultured neurons.
  • FIG. ID Prioritized antibodies underwent a further two rounds of subcloning to ensure monoclonality.
  • FIG. ID Prioritized antibodies underwent a further two rounds of subcloning to ensure monoclonality.
  • FIG. IF A non-limiting candidate antibody was tested in a mouse model of PD for its ability to reduce ⁇ -Synuclein pathology and toxicity. The candidate was tested alongside and IgG control and an ⁇ -Synuclein antibody with proven therapeutic efficacy.
  • FIGs. 2A-2B illustrate non-limiting immunohistochemistry results that reveal antibodies that preferentially bind LBs.
  • FIG. 2B The optical density within Lewy bodies divided by the optical density of a 1 mm 2 tissue section containing those Lewy bodies was defined as the Lewy Body Discrimination Index. Antibodies preferentially recognizing Lewy bodies score high on this measure. Most antibodies showed some enhanced recognition of Lewy bodies, with the exception of those antibodies scoring below 1.5, which show little apparent preference for Lewy bodies above neuropil ⁇ -Synuclein staining.
  • FIGs. 3A-3C illustrate non-limiting epitope mapping that ensures that certain antibodies recognize human and mouse ⁇ -Synuclein.
  • FIG. 3 A Schematic of recombinant ⁇ - Synuclein fragments used to determine the epitope of the 9000 series antibodies.
  • Full-length (FL) ⁇ -Synuclein is 140 amino acids with an internal non-amyloid component (NAC) domain. Constructs used for testing epitopes had truncated N- or C-terminal human ⁇ - Synuclein residues.
  • FIG. 3B Most antibodies recognized both human and mouse ⁇ - Synuclein to some extent.
  • FIGs. 4A-4C illustrate a non-limiting sandwich ELISA that identifies antibodies with a preference for misfolded ⁇ -Synuclein.
  • Antibodies were assessed for a preference for misfolded ⁇ -Synuclein by performing parallel sandwich ELISAs with either human ⁇ - Synuclein monomer or ⁇ -Synuclein PFFs as the antigen. Syn211 was also used on each plate as a non-selective control antibody. Using this method, three classes of antibodies were distinguished — (FIG. 4A) antibodies that did not bind in this assay and thus did not have a signal for either monomer or PFF; (FIG.
  • FIGs. 5A-5B illustrate a non-limiting neuron immunotherapy assay that reveals differential potency of ⁇ -Synuclein antibodies to prevent LB-like pathology.
  • FIG. 5B Quantification of pS 129 ⁇ -Synuclein area/neuron number normalized to IgG-treated neurons. Antibodies had varying effects on ⁇ -Synuclein pathology and are ranked from least to most effective.
  • FIGs. 6A-6B comprise a summary of antibody characteristics, shown as a heat map with the scale bars shown at the top of each column.
  • Antibodies are mostly from IgG subclasses. Most antibodies recognize mouse ⁇ -Synuclein, and all antibodies recognize human ⁇ -Synuclein.
  • the LB discrimination index derived from immunohistochemistry reflects the ability of antibodies to bind selectively to LB ⁇ -Synuclein.
  • the % inhibition measure derived from the primary neuron assay, indicates antibody ability to reduce pathology in a cellular system.
  • an antibody of interest recognizes both mouse and human ⁇ -Synuclein, discriminate LBs from surrounding neuropil, have higher binding affinity for ⁇ -Synuclein PFFs than monomer, and inhibit nearly all in vitro neuronal ⁇ -Synuclein pathology. Based on these measures,
  • FIGs. 7A-7D illustrate non-limiting subclones, which retain properties of parent clones.
  • FIG. 7A Syn9063 subclones were assayed for PFF preference as previously described to ensure that all subclones showed the same selectivity as the parent clone. All but one of the subclones showed a high preference for ⁇ -Synuclein PFFs.
  • FIG. 7B All Syn9048 subclones showed similar selectivity for ⁇ -Synuclein PFFs. Plots in panels (FIG.
  • FIG. 7 A) and (FIG. 7B) represent the means from 3 technical replicates, and error bars represent standard error.
  • FIG. 7D Quantification of pS129 ⁇ -Synuclein area/neuron number normalized to control IgG-treated neurons.
  • FIGs. 8A-8G illustrate that in vivo immunotherapy is well-tolerated and improves dopaminergic tone.
  • FIG. 8 A Wild-type mice were injected with ⁇ -Synuclein PFFs in the dorsal striatum at 2-3 month of age. One week after ⁇ -Synuclein PFF injection, mice were injected with 30 mg/kg control IgGl, Syn303 or Syn9048. Mice were injected once weekly thereafter for 6 months, after which mice were sacrificed and assayed for pathology and motor behavior.
  • FIG. 8B Average weight for mice in each antibody treatment group with standard error represented in shaded bands.
  • FIGs. 9A-9F illustrate that Syn9048 reduces ⁇ -Synuclein pathology in the SN and Amygdala.
  • FIG. 9D Mice injected with ⁇ -Synuclein P
  • FIG. 10 illustrates non-limiting recognition of b-Synuclein.
  • Most antibodies did not recognize b-Synuclein by Western blot.
  • Syn9030 and Syn9066 had slight reactivity with b- Synuclein, indicating some cross-reactivity of these antibodies.
  • Syn7015 is used as a positive control since this antibody cross-reacts with b-Synuclein.
  • FIGs. 11 A-11B illustrate a non-limiting sandwich ELISA that identifies non-binding antibodies.
  • Antibodies were assessed for a preference for misfolded ⁇ -Synuclein by performing parallel sandwich ELIS As with either ⁇ -Synuclein monomer or ⁇ -Synuclein PFFs as the antigen. Syn211 was also used on each plate as a non-selective control antibody. This figure displays antibodies which were non-binding in this assay. Plots represent the means from 3 technical replicates, and error bars represent standard error.
  • FIGs. 12A-12B illustrate a non-limiting sandwich ELISA that identifies non-selective antibodies.
  • Antibodies were assessed for a preference for misfolded ⁇ -Synuclein by performing parallel sandwich ELIS As with either ⁇ -Synuclein monomer or ⁇ -Synuclein PFFs as the antigen. Syn211 was also used on each plate as a non-selective control antibody. This figure displays antibodies which were non-selective in this assay. Plots represent the means from 3 technical replicates, and error bars represent standard error.
  • FIGs. 13A-13B illustrate a non-limiting sandwich ELISA that identifies ⁇ -Synuclein PFF-selective antibodies.
  • Antibodies were assessed for a preference for misfolded ⁇ - Synuclein by performing parallel sandwich ELISAs with either ⁇ -Synuclein monomer or ⁇ - Synuclein PFFs as the antigen. Syn211 was also used on each plate as a non-selective control antibody.
  • This figure displays antibodies which showed a preference for ⁇ -Synuclein PFFs in this assay.
  • Plots represent the means from 3 technical replicates, and error bars represent standard error.
  • FIG. 14 illustrates a non-limiting second sandwich ELISA that confirms ⁇ -Synuclein PFF-selective antibodies.
  • Antibodies were assessed for a preference for misfolded ⁇ - Synuclein by performing second set of parallel sandwich ELISAs with either ⁇ -Synuclein monomer or ⁇ -Synuclein PFFs as the antigen and the polyclonal ⁇ -Synuclein antibody SNL4.
  • Plots represent the means from 3 technical replicates, and error bars represent standard error.
  • FIG. 15 illustrates that Syn9048 prevents ⁇ -Synuclein pathology induced by mouse ⁇ - Synuclein PFFs.
  • Syn9048 was assayed for its ability to prevent ⁇ -Synuclein pathology induced by mouse ⁇ -Synuclein in neurons.
  • Primary hippocampal neurons were cultured as previously described and treated with mouse ⁇ -Synuclein PFFs concurrently with increasing concentrations of Syn9048. Quantification of pS129 ⁇ -Synuclein area/neuron number normalized to IgG treatment is shown.
  • an element means one element or more than one element.
  • ⁇ -Synuclein or " ⁇ -Syn” or “ ⁇ -syn” refers to a protein that is expressed mainly in brain tissues and is primarily located at the presynpatic terminal of neurons.
  • the disclosure contemplates human ⁇ -Syn, which has the sequence SEQ ID NO:245:
  • GVATVAEKTK EQVTNVGGAV VTGVTAVAQK TVEGAGSIAA ATGFVKKDQL
  • ⁇ -Syn refers to total ⁇ -Syn, ⁇ -Syn monomers, ⁇ -Syn fibrils, and/or ⁇ -Syn oligomers.
  • a ⁇ -Syn oligomer refers to any multimeric assembly of ⁇ -Syn comprising two or more ⁇ -Syn monomers.
  • the term “about” will be understood by persons of ordinary skill in the art and will vary to some extent on the context in which it is used. As used herein when referring to a measurable value such as an amount, a concentration, a temporal duration, and the like, the term “about” is meant to encompass variations of ⁇ 20% or ⁇ 10%, more preferably ⁇ 5%, even more preferably ⁇ 1%, and still more preferably ⁇ 0.1% from the specified value, as such variations are appropriate to perform the disclosed methods.
  • affinity for a molecule towards another refers to the degree (or tightness) of binding between the two molecules.
  • a higher affinity means tighter binding between the two molecules.
  • Affinity can be quantified in terms of dissociation constant (or Kd), where a Kd value that is lower in magnitude (closer to zero) indicates a higher affinity.
  • amino acid as used herein is meant to include both natural and synthetic amino acids, and both D and L amino acids.
  • Standard amino acid means any of the twenty L- amino acids commonly found in naturally occurring peptides.
  • Nonstandard amino acid residues means any amino acid, other than the standard amino acids, regardless of whether it is prepared synthetically or derived from a natural source.
  • synthetic amino acid also encompasses chemically modified amino acids, including but not limited to salts, amino acid derivatives (such as amides), and substitutions.
  • Amino acids contained within the peptides, and particularly at the carboxy- or amino-terminus, can be modified by methylation, amidation, acetylation or substitution with other chemical groups which can change a peptide's circulating half-life without adversely affecting activity of the peptide.
  • a disulfide linkage may be present or absent in the peptides.
  • antibody refers to an immunoglobulin molecule able to specifically bind to a specific epitope on an antigen.
  • Antibodies can be intact immunoglobulins derived from natural sources or from recombinant sources and can be immunoreactive portions of intact immunoglobulins. Antibodies are typically tetramers of immunoglobulin molecules.
  • the antibodies in the present disclosure may exist in a variety of forms including, for example, polyclonal antibodies, monoclonal antibodies, intracellular antibodies (“intrabodies”), Fv, Fab and F(ab)2, as well as single chain antibodies (scFv), camelid antibodies and humanized antibodies (Harlow etal.
  • a neutralizing antibody is an immunoglobulin molecule that binds to and blocks the biological activity of the antigen.
  • antigen or "Ag” as used herein is defined as a molecule that provokes an immune response. This immune response may involve either antibody production, or the activation of specific immunologically-competent cells, or both.
  • antigens can be derived from recombinant or genomic DNA. A skilled artisan will understand that any DNA, which comprises a nucleotide sequences or a partial nucleotide sequence encoding a protein that elicits an immune response therefore encodes an "antigen" as that term is used herein.
  • an antigen need not be encoded solely by a full length nucleotide sequence of a gene. It is readily apparent that the present disclosure includes, but is not limited to, the use of partial nucleotide sequences of more than one gene and that these nucleotide sequences are arranged in various combinations to elicit the desired immune response. Moreover, a skilled artisan will understand that an antigen need not be encoded by a "gene” at all. It is readily apparent that an antigen can be generated or synthesized, or can be derived from a biological sample. Such a biological sample can include, but is not limited to a tissue sample, a tumor sample, a cell or a biological fluid.
  • a "coding region" of a gene consists of the nucleotide residues of the coding strand of the gene and the nucleotides of the non-coding strand of the gene that are homologous with or complementary to, respectively, the coding region of an mRNA molecule produced by transcription of the gene.
  • a "coding region" of an mRNA molecule also consists of the nucleotide residues of the mRNA molecule that are matched with an anti-codon region of a transfer RNA molecule during translation of the mRNA molecule or that encode a stop codon.
  • the coding region may thus include nucleotide residues corresponding to amino acid residues not present in the mature protein encoded by the mRNA molecule ( e.g ., amino acid residues in a protein export signal sequence).
  • “Complementary” as used herein to refer to a nucleic acid refers to the broad concept of sequence complementarity between regions of two nucleic acid strands or between two regions of the same nucleic acid strand. It is known that an adenine residue of a first nucleic acid region is capable of forming specific hydrogen bonds ("base pairing") with a residue of a second nucleic acid region which is antiparallel to the first region if the residue is thymine or uracil. Similarly, it is known that a cytosine residue of a first nucleic acid strand is capable of base pairing with a residue of a second nucleic acid strand which is antiparallel to the first strand if the residue is guanine.
  • a first region of a nucleic acid is complementary to a second region of the same or a different nucleic acid if, when the two regions are arranged in an antiparallel fashion, at least one nucleotide residue of the first region is capable of base pairing with a residue of the second region.
  • the first region comprises a first portion and the second region comprises a second portion, whereby, when the first and second portions are arranged in an antiparallel fashion, at least about 50%, and preferably at least about 75%, at least about 90%, or at least about 95% of the nucleotide residues of the first portion are capable of base pairing with nucleotide residues in the second portion. More preferably, all nucleotide residues of the first portion are capable of base pairing with nucleotide residues in the second portion.
  • delivery vehicle is used herein as a generic reference to any delivery vehicle capable of delivering a compound to a subject, including, but not limited to, dermal delivery vehicles and transdermal delivery vehicles.
  • DNA as used herein is defined as deoxyribonucleic acid.
  • Effective amount or “therapeutically effective amount” are used interchangeably herein, and refer to an amount of a compound, formulation, material, or composition, as described herein, effective to achieve a particular biological result. Such results may include, but are not limited to, treatment of a disease or condition as determined by any means suitable in the art.
  • Encoding refers to the inherent property of specific sequences of nucleotides in a polynucleotide, such as a gene, a cDNA, or an mRNA, to serve as templates for synthesis of other polymers and macromolecules in biological processes having either a defined sequence of nucleotides (i.e., rRNA, tRNA and mRNA) or a defined sequence of amino acids and the biological properties resulting therefrom.
  • a gene encodes a protein if transcription and translation of mRNA corresponding to that gene produces the protein in a cell or other biological system.
  • Both the coding strand the nucleotide sequence of which is identical to the mRNA sequence and is usually provided in sequence listings, and the non-coding strand, used as the template for transcription of a gene or cDNA, can be referred to as encoding the protein or other product of that gene or cDNA.
  • fragment refers to a subsequence of a larger protein or peptide.
  • a “fragment” of a protein or peptide can be at least about 20 amino acids in length; for example at least about 50 amino acids in length; at least about 100 amino acids in length, at least about 200 amino acids in length, at least about 300 amino acids in length, and at least about 400 amino acids in length (and any integer value in between).
  • an antibody fragment refers to active fragments thereof, i.e., fragments having the same characteristics that are used for the definition of an antibody according to the disclosure, in certain embodiments high affinity for ⁇ -Syn fibrils (composed of misfolded ⁇ -Syn) and low or high binding affinity to ⁇ -Syn monomers. For convenience when the term antibody is used, fragments thereof exhibiting the same characteristic are also being considered.
  • fragment refers to a subsequence of a larger nucleic acid.
  • a “fragment” of a nucleic acid can be at least about 15 nucleotides in length; for example, at least about 50 nucleotides to about 100 nucleotides; at least about 100 to about 500 nucleotides, at least about 500 to about 1000 nucleotides, at least about 1000 nucleotides to about 1500 nucleotides; or about 1500 nucleotides to about 2500 nucleotides; or about 2500 nucleotides (and any integer value in between).
  • the direction of 5' to 3' addition of nucleotides to nascent RNA transcripts is referred to as the transcription direction.
  • the DNA strand having the same sequence as an mRNA is referred to as the "coding strand”; sequences on the DNA strand which are located 5' to a reference point on the DNA are referred to as “upstream sequences”; sequences on the DNA strand which are 3' to a reference point on the DNA are referred to as "downstream sequences.”
  • an “individual”, “patient” or “subject”, as that term is used herein, includes a member of any animal species including, but are not limited to, birds, humans and other primates, and other mammals including commercially relevant mammals such as cattle, pigs, horses, sheep, cats, and dogs.
  • the subject is a human.
  • “Instructional material,” as that term is used herein, includes a publication, a recording, a diagram, or any other medium of expression which can be used to communicate the usefulness of the composition and/or compound of the disclosure in a kit.
  • the instructional material of the kit may, for example, be affixed to a container that contains the compound and/or composition of the disclosure or be shipped together with a container which contains the compound and/or composition. Alternatively, the instructional material may be shipped separately from the container with the intention that the recipient uses the instructional material and the compound cooperatively. Delivery of the instructional material may be, for example, by physical delivery of the publication or other medium of expression communicating the usefulness of the kit, or may alternatively be achieved by electronic transmission, for example by means of a computer, such as by electronic mail, or download from a website.
  • isolated means altered or removed from the natural state.
  • a nucleic acid or a peptide naturally present in a living animal is not “isolated,” but the same nucleic acid or peptide partially or completely separated from the coexisting materials of its natural state is “isolated.”
  • An isolated nucleic acid or protein can exist in substantially purified form, or can exist in a non-native environment such as, for example, a host cell.
  • isolated nucleic acid refers to a nucleic acid segment or fragment which has been separated from sequences which flank it in a naturally occurring state, i.e., a DNA fragment which has been removed from the sequences which are normally adjacent to the fragment, i.e., the sequences adjacent to the fragment in a genome in which it naturally occurs.
  • the term also applies to nucleic acids which have been substantially purified from other components which naturally accompany the nucleic acid, i.e., RNA or DNA or proteins, which naturally accompany it in the cell.
  • the term therefore includes, for example, a recombinant DNA which is incorporated into a vector, into an autonomously replicating plasmid or virus, or into the genomic DNA of a prokaryote or eukaryote, or which exists as a separate molecule (i.e., as a cDNA or a genomic or cDNA fragment produced by PCR or restriction enzyme digestion) independent of other sequences. It also includes a recombinant DNA which is part of a hybrid gene encoding additional polypeptide sequence.
  • nucleic acid any nucleic acid, whether composed of deoxyribonucleosides or ribonucleosides, and whether composed of phosphodiester linkages or modified linkages such as phosphotriester, phosphoramidate, siloxane, carbonate, carboxymethylester, acetamidate, carbamate, thioether, bridged phosphoramidate, bridged methylene phosphonate, phosphorothioate, methylphosphonate, phosphorodithioate, bridged phosphorothioate or sulfone linkages, and combinations of such linkages.
  • phosphodiester linkages or modified linkages such as phosphotriester, phosphoramidate, siloxane, carbonate, carboxymethylester, acetamidate, carbamate, thioether, bridged phosphoramidate, bridged methylene phosphonate, phosphorothioate, methylphosphonate, phosphorodithioate, bridged phosphorothi
  • nucleic acid also specifically includes nucleic acids composed of bases other than the five biologically occurring bases (adenine, guanine, thymine, cytosine and uracil).
  • a "nucleotide sequence encoding an amino acid sequence” includes all nucleotide sequences that are degenerate versions of each other and that encode the same amino acid sequence.
  • the phrase nucleotide sequence that encodes a protein or an RNA may also include introns to the extent that the nucleotide sequence encoding the protein may in some version contain an intron(s).
  • oligonucleotide typically refers to short polynucleotides, generally no greater than about 60 nucleotides. It will be understood that when a nucleotide sequence is represented by a DNA sequence (i.e., A, T, G, C), this also includes an RNA sequence (i.e.,
  • the term "pharmaceutical composition” refers to a mixture of at least one compound of the disclosure with other chemical components, such as carriers, stabilizers, diluents, dispersing agents, suspending agents, thickening agents, and/or excipients.
  • the pharmaceutical composition facilitates administration of the compound to an organism. Multiple techniques of administering a compound exist in the art including, but not limited to, intravenous, oral, aerosol, parenteral, ophthalmic, pulmonary and topical administration.
  • “Pharmaceutically acceptable” refers to those properties and/or substances that are acceptable to the patient from a pharmacological/toxicological point of view and to the manufacturing pharmaceutical chemist from a physical/chemical point of view regarding composition, formulation, stability, patient acceptance and bioavailability.
  • “Pharmaceutically acceptable carrier” refers to a medium that does not interfere with the effectiveness of the biological activity of the active ingredient(s) and is not toxic to the host to which it is administered.
  • nucleotide as used herein is defined as a chain of nucleotides.
  • nucleic acids are polymers of nucleotides.
  • nucleic acids and polynucleotides as used herein are interchangeable.
  • nucleic acids are polynucleotides, which can be hydrolyzed into the monomeric “nucleotides.” The monomeric nucleotides can be hydrolyzed into nucleosides.
  • polynucleotides include, but are not limited to, all nucleic acid sequences which are obtained by any means available in the art, including, without limitation, recombinant means, i.e., the cloning of nucleic acid sequences from a recombinant library or a cell genome, using ordinary cloning technology and PCRTM, and the like, and by synthetic means.
  • recombinant means i.e., the cloning of nucleic acid sequences from a recombinant library or a cell genome, using ordinary cloning technology and PCRTM, and the like, and by synthetic means.
  • protein As used herein, the terms “protein”, “peptide” and “polypeptide” are used interchangeably, and refer to a compound comprised of amino acid residues covalently linked by peptide bonds.
  • peptide bond means a covalent amide linkage formed by loss of a molecule of water between the carboxyl group of one amino acid and the amino group of a second amino acid.
  • a protein or peptide must contain at least two amino acids, and no limitation is placed on the maximum number of amino acids that may comprise the sequence of a protein or peptide.
  • Polypeptides include any peptide or protein comprising two or more amino acids joined to each other by peptide bonds.
  • Proteins include, for example, biologically active fragments, substantially homologous proteins, oligopeptides, homodimers, heterodimers, variants of proteins, modified proteins, derivatives, analogs, and fusion proteins, among others.
  • the proteins include natural proteins, recombinant proteins, synthetic proteins, or a combination thereof.
  • recombinant DNA as used herein is defined as DNA produced by joining pieces of DNA from different sources.
  • recombinant polypeptide as used herein is defined as a polypeptide produced by using recombinant DNA methods.
  • RNA as used herein is defined as ribonucleic acid.
  • terapéutica as used herein means a treatment and/or prophylaxis.
  • treat means reducing the frequency with which symptoms are experienced by a subject or administering an agent or compound to reduce the frequency and/or severity with which symptoms are experienced.
  • alleviate is used interchangeably with the term “treat.”
  • treating a disease, disorder or condition means reducing the frequency or severity with which a symptom of the disease, disorder or condition is experienced by a subject. Treating a disease, disorder or condition may or may not include complete eradication or elimination of the symptom.
  • BBB blood-brain barrier
  • CDR complementary-determining region
  • DLB dementia with Lewy bodies
  • FL full length
  • LB Lewy body
  • LN Lewy neurite
  • MSA multiple system atrophy
  • NAC non-amyloid component
  • PD Parkinson's disease
  • PDD Parkinson's disease dementia
  • PFF pre-formed fibril
  • VH heavy chain variable region
  • VL light chain variable region.
  • ranges throughout this disclosure, various aspects of the disclosure can be presented in a range format. It should be understood that the description in range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the disclosure. Accordingly, the description of a range should be considered to have specifically disclosed all the possible subranges as well as individual numerical values within that range. For example, description of a range such as from 1 to 6 should be considered to have specifically disclosed subranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6 etc., as well as individual numbers within that range, for example, 1, 2, 2.7, 3, 4, 5, 5.3, and 6. This applies regardless of the breadth of the range.
  • This disclosure is generally directed to certain monoclonal (mouse) antibodies, or fragments thereof, that recognize certain pathogenic forms of ⁇ -Syn, a protein that is misfolded in Parkinson's disease (PD) and related neurodegenerative disorders known as synucleinopathies.
  • PD and dementia with Lewy bodies (DLB) are progressive neurodegenerative diseases for which there is no disease-modifying treatment.
  • PD and DLB are characterized by aggregation of the synaptic protein ⁇ -Synuclein, and there is compelling evidence to suggest that progression of these diseases is associated with the transcellular spread of pathogenic ⁇ -Synuclein through the brains of afflicted individuals. Therapies targeting extracellular, pathogenic ⁇ -Synuclein may therefore hold promise for slowing or halting disease progression.
  • ⁇ -Synuclein antibody targeting all ⁇ -Synuclein species with a pan- ⁇ -Synuclein antibody can have deleterious effects in the central nervous system or in the blood, where ⁇ -Synuclein is abundant in red blood cells. Moreover, the binding of a pan- ⁇ - Synuclein antibody to non-pathogenic forms of the protein would reduce the antibody available for binding to misfolded species.
  • the present studies were directed to identifying an antibody with high selectivity for pathogenic, misfolded ⁇ -Synuclein.
  • antibodies produced by clonal hybridoma cultures were passed through a series of screening assays to select for antibodies that show high selectivity for misfolded ⁇ -Synuclein and are able to inhibit the formation of LB-like structures in a primary neuron model of ⁇ -synucleinopathy.
  • An illustrative candidate antibody, Syn9048 was tested for efficacy in a wildtype mouse model of pathological ⁇ -Synuclein transmission.
  • Syn9048 Chronic 6-month administration of Syn9048 was well-tolerated by mice, and Syn9048 was able to preserve striatal dopamine levels and reduce ⁇ -Synuclein pathology, especially in areas where ⁇ -Synuclein inclusions likely resulted from transcellular spread of pathogenic ⁇ -Synuclein. In all measures, Syn9048 showed improved efficacy over a previously validated ⁇ -Synuclein antibody (Tran, etal. , 2014, Cell Reports 7:2054-2065), indicating that Syn9048 has desirable properties for treating, ameliorating, and/or preventing the diseases contemplated herein. This study highlights the therapeutic potential of ⁇ -Synuclein immunotherapy for the treatment of PD and DLB, and provides a framework for screening of ⁇ -Synuclein antibodies to identify those with desirable properties.
  • the antibodies of the disclosure are highly selective towards pathogenic forms of ⁇ -Synuclein and can be administered as therapeutic agents targeting those pathogenic protein forms.
  • the antibodies of the disclosure recognize a conformational epitope comprising amino acids 110-120 and/or 120-130 in combination with another region of ⁇ -Syn.
  • the antibodies of the disclosure show preferential binding towards the pathological form of ⁇ -Syn (i.e., fibrils and/or oligomers) compared to the native (i.e., monomeric) form.
  • the antibodies of the disclosure reduce formation of pathological ⁇ -Syn inclusions/fibrils that normally form in cultured neurons that are exposed to recombinant ⁇ -Syn fibrils.
  • the antibodies of the disclosure detect pathological ⁇ -Syn fibrils.
  • the antibodies of the disclosure are used as therapeutics for decreasing the development/spread of pathological ⁇ - Syn fibrils and/or oligomers in synucleinopathies.
  • the antibodies of the disclosure do not cross-react with Tau and/or bet ⁇ -amyloid protein.
  • the antibodies of the disclosure bind to ⁇ -Syn fibrils and/or oligomers with a dissociation constant Kd equal to or less than about 10 -6 M, about 10 -7 M, about 10 -8 M, about 10 -9 M, about 10 -10 M, or about 10 -11 M. In other embodiments, the antibodies of the disclosure bind to ⁇ -Syn monomers with an affinity that at least about 10 times, 30 times, 100 times, 300 times, or 1000 times lower than the affinity of the antibodies for ⁇ -Syn fibrils.
  • the antibodies of the disclosure bind to ⁇ -Syn monomers with a dissociation constant K d equal to or higher than about 10 -10 M, about 10 -9 M, about 10 -8 M, about 10 -7 M, about 10 -6 M, about 10 -5 M, about 10 -4 M, or about 10 -3 M. In yet other embodiments, the antibodies of the disclosure bind with nearly equal affinity to ⁇ - Syn fibrils and monomers.
  • the antibodies of the disclosure bind with nearly equal affinity to ⁇ -Syn fibrils, oligomers and monomers, with a dissociation constant Kd equal to or less than about 10 -7 M, about 10 -8 M, about 10 -9 M, about 10 -10 M, or about 10 -11 M.
  • Binding affinities of the antibodies can be determined by using a variety of methods recognized in the art, including methods described elsewhere herein, such as but not limited to isothermal calorimetry, surface plasmon resonance, immunoassays such as ELISA or RIAs, and the like.
  • compositions comprising Antibodies
  • the disclosure comprises isolated monoclonal antibodies that selectively bind ⁇ -Syn in the fibrillar and/or oligomeric conformation, and/or bind both soluble, oligomeric, and fibrillar ⁇ -Syn with high affinity.
  • the antibody comprises a heavy chain.
  • the heavy chain comprises three complementary-determining regions (CDR), namely CDR1, CDR2, and CDR3.
  • the light chain comprises three complementary-determining regions (CDR), namely CDR1, CDR2, and CDR3.
  • the monoclonal antibody (named 9003 herein) comprises light and heavy variable chains having the sequences shown below:
  • SEQ ID NO: 1 SEQ ID NO:2 — SEP ID NO:3 — SEQ ID NO:4 — SEP ID NO: 5 — SEQ ID NO:6 — SEP ID NO: 7 — SEQ ID NO:8
  • Heavy chain Amino acid sequence (138 aa)
  • SEQ ID NO:9 SEQ ID NO:10 — SEP ID NO: 11 — SEQ ID NO:12 — SEP ID NO: 13
  • SEQ ID NO: 17 SEQ ID NO: 18 — SEP ID NO: 19 — SEQ ID NO:20 — SEO ID NO:21
  • the monoclonal antibody (named 9004 herein) comprises light and heavy variable chains having the sequences shown below:
  • SEQ ID N0 33 SEQ ID NO:34 — SEP ID NO:3 — SEQ ID NO:4 — SEP ID NO :35 — SEQ ID NO:36 — SEP ID NO:7 — SEQ ID NO:37
  • SEQ ID NO:38 SEQ ID NO:39 — SEP ID NO: 11 — SEQ ID NO:12 — SEP ID NQ:40 — SEQ ID NO:41 — SEP ID NO: 15 — SEQ ID NO:16
  • SEQ ID NO: 17 SEQ ID NO: 18 — SEP ID NO: 19 — SEQ ID NO:42 — SEP ID NO:43 — SEP ID NO:22 — SEP ID N0 44 — SEP ID NO:45
  • SEQ ID NO:25 SEQ ID NO:26 — SEP ID NO:46 — SEQ ID NO:28 — SEP ID NO:29 — SEQ ID NO:30 — SEO ID NO:31 — SEQ ID NO:47
  • the monoclonal antibody (named 9005 herein) comprises light and heavy variable chains having the sequences shown below:
  • SEQ ID NO:48 SEQ ID NO:49 — SEQ ID NO:50 — SEQ ID NO:51 — SEP ID NO: 52 — SEQ ID NO:53 — SEP ID NO: 54 — SEQ ID NO:55 ATGAACTTCGGGCTCAGCTTGATTTTCCTTGTCCTTGTTTTAAAAGGTGTCCAGTGTGAAGTGATGC
  • Heavy chain Amino acid sequence (138 aa)
  • SEQ ID NO:56 SEQ ID NO:57 — SEO ID NO:58 — SEQ ID NO:59 — SEP ID NO: 60
  • SEQ ID NO:64 SEQ ID NO: 18 — SEP ID NO: 19 — SEQ ID NO:65 — SEP ID NO: 66
  • SEQ ID NO:69 SEQ ID NO:26 — SEP ID NO: 70 — SEQ ID NO:71 — SEP ID NO: 72
  • the monoclonal antibody (named 9009 herein) comprises light and heavy variable chains having the sequences shown below:
  • SEQ ID NO: 1 SEQ ID NO:2 — SEP ID NO:3 — SEQ ID NO:4 — SEP ID NO: 5 — SEQ ID NO:6 — SEP ID NO: 7 — SEQ ID NO:8
  • Heavy chain Amino acid sequence (138 aa)
  • SEQ ID NO:9 SEQ ID NO:10 — SEP ID NO: 11 — SEQ ID NO:12 — SEP ID NO: 13
  • SEQ ID NO: 17 SEQ ID NO: 18 — SEP ID NO: 19 — SEQ ID NO:20 — SEO ID NO:21
  • the monoclonal antibody (named 9014 herein) comprises light and heavy variable chains having the sequences shown below:
  • SEQ ID NO: 1 SEQ ID NO:2 — SEP ID NO:3 — SEQ ID NO:4 — SEP ID NO: 5 — SEQ ID NO:6 — SEP ID NO: 7 — SEQ ID NO:8
  • Heavy chain Amino acid sequence (138 aa)
  • SEQ ID NO:9 SEQ ID NO:10 — SEP ID NO: 11 — SEQ ID NO:12 — SEP ID NO: 13
  • SEQ ID NO: 17 SEQ ID NO: 18 — SEP ID NO: 19 — SEQ ID NO:20 — SEO ID NO:21
  • the monoclonal antibody (named 9018 herein) comprises light and heavy variable chains having the sequences shown below:
  • Heavy chain Amino acid sequence (138 aa)
  • SEQ ID NO:56 SEQ ID NO:79 — SEO ID NO:58 — SEQ ID NO:59 — SEP ID NO: 60
  • SEQ ID NO:64 SEQ ID NO:82 — SEP ID NO: 19 — SEQ ID NO:65 — SEP ID NO: 66
  • SEQ ID NO:69 SEQ ID NO:84 — SEP ID NO: 70 — SEQ ID NO:71 — SEP ID NO: 72
  • the monoclonal antibody (named 9021 herein) comprises light and heavy variable chains having the sequences shown below:
  • SEQ ID NO:48 SEQ ID NO:87 — SEO ID NO:88 — SEQ ID NO:51 — SEP ID NO: 89
  • Heavy chain Amino acid sequence (138 aa)
  • SEQ ID NO:56 SEQ ID NO:91 — SEP ID NO: 92 — SEQ ID NO:59 — SEP ID NO: 93
  • SEQ ID NO:64 SEQ ID NO: 18 — SEP ID NO: 19 — SEQ ID NO:65 — SEP ID NO: 66
  • SEQ ID NO:69 SEQ ID NO:26 — SEP ID NO: 70 — SEQ ID NO:71 — SEP ID NO: 72
  • the monoclonal antibody (named 9023 herein) comprises light and heavy variable chains having the sequences shown below: Individual positive clones with correct VH and VL insert sizes were sequenced, one kind of VH DNA sequence and Two kinds ofVLDNA sequences were obtained in the trial.
  • SEQ ID NO:48 SEQ ID NO:74 — SEP ID NO: 97 — SEQ ID NO:98 — SEP ID NO: 99 — SEQ ID NO: 100 — SEP ID NO: 54 — SEQ ID NO:55
  • Heavy chain Amino acid sequence (138 aa)
  • SEQ ID NO:56 SEQ ID NO:79 — SEP ID NO: 101 — SEQ ID NO:59 — SEP ID NO: 102 — SEQ ID NO:103 — SEP ID NO: 62 — SEQ ID NO:63
  • Light chain 1 DNA sequence (381 bp)
  • SEQ ID NO: 104 SEQ ID NO: 105 — SEP ID NO: 106 — SEQ ID NO: 107 — SEP ID NO: 108 — SEQ ID NO:109 — SEP ID NO: 110 — SEQ ID NO:lll
  • Light chain 1 Amino acid sequence (127 aa)
  • SEQ ID NO: 112 SEQ ID NO:113 — SEP ID NO: 114 — SEQ ID NO:115 — SEP ID NO:116 — SEQ ID NO:117 — SEP ID NO: 118 — SEQ ID NO:119
  • Light chain 2 DNA sequence (384 bp)
  • SEQ ID NO:64 SEQ ID NO:120 — SEP ID NO: 121 — SEQ ID NO:122 — SEP ID NO: 66 — SEQ ID NO: 123 — SEP ID NO: 68 — SEQ ID NO: 124
  • Light chain 2 Amino acid sequence (128 aa)
  • SEQ ID NO:69 SEQ ID NO:125 — SEP ID NO: 126 — SEQ ID NO:127 — SEP ID NO: 72 — SEQ ID NO: 128 — SEP ID NO: 129 — SEQ ID NO: 130
  • the monoclonal antibody (named 9060 herein) comprises light and heavy variable chains having the sequences shown below:
  • SEQ ID N0 33 SEQ ID NO: 131 — SEP ID NO:3 — SEQ ID NO:4 — SEP ID NO: 132 — SEQ ID NO: 133 — SEP ID NO:7 — SEQ ID NO:37
  • SEQ ID N0 38 SEQ ID NO:39 — SEP ID NO: 11 — SEQ ID NO:12 — SEP ID NO:134 — SEQ ID NO: 135 — SEP ID NO: 15 — SEQ ID NO: 16 MTLNVLLGLKWVFFVVFYQGVHCEVHLVESGGGLVQPKGSLKLSCAASGFTFNTYAMHWVRQAPGKG
  • SEQ ID NO: 17 SEQ ID NO: 18 — SEP ID NO: 19 — SEQ ID NO:42 — SEP ID NO:43
  • the monoclonal antibody (named 9064 herein) comprises light and heavy variable chains having the sequences shown below:
  • SEQ ID N0 33 SEQ ID NO: 131 — SEP ID NO:3 — SEQ ID NO:4 — SEP ID NO: 132
  • SEQ ID N0 38 SEQ ID NO:39 — SEP ID NO: 11 — SEQ ID NO:12 — SEP ID NO:134 — SEQ ID NO: 135 — SEP ID NO: 15 — SEQ ID NO: 16
  • SEQ ID NO: 17 SEQ ID NO: 18 — SEP ID NO: 19 — SEQ ID NO:42 — SEP ID NO:43
  • the monoclonal antibody (named 9071 herein) comprises light and heavy variable chains having the sequences shown below:
  • SEQ ID N0 33 SEQ ID NO: 131 — SEP ID NO:3 — SEQ ID NO:4 — SEP ID NO: 132
  • SEQ ID NO: 17 SEQ ID NO: 18 — SEP ID NO: 19 — SEQ ID NO:42 — SEP ID NO:43
  • the monoclonal antibody (named 9096 herein) comprises light and heavy variable chains having the sequences shown below:
  • SEQ ID NO: 136 SEQ ID NO:137 — SEP ID NO: 138 — SEQ ID NO:51 — SEP ID NO:139 — SEQ ID NO:140 — SEP ID NO: 141 — SEQ ID NO:8
  • SEQ ID NO: 142 SEQ ID NO: 143 — SEP ID NO: 144 — SEQ ID NO:59 — SEP ID NO: 145 — SEQ ID NO: 146 — SEP ID NO: 147 — SEQ ID NO: 16
  • SEQ ID NO:64 SEQ ID NO:18 — SEP ID NO: 19 — SEQ ID NO:122 — SEP ID NO: 148 — SEQ ID NO:149 — SEP ID NO: 150 — SEQ ID NO:lll
  • SEQ ID NO:69 SEQ ID NO:26 — SEP ID NO: 70 — SEQ ID NO:127 — SEP ID NO:29 — SEQ ID NO:151 — SEP ID NO: 152 — SEQ ID NO:119
  • the monoclonal antibody (named 9110 herein) comprises light and heavy variable chains having the sequences shown below:
  • SEQ ID N0 33 SEQ ID NO: 131 — SEP ID NO:3 — SEQ ID NO:4 — SEP ID NO: 132 — SEQ ID NO: 133 — SEP ID NO:7 — SEQ ID NO:37
  • GGCACCACACTCACAGTCTCCTCA Heavy chain Amino acid sequence (142 aa)
  • SEQ ID N0 38 SEQ ID NO:39 — SEP ID NO: 11 — SEQ ID NO:12 — SEP ID NO:134 — SEQ ID NO: 135 — SEP ID NO: 15 — SEQ ID NO: 16
  • SEQ ID NO: 17 SEQ ID NO: 18 — SEP ID NO: 19 — SEQ ID NO:42 — SEP ID NO:43
  • the monoclonal antibody (named 9035 herein) comprises light and heavy variable chains having the sequences shown below:
  • SEQ ID NO: 136 SEQ ID NO:153 — SEO ID NO:5Q — SEQ ID NO:154 — SEP ID NO:155 — SEQ ID NO: 156 — SEP ID NO: 157 — SEQ ID NO: 158
  • Heavy chain Amino acid sequence (138 aa)
  • SEQ ID NO: 142 SEQ ID NO: 159 — SEP ID NO: 160 — SEQ ID NO:59 — SEP ID NO:161 — SEQ ID NO: 162 — SEP ID NO: 163 — SEQ ID NO: 164
  • SEQ ID NO: 165 SEQ ID NO: 166 — SEP ID NO: 167 — SEQ ID NO: 122 — SEP ID NO: 168 — SEQ ID NO:169 — SEP ID NO: 170 — SEQ ID NO:lll
  • SEQ ID NO:69 SEQ ID NO:171 — SEP ID NO: 70 — SEQ ID NO:127 — SEP ID NO:29 — SEQ ID NO: 172 — SEP ID NO: 152 — SEQ ID NO: 119
  • the monoclonal antibody (named 9047 herein) comprises light and heavy variable chains having the sequences shown below:
  • SEQ ID NO: 173 SEQ ID NO: 153 — SEO ID NO:5Q — SEQ ID NO: 154 — SEP ID NO:139 — SEQ ID NO: 174 — SEP ID NO: 175 — SEQ ID NO: 176
  • Heavy chain Amino acid sequence (138 aa)
  • SEQ ID NO: 142 SEQ ID NO: 159 — SEP ID NO: 160 — SEQ ID NO:59 — SEP ID NO: 145 — SEQ ID NO: 177 — SEP ID NO: 163 — SEQ ID NO: 178
  • SEQ ID NO: 179 SEQ ID NO: 166 — SEP ID NO: 180 — SEQ ID NO: 181 — SEP ID NO: 168 — SEQ ID NO: 182 — SEP ID NO: 68 — SEQ ID NO: 183
  • SEQ ID NO: 184 SEQ ID NO: 171 — SEP ID NO: 185 — SEQ ID NO: 186 — SEP ID NO:29 — SEQ ID NO: 187 — SEP ID NO: 129 — SEQ ID NO: 188
  • the monoclonal antibody (named 9052 herein) comprises light and heavy variable chains having the sequences shown below:
  • SEQ ID NO: 136 SEQ ID NO:189 — SEO ID NO:5Q — SEQ ID NO:154 — SEP ID NO:139 — SEQ ID NO:190 — SEP ID NO: 191 — SEQ ID NO:8
  • Heavy chain Amino acid sequence (138 aa)
  • SEQ ID NO: 142 SEQ ID NO: 192 — SEP ID NO: 160 — SEQ ID NO:59 — SEP ID NO: 145 — SEQ ID NO: 193 — SEP ID NO: 194 — SEQ ID NO: 16
  • SEQ ID NO: 165 SEQ ID NO: 166 — SEP ID NO: 167 — SEQ ID NO: 122 — SEP ID NO: 168 — SEQ ID NO:169 — SEP ID NO: 195 — SEQ ID NO:lll
  • SEQ ID NO:69 SEQ ID NO:171 — SEP ID NO: 70 — SEQ ID NO:127 — SEP ID NO:29 — SEQ ID NO: 172 — SEP ID NO: 152 — SEQ ID NO: 119
  • the monoclonal antibody (named 9061 herein) comprises light and heavy variable chains having the sequences shown below:
  • SEQ ID NO: 136 SEQ ID NO:196 — SEO ID NO:5Q — SEQ ID NO:51 — SEP ID NO: 197 — SEQ ID NO:90 — SEP ID NO: 198 — SEQ ID NO:8
  • Heavy chain Amino acid sequence (138 aa)
  • SEQ ID NO: 142 SEQ ID NO: 199 — SEO ID NO:58 — SEQ ID NO:59 — SEP ID NO:2QO — SEQ ID NO:94 — SEO ID NO:2Ql — SEQ ID NO: 16
  • Light chain 1 DNA sequence (384 bp)
  • SEQ ID NO:64 SEQ ID NO:18 — SEP ID NO: 19 — SEQ ID NO:122 — SEP ID NO: 66 — SEQ ID NO:202 — SEP ID NO:2Q3 — SEQ ID NO: 111
  • Light chain 1 Amino acid sequence (128 aa)
  • SEQ ID NO:69 SEQ ID NO:26 — SEP ID NO: 70 — SEQ ID NO:127 — SEP ID NO: 72 — SEQ ID NO:204 — SEP ID NO:2Q5 — SEQ ID NO: 119
  • Light chain 2 Amino acid sequence (127 aa)
  • SEQ ID NQ 212 SEQ ID NO:113 — SEO ID NQ:213 — SEQ ID NO:115 — SEP ID NO:214 — SEQ ID NO:215 — SEO ID NQ:216 — SEQ ID NO:32
  • the monoclonal antibody (named 9092 herein) comprises light and heavy variable chains having the sequences shown below:
  • SEQ ID NO:217 SEQ ID NO:218 — SEQ ID NQ:219 — SEQ ID NO:220 — SEQ ID NO:221 — SEQ ID NO:222 — SEQ ID NQ:223 — SEQ ID NO:8
  • SEQ ID NO:224 SEQ ID NO:225 — SEP ID NO:226 — SEQ ID NO:227 — SEP ID NQ:228 — SEQ ID NO:229 — SEQ ID NQ:230 — SEQ ID NO: 16
  • SEQ ID NO:231 SEQ ID NO:232 — SEP ID NO:233 — SEQ ID NO:234 — SEP ID NP:235 — SEQ ID NO:236 — SEP ID NP:237 — SEQ ID NO: 124
  • SEQ ID NO:238 SEQ ID NO:239 — SEP ID NO:24Q — SEQ ID NO:241 — SEP ID NO:242 — SEQ ID NO:243 — SEO ID NO:244 — SEQ ID NO: 130
  • the monoclonal antibody (named 9099 herein) comprises light and heavy variable chains having the sequences shown below:
  • SEQ ID NO: 136 SEQ ID NO:189 — SEO ID NO:5Q — SEQ ID NO:154 — SEP ID NO:139 — SEQ ID NO:190 — SEP ID NO: 191 — SEQ ID NO:8
  • Heavy chain Amino acid sequence (138 aa)
  • SEQ ID NO: 142 SEQ ID NO: 192 — SEP ID NO: 160 — SEQ ID NO:59 — SEP ID NO: 145 — SEQ ID NO: 193 — SEP ID NO: 194 — SEQ ID NO: 16
  • SEQ ID NO: 165 SEQ ID NO: 166 — SEP ID NO: 167 — SEQ ID NO: 122 — SEP ID NO: 168 — SEQ ID NO:169 — SEP ID NO: 195 — SEQ ID NO:lll
  • SEQ ID NO:69 SEQ ID NO:171 — SEP ID NO: 70 — SEQ ID NO:127 — SEP ID NO:29 — SEQ ID NO: 172 — SEP ID NO: 152 — SEQ ID NO: 119
  • the monoclonal antibody (named 9100 herein) comprises light and heavy variable chains having the sequences shown below:
  • SEQ ID NO: 136 SEQ ID NO:189 — SEO ID NO:5Q — SEQ ID NO:154 — SEP ID NO:139 — SEQ ID NO:190 — SEP ID NO: 191 — SEQ ID NO:8
  • Heavy chain Amino acid sequence (138 aa)
  • SEQ ID NO: 142 SEQ ID NO: 192 — SEP ID NO: 160 — SEQ ID NO:59 — SEP ID NO: 145 — SEQ ID NO: 193 — SEP ID NO: 194 — SEQ ID NO: 16
  • SEQ ID NO: 165 SEQ ID NO: 166 — SEP ID NO: 167 — SEQ ID NO: 122 — SEP ID NO: 168 — SEQ ID NO:169 — SEP ID NO: 195 — SEQ ID NO:lll
  • SEQ ID NO:69 SEQ ID NO:171 — SEP ID NO: 70 — SEQ ID NO:127 — SEP ID NO:29 — SEQ ID NO: 172 — SEP ID NO: 152 — SEQ ID NO: 119
  • the isolated monoclonal antibody comprises a light chain variable region (VL) and a heavy chain variable region (VH).
  • VL comprises a CDR1 region comprising the amino acid sequence of SEQ ID NO:27, 46, 70, 114, 126, 185, 213, or 240.
  • the VL comprises a CDR2 region comprising the amino acid sequence of SEQ ID NO:29, 72, 116, 214, or 242.
  • the VL comprises a CDR3 region comprising the amino acid sequence of SEQ ID NQ:31, 85, 118, 129, 152, 205, 216, or 244.
  • the VH comprises a CDR1 region comprising the amino acid sequence of SEQ ID NQ: 11, 58, 92, 101, 144, 160, or 226.
  • the VH comprises a CDR2 region comprising the amino acid sequence of SEQ ID NQ:13, 40, 60, 93, 102, 134, 145, 161, 200, or 228.
  • the VH comprises a CDR3 region comprising the amino acid sequence of SEQ ID NO: 15, 62, 81, 147, 163, 194, 201, or 230.
  • the VL comprises a CDR1 region comprising the amino acid sequence of SEQ ID NO:27, 46, 70, 114, or 126.
  • the VL comprises a CDR2 region comprising the amino acid sequence of SEQ ID NO:29, 72, or 116. In certain embodiments, the VL comprises a CDR3 region comprising the amino acid sequence of SEQ ID NO:31, 85, 118, 129, or 152.
  • the VL comprises a CDR1 region comprising the amino acid sequence of SEQ ID NO:70, 185, 213, or 240.
  • the VL comprises a CDR2 region comprising the amino acid sequence of SEQ ID NO:29, 72, 214, or 242.
  • the VL comprises a CDR3 region comprising the amino acid sequence of SEQ ID NO: 152, 129, 205, 216, or 244.
  • the VL comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO:27; a CDR2 region comprising the amino acid sequence of SEQ ID NO:29; and a CDR3 region comprising the amino acid sequence of SEQ ID NO:31.
  • the VL comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO:46; a CDR2 region comprising the amino acid sequence of SEQ ID NO:29; and a CDR3 region comprising the amino acid sequence of SEQ ID NO:31.
  • the VL comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO:70; a CDR2 region comprising the amino acid sequence of SEQ ID NO:29; and a CDR3 region comprising the amino acid sequence of SEQ ID NO:152.
  • the VL comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO:70; a CDR2 region comprising the amino acid sequence of SEQ ID NO:72; and a CDR3 region comprising the amino acid sequence of SEQ ID NO:85.
  • the VL comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO:70; a CDR2 region comprising the amino acid sequence of SEQ ID NO:72; and a CDR3 region comprising the amino acid sequence of SEQ ID NO:205.
  • the VL comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO: 114; a CDR2 region comprising the amino acid sequence of SEQ ID NO: 116; and a CDR3 region comprising the amino acid sequence of SEQ ID NO:118.
  • the VL comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO: 126; a CDR2 region comprising the amino acid sequence of SEQ ID NO:72; and a CDR3 region comprising the amino acid sequence of SEQ ID NO: 129.
  • the VL comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO: 185; a CDR2 region comprising the amino acid sequence of SEQ ID NO:29; and a CDR3 region comprising the amino acid sequence of SEQ ID NO: 129.
  • the VL comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO:213; a CDR2 region comprising the amino acid sequence of SEQ ID NO:214; and a CDR3 region comprising the amino acid sequence of SEQ ID NO:216.
  • the VL comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO:240; a CDR2 region comprising the amino acid sequence of SEQ ID NO:242; and a CDR3 region comprising the amino acid sequence of SEQ ID NO:244.
  • the VH comprises a CDR1 region comprising the amino acid sequence of SEQ ID NO: 11, 58, 92, 101, or 144.
  • the VH comprises a CDR2 region comprising the amino acid sequence of SEQ ID NO: 13, 40, 60, 93, 102, 134, or 145.
  • the VH comprises a CDR3 region comprising the amino acid sequence of SEQ ID NO: 15, 62, 81, or 147.
  • the VH comprises a CDR1 region comprising the amino acid sequence of SEQ ID NO: 160, 58, or 226.
  • the VH comprises a CDR2 region comprising the amino acid sequence of SEQ ID NO: 161, 145, 200, or 228.
  • the VH comprises a CDR3 region comprising the amino acid sequence of SEQ ID NO: 163, 194, 201, or 230.
  • the VH comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO: 11; a CDR2 region comprising the amino acid sequence of SEQ ID NO:13; and a CDR3 region comprising the amino acid sequence of SEQ ID NO:15;
  • the VH comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO: 11; a CDR2 region comprising the amino acid sequence of SEQ ID NO:40; and a CDR3 region comprising the amino acid sequence of SEQ ID NO: 15.
  • the VH comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO: 11; a CDR2 region comprising the amino acid sequence of SEQ ID NO: 134; and a CDR3 region comprising the amino acid sequence of SEQ ID NO:15.
  • the VH comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO:58; a CDR2 region comprising the amino acid sequence of SEQ ID NO:60; and a CDR3 region comprising the amino acid sequence of SEQ ID NO:62.
  • the VH comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO:58; a CDR2 region comprising the amino acid sequence of SEQ ID NO:60; and a CDR3 region comprising the amino acid sequence of SEQ ID NO:81.
  • the VH comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO:58; a CDR2 region comprising the amino acid sequence of SEQ ID NO:200; and a CDR3 region comprising the amino acid sequence of SEQ ID NO:201.
  • the VH comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO:92; a CDR2 region comprising the amino acid sequence of SEQ ID NO:93; and a CDR3 region comprising the amino acid sequence of SEQ ID NO:62.
  • the VH comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO: 101; a CDR2 region comprising the amino acid sequence of SEQ ID NO: 102; and a CDR3 region comprising the amino acid sequence of SEQ ID NO:62.
  • the VH comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO: 144; a CDR2 region comprising the amino acid sequence of SEQ ID NO: 145; and a CDR3 region comprising the amino acid sequence of SEQ ID NO: 147.
  • the VH comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO: 160; a CDR2 region comprising the amino acid sequence of SEQ ID NO: 145; and a CDR3 region comprising the amino acid sequence of SEQ ID NO:163.
  • the VH comprises a CDR1 region comprising the amino acid sequence of SEQ ID NO: 160; a CDR2 region comprising the amino acid sequence of SEQ ID NO: 145; and a CDR3 region comprising the amino acid sequence of SEQ ID NO: 194.
  • the VH comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO: 160; a CDR2 region comprising the amino acid sequence of SEQ ID NO: 161; and a CDR3 region comprising the amino acid sequence of SEQ ID NO:163.
  • the VH comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO:226; a CDR2 region comprising the amino acid sequence of SEQ ID NO:228; and a CDR3 region comprising the amino acid sequence of SEQ ID NO:230.
  • the VL comprises the amino acid sequence of SEQ ID NO:27-SEQ ID NO:28-SEQ ID NO:29-SEQ ID NO:30-SEQ ID NO:31,
  • the VH comprises the amino acid sequence of SEQ ID NO: 11-SEQ ID NO: 12-SEQ ID NO: 13-SEQ ID NO: 14-SEQ ID NO: 15,
  • SEQ ID NO: 144-SEQ ID NO:59-SEQ ID NO: 145-SEQ ID NO: 146-SEQ ID NO: 147 SEQ ID NO:160-SEQ ID NO:59-SEQ ID NO: 145-SEQ ID NO:177-SEQ ID NO: 163, SEQ ID NO:160-SEQ ID NO:59-SEQ ID NO: 145-SEQ ID NO:193-SEQ ID NO: 194, SEQ ID NO:160-SEQ ID NO:59-SEQ ID NO:161-SEQ ID NO:162-SEQ ID NO: 163, or SEQ ID NO:226-SEQ ID NO:227-SEQ ID NO:228-SEQ ID NO:229-SEQ ID NO:230.
  • the VL comprises the amino acid sequence of:
  • the VH comprises the amino acid sequence of:
  • the VL comprises the amino acid sequence of:
  • SEQ ID NO:213-SEQ ID NO:l 15-SEQ ID NO:214-SEQ ID NO:215-SEQ ID NO:216, or SEQ ID NO:240-SEQ ID NO:241-SEQ ID NO:242-SEQ ID NO:243-SEQ ID NO:244.
  • the VH comprises the amino acid sequence of:
  • the monoclonal antibody is humanized.
  • the monoclonal antibody is labeled.
  • the antibody of the disclosure is capable of crossing the blood-brain barrier (BBB).
  • BBB blood-brain barrier
  • the antibody of the disclosure is bispecific, being IgG-like or non-IgG-like.
  • the antibody can bind to alph ⁇ -synuclein, as described elsewhere herein and using any of the CDR sequences recited herein, and can also bind to a BBB target receptor that allows for transport of the antibody through the BBB (in a non-limiting example, through receptor-mediated transcytosis).
  • BBB target receptor is transferrin receptor, which activates a molecular channel that normally imports iron into the brain.
  • Anti-human transferrin receptor antibodies contemplated within the invention include those recited in US20160369001, which is incorporated herein in its entirety by reference.
  • BBB target receptors are low-density lipoprotein (LDL) receptor and insulin receptor.
  • the antibodies of the disclosure comprise a single-chain anti-BBB target receptor antibody.
  • the antibodies of the disclosure have an Fc fragment engineered to be capable of binding to a BBB target receptor. Approaches contemplated in the present disclosure are described in Pulgar, Front. Neurosci., January 2019, Vol. 12, Article 2019, and Kariolis, et al ., Science Translational Medicine 12(545), eaayl359, which are incorporated herein in their entireties by reference.
  • the disclosure further provides isolated polynucleotides (including RNA and/or DNA) encoding the antibodies or antigen binding fragments thereof, for example a nucleic acid encoding for one or more CDRs, or a variable heavy chain or variable light chain region of the ⁇ -Syn antibodies of the disclosure.
  • Nucleic acid includes DNA and RNA.
  • the disclosure provides an isolated polynucleotide comprising the nucleic acid sequence of SEQ ID NOs:3, 5, 7, 19, 21, 23, 35, 43, 44, 50, 52,
  • the disclosure provides an isolated polynucleotide comprising at least one nucleic acid sequence selected from the group consisting of SEQ ID NO: 1
  • the disclosure provides an isolated polynucleotide comprising at least one nucleic acid sequence selected from the group consisting of SEQ ID NOs:19, 21, 23, 43, 44, 66, 68, 96, 106, 108, 110, 121, 148, 150, 167, 168, 170, 180, 195, 203, 207, 209, 211, 233, 235, and 237.
  • the antibody has a VL encoded by a nucleic acid sequence group comprising a nucleic acid sequence set selected from the group consisting of: SEQ ID NOs: 19, 21, 23; SEQ ID NOs: 19, 43, 44; SEQ ID NOs: 19, 66, 68; SEQ ID NOs: 19, 66, 96;
  • the antibody has a VH encoded by a nucleic acid sequence group comprising a nucleic acid sequence set selected from the group consisting of: SEQ ID NOs:3, 5, 7; SEQ ID NOs:3, 35, 7; SEQ ID NOs:3, 132, 7; SEQ ID NOs:50, 52, 54; SEQ ID NOs:50, 75, 77; SEQ ID NOs:50, 139, 175; SEQ ID NOs:50, 139, 191; SEQ ID NOs:50, 155, 157; SEQ ID NOs:50, 197, 198; SEQ ID NOs:88, 89, 54; SEQ ID NOs:97, 99, 54; SEQ ID NOs:138, 139, 141; and SEQ ID NOs:219, 221, 223.
  • a nucleic acid sequence group comprising a nucleic acid sequence set selected from the group consisting of: SEQ ID NOs:3, 5, 7; SEQ ID NOs:3, 35, 7; SEQ
  • the disclosure provides an autonomously replicating or an integrative mammalian cell vector comprising a recombinant nucleic acid of the disclosure.
  • the disclosure provides a vector comprising a recombinant nucleic acid of the disclosure.
  • the recombinant nucleic acid of the disclosure encodes an antibody comprising a light chain variable region (VL) and a heavy chain variable region (VH).
  • the VL comprises a CDR1 region comprising the amino acid sequence of SEQ ID NO:27, 46, 70, 114, 126, 185, 213, or 240.
  • the VL comprises a CDR2 region comprising the amino acid sequence of SEQ ID NO:29, 72, 116, 214, or 242. In certain embodiments, the VL comprises a CDR3 region comprising the amino acid sequence of SEQ ID NO:31, 85, 118, 129, 152, 205, 216, or 244. In certain embodiments, the VH comprises a CDR1 region comprising the amino acid sequence of SEQ ID NO: 11, 58, 92, 101, 144, 160, or 226. In certain embodiments, the VH comprises a CDR2 region comprising the amino acid sequence of SEQ ID NO: 13, 40, 60, 93, 102, 134, 145, 161, 200, or 228.
  • the VH comprises a CDR3 region comprising the amino acid sequence of SEQ ID NO: 15, 62, 81, 62, 147, 163, 194, 201, or 230.
  • the vector comprises a plasmid or virus.
  • the vector comprises a mammalian cell expression vector.
  • the expression vector can comprise nucleic acid sequences that direct and/or control expression of the inserted polynucleotide. Such nucleic acid sequences can include regulatory sequence, including promoter sequences, terminator sequences, polyadenylation sequences, and enhancer sequences. Systems for cloning and expression of a polypeptide in a variety of cells are well known in the art.
  • the disclosure further provides a host cell comprising the expression vector of the disclosure.
  • the host cell is isolated.
  • the host cell is a non-human cell.
  • the host cell is mammalian.
  • the antibody of the disclosure can be a mammalian antibody, such as primate, human, rodent, rabbit, ovine, porcine or equine antibody.
  • the antibody can be any class or isotype antibody, for example IgM or IgG. In certain embodiments, the antibody is IgG.
  • the disclosure further provides a kit comprising an antibody of the disclosure.
  • the antibody may be an intact immunoglobulin molecule or fragment thereof such as Fab, F(ab)2 or Fv fragment.
  • the antibody can be labelled as described elsewhere herein.
  • the kit can be for use in a method of determining whether a subject has a neurodegenerative disease, and/or for treating, ameliorating, and/or preventing a subject afflicted or thought to be afflicted with a neurodegenerative disease.
  • the kit can further any other reagent or instrument that is required to implement a method of the disclosure, such as a buffer, an applicator, and the like.
  • the disclosure comprises pharmaceutical compositions comprising each of these antibodies in combination with one or more pharmaceutically acceptable excipients.
  • the pharmaceutical composition is formulated for parenteral delivery.
  • the antibodies are humanized.
  • the disclosure provides a method of treating, ameliorating, and/or preventing a synucleopathic disease comprising administering a therapeutically effective amount of an isolated monoclonal antibody of the disclosure to a patient.
  • the disclosure provides an isolated monoclonal antibody of the disclosure for use as a medicament for treating, ameliorating, and/or preventing a synucleopathic disease.
  • the disclosure provides use of an isolated monoclonal antibody of the disclosure in the manufacture of a medicament for the treatment, amelioration, and/or prevention of a synucleopathic disease.
  • the disclosure provides an isolated monoclonal antibody of the disclosure for use in a method for treating, ameliorating, and/or preventing a synucleopathic disease.
  • the antibody is humanized.
  • the antibody is administered as a pharmaceutical composition.
  • the monoclonal antibodies described above may be used to treat, ameliorate, and/or prevent a synucleopathic disease by reducing ⁇ -Syn pathology in neurons induced by ⁇ -Syn fibrils and/or oligomers.
  • the neurodegenerative disorders associated with ⁇ -Syn include but are not limited to Parkinson's disease, dementia (such as Parkinson's disease with dementia and/or dementia with Lewy bodies), Alzheimer's disease, Down's syndrome, multiple-system atrophy, prion diseases, and other ⁇ -Syn related neurodegenerative disorders.
  • the antibody can be administered systemically or directly to the site where ⁇ -Syn fibrils, e.g. a Lewy body, are observed or thought to be present.
  • the antibody can be administered by injection into a blood vessel supplying the brain or into the brain itself.
  • the subject can be a mammal, such as a human or a non-human mammal.
  • the disclosure provides methods of detecting synucleopathic disease in a patient.
  • the antibodies of the disclosure can be used as diagnostic tools for neurodegenerative disorders associated with ⁇ -Syn, including but not limited to Parkinson's disease, dementia (such as Parkinson's disease with dementia and/or dementia with Lewy bodies), Alzheimer's disease, Down's syndrome, multiple-system atrophy, prion diseases, and other ⁇ -Syn related neurodegenerative disorders.
  • the methods are performed in vitro. In certain embodiments, the methods are performed ex vivo.
  • the method of detecting a synucleopathic disease in a subject comprises the steps of administering a labeled, isolated monoclonal antibody of the disclosure to the subject, and detecting the presence of absence of a complex between any ⁇ - Syn fibrils and/or oligomers in the subject and the antibody. If the complex is present, that indicates that ⁇ -Syn fibrils and/or oligomers exist in the subject. In certain embodiments, if ⁇ -Syn fibrils and/or oligomers are present in the subject, the subject has a neurodegenerative disease. In other embodiments, if ⁇ -Syn fibrils or oligomers are not present in the subject, the subject does not have a neurodegenerative disease.
  • the individual if the subject has a neurodegenerative disease, the individual is counseled to undergo therapy and/or pharmacological treatment for the neurodegenerative disease. In yet other embodiments, if the subject has a neurodegenerative disease, the individual is provided therapy and/or pharmacological treatment for the neurodegenerative disease.
  • the method further comprises comparing the level of antibody/ ⁇ -Syn fibrils and/or oligomer complexes formed in the subject with the level of antibody/ ⁇ -Syn fibrils and/or oligomer complexes formed in a reference subject.
  • the reference subject can be a subject known not to have ⁇ -Syn fibrils and/or oligomers, a subject known to have detectable ⁇ -Syn fibrils and/or oligomers, and/or a subject known to have a certain level of ⁇ -Syn fibrils and/or oligomers.
  • the reference subject can further be the same subject being treated or evaluated, but corresponding to an earlier ⁇ -Syn fibrils and/or oligomers detection experiment, as a way to evaluate disease progression and/or treatment efficacy in the subject.
  • the disclosure provides methods of detecting ⁇ -Syn fibrils in a sample.
  • the antibodies of the disclosure can be used as diagnostic tools for detecting the presence of ⁇ -Syn fibrils, oligomers or other misfolded ⁇ -Syn species in a sample.
  • the method of detecting ⁇ -Syn fibrils, oligomers, or other misfolded ⁇ -Syn species in a sample comprises the steps of contacting the sample with a labeled, isolated monoclonal antibody of the disclosure, and detecting the presence or absence of a complex between any ⁇ -Syn fibrils, oligomers, or other misfolded ⁇ -Syn species in the sample and the antibody. If the complex is detected, that indicates the presence of ⁇ -Syn fibrils, oligomers, or other misfolded ⁇ -Syn species in the sample.
  • the sample can be, in non-limiting examples, cerebrospinal fluid (CSF), blood, urine, saliva, or tissues from brain, gut, colon, skin, or salivary gland.
  • CSF cerebrospinal fluid
  • the sample is a CSF sample and/or a brain tissue sample.
  • the sample is used as is after being removed from the subject.
  • the sample is pre-treated being used within the present methods.
  • the method further comprises comparing the level of antibody- ⁇ -Syn fibril s/oligomers or other antibody-misfolded ⁇ -Syn complexes formed in the sample with the level of antibody- ⁇ -Syn fibril s/oligomers or other antibody-misfolded ⁇ -Syn complexes formed in a reference sample.
  • the reference sample can be from a subject known not to have ⁇ -Syn fibril s/oligomers or other misfolded ⁇ -Syn species, a subject known to have detectable ⁇ -Syn fibrils/oligomers or other misfolded ⁇ -Syn species, and/or a subject known to have a certain level of ⁇ -Syn fibril s/oligomers or other misfolded ⁇ -Syn species.
  • the reference sample can further be from the same subject being treated or evaluated, but corresponding to an earlier ⁇ -Syn fibrils/oligomers or other misfolded ⁇ -Syn species detection, as a way to evaluate disease progression and/or treatment efficacy in the subject.
  • the level of ⁇ -Syn fibril s/oligomers or other misfolded ⁇ -Syn species detected in a subject or in a sample from a subject correlates with severity or progression of a neurodegenerative disease in the subject.
  • the methods of the disclosure can be used to monitor severity or progression of a neurodegenerative disease in the subject.
  • the methods of the disclosure can be used to monitor effectiveness of a therapy and/or pharmacological intervention in a subject afflicted or believed to be afflicted with a neurodegenerative disease.
  • the sample comprises or is an in vitro sample. In certain embodiments, the sample comprises or is an ex vivo sample.
  • Methods for detecting formation of a complex between the antibody and ⁇ -Syn fibrils/oligomers or other misfolded ⁇ -Syn species comprise, but are not limited to, radioimmunoassay, enzyme-linked immunosorbant assay (ELISA), sandwich immunoassay, fluorescent immunoassay, precipitation reaction, gel immunodiffusion assay, agglutination assay, protein A immunoassay, immunoelectrophoresis assay, electrophoresis, western blotting, or any other technique known in the art.
  • ELISA enzyme-linked immunosorbant assay
  • the antibodies of the disclosure can be combined with a label and used to detect over ⁇ -Syn levels in a patient or in a sample. In other embodiments, the antibodies of the disclosure can be combined with a label and used to detect ⁇ -Syn fibrils/oligomers or other misfolded ⁇ -Syn species in a patient or in a sample. Methods of labeling antibodies are known in the art and a variety of approaches may be employed.
  • the label is a radiolabel, such as but not limited to F 18 , 1 123 , In 111 , 1 131 , C 14 , H 3 , Tc 99m , P 32 , 1 125 , Ga 68 and the like.
  • the label is a fluorescent label, such as but not limited to fluorescein, rhodamine and the like.
  • the label is a contrast agent, such as but not limited to gadolinium (Gd), dysprosium and iron, magnetic agents, and the like.
  • Other labels include nuclear magnetic resonance active labels, positron emitting isotopes detectable by a PET scanner, chemiluminescent and enzymatic markers.
  • Non-limiting imaging techniques include electron microscopy, confocal microscopy, light microscopy, positron emission tomography (PET), gamm ⁇ -scintigraphy, magnetic resonance imaging (MRI), functional magnetic resonance imaging (FMRI), magnetoencephalography (MEG), and single photon emission computerized tomography (SPECT).
  • PET positron emission tomography
  • MRI magnetic resonance imaging
  • FMRI functional magnetic resonance imaging
  • MEG magnetoencephalography
  • SPECT single photon emission computerized tomography
  • the label is on a secondary antibody that binds a primary antibody comprising the above described sequences.
  • Administration of the compounds and/or compositions of the present disclosure to a patient, preferably a mammal, more preferably a human, may be carried out using known procedures, at dosages and for periods of time effective to perform a therapeutic and/or imaging method contemplated in the disclosure.
  • An effective amount of the compound necessary for adequate therapeutic treatment and/or imaging signal may vary according to factors such as the state of a disease or disorder in the patient; the age, sex, and weight of the patient; and/or the equipment used to detect the compound of the disclosure.
  • One of ordinary skill in the art would be able to study the relevant factors and make the determination regarding the effective amount of the therapeutic and/or imaging compound without undue experimentation.
  • Actual dosage levels of the active ingredients in the pharmaceutical compositions of this disclosure may be varied so as to obtain an amount of the active ingredient that is effective to achieve successful therapy and/or imaging for a particular patient, composition, and mode of administration, without being toxic to the patient.
  • compositions of the disclosure are formulated using one or more pharmaceutically acceptable excipients or carriers.
  • pharmaceutical compositions of the disclosure comprise an effective amount of a compound of the disclosure and a pharmaceutically acceptable carrier.
  • the carrier may be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetable oils.
  • the proper fluidity may be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants.
  • Prevention of the action of microorganisms may be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like.
  • isotonic agents for example, sugars, sodium chloride, or polyalcohols such as mannitol and sorbitol, in the composition.
  • Prolonged absorption of the injectable compositions may be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate or gelatin.
  • Formulations may be employed in admixtures with conventional excipients, i.e., pharmaceutically acceptable organic or inorganic carrier substances suitable for oral, parenteral, nasal, intravenous, subcutaneous, enteral, or any other suitable mode of administration, known to the art.
  • the pharmaceutical preparations may be sterilized and if desired mixed with auxiliary agents, e.g. , lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure buffers, coloring, flavoring and/or aromatic substances and the like.
  • Routes of administration of any of the compositions of the disclosure include oral, nasal, rectal, intravaginal, parenteral, buccal, sublingual or topical.
  • the compounds for use in the disclosure may be formulated for administration by any suitable route, such as for oral or parenteral, for example, transdermal, transmucosal (e.g ., sublingual, lingual, (trans) buccal, (trans)urethral, vaginal (e.g., trans- and perivaginally), (intra)nasal and (trans)rectal), intravesical, intrapulmonary, intraduodenal, intragastrical, intrathecal, subcutaneous, intramuscular, intradermal, intr ⁇ -arterial, intravenous, intrabronchial, inhalation, and topical administration.
  • transdermal transmucosal
  • transmucosal e.g ., sublingual, lingual, (trans) buccal
  • vaginal e.g., trans- and perivaginally
  • vaginal e.g., trans- and perivaginally
  • intravesical, intrapulmonary, intraduodenal, intragastrical, intrathecal subcutaneous
  • compositions and dosage forms include, for example, tablets, capsules, caplets, pills, gel caps, troches, dispersions, suspensions, solutions, syrups, granules, beads, transdermal patches, gels, powders, pellets, magmas, lozenges, creams, pastes, plasters, lotions, discs, suppositories, liquid sprays for nasal or oral administration, dry powder or aerosolized formulations for inhalation, compositions and formulations for intravesical administration and the like. It should be understood that the formulations and compositions that would be useful in the present disclosure are not limited to the particular formulations and compositions that are described herein.
  • parenteral administration of a pharmaceutical composition includes any route of administration characterized by physical breaching of a tissue of a subject and administration of the pharmaceutical composition through the breach in the tissue.
  • Parenteral administration thus includes, but is not limited to, administration of a pharmaceutical composition by injection of the composition, by application of the composition through a surgical incision, by application of the composition through a tissue-penetrating non-surgical wound, and the like.
  • parenteral administration is contemplated to include, but is not limited to, subcutaneous, intravenous, intraperitoneal, intramuscular, intrastemal injection, and kidney dialytic infusion techniques.
  • Formulations of a pharmaceutical composition suitable for parenteral administration comprise the active ingredient combined with a pharmaceutically acceptable carrier, such as sterile water or sterile isotonic saline. Such formulations may be prepared, packaged, or sold in a form suitable for bolus administration or for continuous administration. Injectable formulations may be prepared, packaged, or sold in unit dosage form, such as in ampules or in multidose containers containing a preservative. Formulations for parenteral administration include, but are not limited to, suspensions, solutions, emulsions in oily or aqueous vehicles, pastes, and implantable sustained-release or biodegradable formulations. Such formulations may further comprise one or more additional ingredients including, but not limited to, suspending, stabilizing, or dispersing agents.
  • the active ingredient is provided in dry (i.e., powder or granular) form for reconstitution with a suitable vehicle (e.g ., sterile pyrogen free water) prior to parenteral administration of the reconstituted composition.
  • a suitable vehicle e.g ., sterile pyrogen free water
  • compositions may be prepared, packaged, or sold in the form of a sterile injectable aqueous or oily suspension or solution.
  • This suspension or solution may be formulated according to the known art, and may comprise, in addition to the active ingredient, additional ingredients such as the dispersing agents, wetting agents, or suspending agents described herein.
  • Such sterile injectable formulations may be prepared using a nontoxic parenterally-acceptable diluent or solvent, such as water or 1,3-butanediol, for example.
  • a nontoxic parenterally-acceptable diluent or solvent such as water or 1,3-butanediol, for example.
  • Other acceptable diluents and solvents include, but are not limited to, Ringer's solution, isotonic sodium chloride solution, and fixed oils such as synthetic mono- or di-glycerides.
  • compositions for sustained release or implantation may comprise pharmaceutically acceptable polymeric or hydrophobic materials such as an emulsion, an ion exchange resin, a sparingly soluble polymer, or a sparingly soluble salt.
  • Additional dosage forms of this disclosure include dosage forms as described in U.S. Patents Nos. 6,340,475; 6,488,962; 6,451,808; 5,972,389; 5,582,837; and 5,007,790. Additional dosage forms of this disclosure also include dosage forms as described in U.S. Patent Applications Nos. 2003/0147952; 2003/0104062; 2003/0104053; 2003/0044466; 2003/0039688; and 2002/0051820. Additional dosage forms of this disclosure also include dosage forms as described in PCT Applications Nos.
  • mice used for antibody generation were Balb/c; mice used for primary neuron culture were CD-1 (Charles River, Cat# CRL:22, RRID:IMSR_CRL:22), and mice used for in vivo studies were B6C3F1 (Charles River, Cat# CRL:31, RRID:IMSR_CRL:31).
  • a single colony from this transformation was expanded in Terrific Broth (12 g/L of Bacto-tryptone, 24 g/L of yeast extract 4% (vol/vol) glycerol, 17 mM KH 2 PO 4 and 72 mM KH 2 PO 4 ) with ampicillin.
  • Bacterial pellets from the growth were sonicated and sample was boiled to precipitate undesired proteins. The supernatant was dialyzed with 10 mM Tris, pH 7.6, 50 mM NaCl, 1 mM EDTA overnight. Protein was filtered with a 0.22 ⁇ m filter and concentrated using Amicon Ultr ⁇ -15 centrifugal filter units (Millipore Sigma Cat# UFC901008).
  • Protein was then loaded onto a Superdex 200 column and 1 mL fractions were collected. Fractions were run on SDS-PAGE and stained with Coomassie blue to select fractions that were highly enriched in ⁇ -Synuclein. These fractions were combined and dialyzed in 10 mM Tris, pH 7.6, 50 mM NaCl, 1 mM EDTA overnight. Dialyzed fractions were applied to the MonoQ column (GE Health, HiTrap Q HP 645932) and run using a linear gradient from 25 mM NaCl to 1 M NaCl. Collected fractions were run on SDS-PAGE and stained with Coomassie blue.
  • mouse ⁇ -Synuclein PFFs For treatment of neurons, mouse ⁇ -Synuclein PFFs, which were generated at a concentration of 5 mg/mL, were vortexed and diluted with Dulbecco's phosphate-buffered saline (DPBS, Corning Cat#21-031-CV) to 100 ⁇ g/mL. They were then sonicated on high for 10 cycles of 30 seconds on, 30 seconds off (Diagenode Biorupter UCD-300 bath sonicator). ⁇ -Synuclein PFFs were then diluted in neuron media to 5 ⁇ g/mL and added to neuron cultures at the noted concentrations.
  • DPBS Dulbecco's phosphate-buffered saline
  • Mouse ⁇ -Synuclein PFFs which were generated at a concentration of 5 mg/mL were vortexed and diluted with DPBS to 2 mg/mL. They were then sonicated on high for 10 cycles of 30 seconds on, 30 seconds off (Diagenode Biorupter UCD-300 bath sonicator). Mice were injected when 3 months old. Mice were injected unilaterally by insertion of a single needle into the right forebrain (coordinates: +0.2 mm relative to Bregma, +2.0 mm from midline) targeting the dorsal striatum (2.6 mm beneath the dura) with 5 ⁇ g ⁇ -Synuclein PFFs (2.5 ⁇ L).
  • mice were perfused transcardially with PBS, brains were removed and underwent overnight fixation in 70% ethanol in 150 mM NaCl, pH 7.4.
  • Murine monoclonal antibodies were raised as described previously (Gibbons, et al. , 2018, Neuropathol Exp Neurol 77:216-228) against sonicated, human ⁇ -Synuclein PFFs emulsified with complete Freund's adjuvant (0.05 mg ⁇ -Synuclein /mouse) followed by 2 subsequent boosts of 0.025 mg ⁇ -Synuclein emulsified with incomplete Freund's adjuvant 3 and 6 weeks following the initial injections.
  • mice received an intravenous boost of 0.025 mg/mouse.
  • Hybridoma cells were selected for 7 days in medium containing 5.7 mM azaserine-10; 100 pM hypoxanthine (Sigma Cat# A9666) and cultured in Kennetfs HY (90% DMEM, 10% NCTC135, 4.15 g/L glucose, 3.55 g/L NaHCO 3 ), supplemented with 20% fetal bovine serum (FBS; Atlanta Biological Cat# E0118), 100 U/mL penicillin/100 ⁇ g/mL streptomycin (Gibco Cat# 15140-122); 2 mM L-glutamine (Coming Cat# 25-005-Cl) and OPI media supplement (1 mM oxoloacetate, 0.45 mM pyruvate, 0.2 U/mL insulin; Sigma Cat# 0
  • Monoclonal populations were isolated by limiting dilution to 0.3 cells/well in 96-well plates. Antibodies were further characterized as described below. Hybridomas with selectivity for pathological misfolded ⁇ -syn were expanded and subcloned at least twice.
  • ⁇ -Synuclein constructs were produced in E. coli as previously established (Volpicelli-Daley, et al. , 2014, Nature Protocols 9:2135-2146). Total protein concentration in each sample was determined by a bicinchoninic acid colorimetric assay (Fisher Cat#23223 and 23224), using bovine serum albumin as a standard (Thermo Fisher Cat#23210). Protein was resolved on 5-20% gradient polyacrylamide gels using equal protein loading (250 ng ⁇ -Synuclein/well). Proteins were transferred to 0.2 ⁇ m nitrocellulose membranes and detected with primary antibodies (1 : 1000). Primary antibodies were detected using IRDye 800 (LI-COR 925-32210) or IRDye 680 (LI-COR 925-68071) secondary antibodies, scanned on a LI-COR Odyssey Imaging System and analyzed using Image Studio software.
  • Neurons were treated using a modified version of the procedure previously described (Tran, et al. , 2014, Cell Reports 7:2054-2065). Neurons were fed every three days after plating until 10 DIV. At that point, 125 ⁇ L of media was removed from each well, and sterile ⁇ -Synuclein antibodies were added in 20 ⁇ L of fresh neuron media at incubated at 37°C for 30 minutes. 125 ⁇ g of freshly sonicated PFFs were added in an additional 20 ⁇ L of neuron media. Neurons were fed at 1 and 4 DPT and fixed and stained at 7-days post transduction as described previously (Tran, et al. , 2014, Cell Reports 7:2054-2065).
  • a 384-well Maxisorp clear plate (Thermo Fisher Scientific, Cat# 12565347) was coated with 30 ⁇ L per well (50 ng) of antibody in Takeda coating buffer, then plate was spun at 1000 x g for 1 minute and incubated overnight at 4°C. The plate was washed 4 times with PBST (PBS with 0.05% Tween) and blocked using Block Ace blocking solution (95 ⁇ L per well) (AbD Serotec) overnight at 4°C.
  • PBST PBS with 0.05% Tween
  • antibodies were purified using a HiTrap MabSelect SuRe column (GE Healthcare Life Sciences, Cat# 11003494) on an AKTA Pure FPLC system (GE Healthcare Life Sciences). Supernatant was sterile filtered with a 0.2 ⁇ m filter and loaded on the column. After washing, antibodies were eluted with 100 mM glycine, 150 mM NaCl, pH 3.0. Eluate was immediately neutralized with 1 M Tris- base, pH 9.0. The UV trace was used to select and pool fractions containing antibody.
  • Antibody was concentrated using Amicon Ultr ⁇ - 15 50 K centrifugal filter units (Millipore Sigma, Cat# UFC905024) and dialyzed into phosphate-buffered saline, pH 7.2. Antibodies were then sterile filtered with a 0.2 ⁇ m filter, protein concentration in each sample was determined by a bicinchoninic acid colorimetric assay (Fisher Cat# 23223 and 23224), using bovine serum albumin as a standard (Thermo Fisher Cat# 23210). Samples were run on a 15% SDS-PAGE gel and coomassie stained to ensure presence of heavy and light changes and protein purity. After purification from hybridoma supernatant, antibodies were frozen in 1 mL aliquots and stored at -20°C.
  • a 1 mm coronal section was removed from the rostral brain between approximately Bregma and Bregma + 1 mm.
  • the dorsal striatum was manually dissected from both the right (ipsilateral) and left (contralateral) side of the brain and flash frozen on dry ice for liquid chromatography-mass spectrometry (LC-MS) analysis of dopamine (DA) and dihydroxyphenylacetic acid (DOPAC).
  • LC-MS liquid chromatography-mass spectrometry
  • DA dopamine
  • DOPAC dihydroxyphenylacetic acid
  • Frozen tissue was suspended in 10 ⁇ L Milli-Q water/mg tissue and sonicated at power level 1.5 using 15-20 short pulses (QSONICA MICROSONTM XL-2000) until solution was homogenous.
  • Lysate was briefly spun down and 30 ⁇ L was transferred to a new tube containing 30 ⁇ L 0.4 M perchloric acid. Remaining lysate was suspended in 2x RIPA buffer with protease inhibitors for assay of protein levels. Perchlorate sample were spun at 3000 x g and 4°C for 15 minutes. Two volumes of 0.4 M sodium acetate was added to supernatant and spin filtered through a 0.65 ⁇ m filter. DA and DOPAC were subsequently quantitated using a Waters Acquity UPLC- TQD LC-MS system.
  • Slides were then rinsed for 5 minutes with 0.1 M Tris, then developed with ImmPACT DAB peroxidase substrate (Vector SK-4105, RRID:AB_2336520) and counterstained briefly with Harris Hematoxylin (Fisher 67-650-01). Slides were washed in running tap water for 5 minutes, dehydrated in ascending ethanol for 1 minute each: 70%, 80%, 95%, 100%, 100%, then washed twice in xylenes for 5 minutes and coversliped in Cytoseal Mounting Media (Fisher 23-244-256). Digitized slides were then used for quantitative pathology.
  • mice All section selection, annotation and quantification was done blinded to treatment group. All quantitation was performed in HALO quantitative pathology software (Indica Labs). Every 10 th slide through the midbrain was stained with tyrosine hydroxylase (TH). TH-stained sections were used to annotate the SN, and cell counting was performed manually in a blinded manner for all sections. The sum of all sections was multiplied by 10 to estimate the total count that would be obtained by counting every section. The SN annotations drawn onto the TH-stained sections were then transferred to sequential sections that had been stained for misfolded ⁇ -Synuclein (Syn506).
  • TH tyrosine hydroxylase
  • Amygdala regions were also annotated on every 10 th section through the length of the amygdala.
  • a single analysis algorithm was then applied equally to all stained sections to quantify the percentage of area occupied by Syn506 staining. Specifically, the analysis included all DAB signal that was above a 0.157 optical density threshold, which was empirically determined to not include any background signal. This signal was then normalized to the total tissue area. A minimal tissue optical density of 0.02 was used to exclude any areas where tissue was split.
  • n represents the number of independent wells assayed.
  • n represents the number of mice.
  • pan- ⁇ -Synuclein antibodies may have liabilities as a therapeutic approach for PD.
  • pan- ⁇ -Synuclein antibodies may have liabilities as a therapeutic approach for PD.
  • the abundance of ⁇ - Synuclein in red blood cells also raises the possibility that a pan- ⁇ -Synuclein antibody could cause on-target side effects in the blood, as antibody concentrations in the blood are approximately 1000-fold higher than in the brain.
  • serum ⁇ -Synuclein could act as a sink for a pan- ⁇ -Synuclein antibodies, thereby reducing engagement with the intended target in the brain.
  • mice were first immunized with misfolded ⁇ -Synuclein pre-formed fibrils (PFFs) formed from recombinant human ⁇ -Synuclein (FIG. 1 A). Mice developed an immune response to the ⁇ -Synuclein PFF immunogen, and antibody-producing B cells were harvested and fused to myeloma cells to generate antibody-producing hybridoma cells (FIG. IB).
  • PFFs misfolded ⁇ -Synuclein pre-formed fibrils
  • Monoclonal hybridomas were isolated by limiting dilution, and antibody-containing supernatant from these clones was tested in several assays to determine which hybridoma clones were producing antibodies with preferred properties (FIG. 1C).
  • Candidate antibodies were further subcloned to ensure monoclonality (FIG. ID), with antibody properties confirmed through a screen to ensure retention of properties (FIG. IE).
  • a non-limiting candidate antibody was selected for efficacy testing in an in vivo model of PD (FIG. IF), where it was compared to a previously characterized immunotherapy antibody.
  • certain antibodies of interest have a high binding preference for misfolded LB ⁇ -Synuclein over monomeric ⁇ -Synuclein.
  • amygdala sections from PD patients with abundant LB pathology were immunostained.
  • Hybridoma supernatants were used undiluted or at a 1:3 dilution on screening slides processed in parallel to allow direct comparison of immunostaining.
  • Most antibodies tested showed a preference for binding to LB ⁇ -Synuclein over normal synaptic ⁇ -Synuclein in the neuropil (FIG. 2A).
  • a LB discrimination index (optical density of LB/optical density of all tissue) was developed to better compare the relative binding of antibodies to LB over the neuropil pool (FIG. 2B).
  • a value of 1 indicates no discrimination of LBs over normal synaptic neuropil staining. While most of the antibodies had a preference for LBs, a cutoff of 1.5 was established to remove antibodies that showed relatively non-selective staining of LBs from further consideration.
  • Example 3 Epitope Mapping Ensures that Preferred Antibodies Recognize Human and Mouse ⁇ -Synuclein
  • Example 4 Sandwich ELISA Identifies Antibodies with a Preference for Misfolded ⁇ - Synuclein
  • This assay retains the conformation of ⁇ -Synuclein by allowing binding of ⁇ -Synuclein that is in solution to immobilized antibody, and allows a broad range of affinity detection.
  • Antibodies of interest were coated on an ELISA plate and either ⁇ - Synuclein monomer or PFF were incubated with the antibodies at increasing ⁇ -Synuclein concentrations to determine relative affinity of the antibodies for each form of ⁇ -Synuclein.
  • the previously characterized Syn211 antibody (Giasson, et al. , 2000, J. Neurosci. Res. 59:528-533) was also coated on each plate as a non-selective antibody control. Bound ⁇ - Synuclein was detected with a monoclonal antibody (MJF-R1, Abeam, Cat#138501) and a goat-anti-rabbit IgG-HRP conjugate.
  • Capture antibodies could be categorized almost evenly into three categories: 17 nonbinding (FIGs. 4A & 11), 18 non-selective (FIG. 4B & 12), 19 PFF-selective (FIG. 4C & 13).
  • 17 nonbinding FIGS. 4A & 11
  • 18 non-selective FIG. 4B & 12
  • 19 PFF-selective FIG. 4C & 13
  • the lack of activity in the sandwich ELISA can suggest that immobilization on ELISA plate wells affected their ability to capture ⁇ -Synuclein.
  • Example 5 Primary Neuron Immunotherapy Assay Reveals Differential Potency of ⁇ - Synuclein Antibodies to Prevent LB-Like Pathology
  • Neurons were fixed 7 days later and assayed for pathological pS129 ⁇ -Synuclein and neuron number (NeuN; FIG. 5 A).
  • Antibodies showed a wide range of efficacy in this assay with 22 of the 41 antibodies causing over 75 percent reduction in pathology (FIG. 5B).
  • ⁇ -Synuclein antibodies The thorough characterization of ⁇ -Synuclein antibodies in multiple assays allowed one to compare antibodies quantitatively and select favored antibodies for subcloning and further screening (FIGs. 6A-6B).
  • certain antibodies of interest recognize both mouse and human ⁇ -Synuclein, bind LBs preferentially in human tissue, show greater affinity for misfolded ⁇ -Synuclein than monomeric ⁇ -Synuclein, and reduce PFF- seeded ⁇ -Synuclein pathology in primary neurons. Based on these criteria, two antibodies (Syn9063 and Syn9048) were selected for subcloning, large-scale production and in vivo testing.
  • Syn9048 was diluted over several log concentrations and assessed in the human ⁇ -Synuclein PFF-seeded primary hippocampal neuron assay as described above.
  • Syn9048 reduced neuronal ⁇ -Synuclein pathology in a dose-dependent manner, with a molar antibody: ⁇ -Synuclein ratio IC 50 of 0.006 (1:166) (FIGs. 7C-7D).
  • Syn9048 showed almost complete inhibition of ⁇ -Synuclein pathology at a molar ratio of 0.03 or higher, suggesting that only one antibody per 33 ⁇ - Synuclein monomer units is sufficient to fully inhibit ⁇ -Synuclein seeding in neurons.
  • Syn9048 was also capable of reducing ⁇ -Synuclein pathology induced by mouse ⁇ -Synuclein PFFs with a similar IC 50 (FIG. 15), suggesting that it would be suitable for testing in a non- transgenic mouse model of PD.
  • mice/group 16 mice/group.
  • An additional group of mice was treated with a comparator antibody, Syn303, which has previously been validated for in vivo immunotherapy models (Tran, et al. , 2014, Cell Reports 7:2054-2065).
  • the one-week delay in antibody dosing after intrastriatal PFF injection was intended to minimize inhibition of initial PFF-seeding in neurons.
  • sites of secondary ⁇ -Synuclein pathology formation that result from pathology transmission are most affected by antibody treatment. Mice in all three groups gained weight steadily over the course of the study, suggesting that the passive immunotherapy was well-tolerated (FIG. 8B).
  • Dopaminergic neuron loss in the substantia nigra (SN) is a primary feature of PD and is recapitulated in the PFF injection mouse model (Henderson, et al., 2019, Nature Neuroscience 22:1248-1257; Luk, etal., 2012, Science 338:949-953) (FIG. 8C).
  • IgGl- treated mice have dramatic tyrosine hydroxylase (TH)-positive neuron loss ipsilateral to the injection site, and this neuron loss was not abrogated by either Syn303 or Syn9048 treatment (FIGs. 8D-8E).
  • Embodiment 1 provides an isolated monoclonal antibody comprising a light chain variable region (VL) and a heavy chain variable region (VH), wherein the VL comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO:27, 46, 70, 114, 126, 185, 213, or 240; a CDR2 region comprising the amino acid sequence of SEQ ID NO:29, 72, 116, 214, or 242; and a CDR3 region comprising the amino acid sequence of SEQ ID NO:31, 85, 118, 129, 152, 205, 216, or 244; and wherein the VH comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO: 11, 58, 92, 101, 144, 160, or 226; a CDR2 region comprising the amino acid sequence of SEQ ID NO: 13, 40, 60, 93, 102, 134, 145, 161, 200, or 228; and a CDR3 region comprising the amino
  • Embodiment 2 provides the monoclonal antibody of Embodiment 1, wherein the VL comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO:27, 46, 70, 114, or
  • VH comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO: 11, 58, 92, 101, or 144; a CDR2 region comprising the amino acid sequence of SEQ ID NO: 13, 40, 60, 93, 102, 134, or 145; and a CDR3 region comprising the amino acid sequence of SEQ ID NO: 15, 62, 81, or 147.
  • Embodiment 3 provides the monoclonal antibody of Embodiment 1, wherein the VL comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO:70, 185, 213, or 240; a CDR2 region comprising the amino acid sequence of SEQ ID NO:29, 72, 214, or 242; and a CDR3 region comprising the amino acid sequence of SEQ ID NO: 152, 129, 205, 216, or 244; and wherein the VH comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO: 160, 58, or 226; a CDR2 region comprising the amino acid sequence of SEQ ID NO: 161, 145, 200, or 228; and a CDR3 region comprising the amino acid sequence of SEQ ID NO: 163, 194, 201, or 230.
  • the VL comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO:70, 185, 213, or 240; a CDR2 region
  • Embodiment 4 provides the monoclonal antibody of any one of Embodiments 1-3, wherein at least one applies:
  • the VL comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO:27; a CDR2 region comprising the amino acid sequence of SEQ ID NO:29; and a CDR3 region comprising the amino acid sequence of SEQ ID NO:31; and the VH comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO: 11; a CDR2 region comprising the amino acid sequence of SEQ ID NO: 13; and a CDR3 region comprising the amino acid sequence of SEQ ID NO: 15;
  • the VL comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO:46; a CDR2 region comprising the amino acid sequence of SEQ ID NO:29; and a CDR3 region comprising the amino acid sequence of SEQ ID NO:31; and the VH comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO: 11; a CDR2 region comprising the amino acid sequence of SEQ ID NO:40; and a CDR3 region comprising the amino acid sequence of SEQ ID NO: 15;
  • the VL comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO:70; a CDR2 region comprising the amino acid sequence of SEQ ID NO:72; and a CDR3 region comprising the amino acid sequence of SEQ ID NO:85; and the VH comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO:58; a CDR2 region comprising the amino acid sequence of SEQ ID NO:60; and a CDR3 region comprising the amino acid sequence of SEQ ID NO:62;
  • the VL comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO:70; a CDR2 region comprising the amino acid sequence of SEQ ID NO:72; and a CDR3 region comprising the amino acid sequence of SEQ ID NO:85; and the VH comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO:58; a CDR2 region comprising the amino acid sequence of SEQ ID NO:60; and a CDR3 region comprising the amino acid sequence of SEQ ID NO:81;
  • the VL comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO:70; a CDR2 region comprising the amino acid sequence of SEQ ID NO:72; and a CDR3 region comprising the amino acid sequence of SEQ ID NO:85; and the VH comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO:92; a CDR2 region comprising the amino acid sequence of SEQ ID NO:93; and a CDR3 region comprising the amino acid sequence of SEQ ID NO:62;
  • the VL comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO: 114; a CDR2 region comprising the amino acid sequence of SEQ ID NO: 116; and a CDR3 region comprising the amino acid sequence of SEQ ID NO: 118; and the VH comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO: 101; a CDR2 region comprising the amino acid sequence of SEQ ID NO: 102; and a CDR3 region comprising the amino acid sequence of SEQ ID NO:62;
  • the VL comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO: 126; a CDR2 region comprising the amino acid sequence of SEQ ID NO:72; and a CDR3 region comprising the amino acid sequence of SEQ ID NO: 129; and the VH comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO: 101; a CDR2 region comprising the amino acid sequence of SEQ ID NO: 102; and a CDR3 region comprising the amino acid sequence of SEQ ID NO:62;
  • the VL comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO:46; a CDR2 region comprising the amino acid sequence of SEQ ID NO:29; and a CDR3 region comprising the amino acid sequence of SEQ ID NO:31; and the VH comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO: 11; a CDR2 region comprising the amino acid sequence of SEQ ID NO: 134; and a CDR3 region comprising the amino acid sequence of SEQ ID NO: 15;
  • the VL comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO:70; a CDR2 region comprising the amino acid sequence of SEQ ID NO:29; and a CDR3 region comprising the amino acid sequence of SEQ ID NO: 152; and the VH comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO: 144; a CDR2 region comprising the amino acid sequence of SEQ ID NO: 145; and a CDR3 region comprising the amino acid sequence of SEQ ID NO: 147;
  • the VL comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO:70; a CDR2 region comprising the amino acid sequence of SEQ ID NO:29; and a CDR3 region comprising the amino acid sequence of SEQ ID NO: 152; and the VH comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO: 160; a CDR2 region comprising the amino acid sequence of SEQ ID NO: 161; and a CDR3 region comprising the amino acid sequence of SEQ ID NO: 163;
  • the VL comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO: 185; a CDR2 region comprising the amino acid sequence of SEQ ID NO:29; and a CDR3 region comprising the amino acid sequence of SEQ ID NO: 129; and the VH comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO: 160; a CDR2 region comprising the amino acid sequence of SEQ ID NO: 145; and a CDR3 region comprising the amino acid sequence of SEQ ID NO: 163;
  • the VL comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO:70; a CDR2 region comprising the amino acid sequence of SEQ ID NO:29; and a CDR3 region comprising the amino acid sequence of SEQ ID NO: 152; and the VH comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO: 160; a CDR2 region comprising the amino acid sequence of SEQ ID NO: 145; and a CDR3 region comprising the amino acid sequence of SEQ ID NO: 194;
  • the VL comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO:70; a CDR2 region comprising the amino acid sequence of SEQ ID NO:72; and a CDR3 region comprising the amino acid sequence of SEQ ID NO:205; and the VH comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO:58; a CDR2 region comprising the amino acid sequence of SEQ ID NO:200; and a CDR3 region comprising the amino acid sequence of SEQ ID NO:201;
  • the VL comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO:213; a CDR2 region comprising the amino acid sequence of SEQ ID NO:214; and a CDR3 region comprising the amino acid sequence of SEQ ID NO:216; and the VH comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO:58; a CDR2 region comprising the amino acid sequence of SEQ ID NO:200; and a CDR3 region comprising the amino acid sequence of SEQ ID NO:201; (o) the VL comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO:240; a CDR2 region comprising the amino acid sequence of SEQ ID NO:242; and a CDR3 region comprising the amino acid sequence of SEQ ID NO:244; and the VH comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO:226; a CDR2 region comprising the amino acid sequence of SEQ ID NO:228
  • Embodiment 5 provides the monoclonal antibody of any one of Embodiments 1-4, wherein the VL comprises the amino acid sequence of
  • VH comprises the amino acid sequence of
  • SEQ ID NO: 144-SEQ ID NO:59-SEQ ID NO: 145-SEQ ID NO: 146-SEQ ID NO: 147 SEQ ID NO:160-SEQ ID NO:59-SEQ ID NO: 145-SEQ ID NO:177-SEQ ID NO: 163, SEQ ID NO:160-SEQ ID NO:59-SEQ ID NO: 145-SEQ ID NO:193-SEQ ID NO: 194, SEQ ID NO:160-SEQ ID NO:59-SEQ ID NO:161-SEQ ID NO:162-SEQ ID NO: 163, or SEQ ID NO:226-SEQ ID NO:227-SEQ ID NO:228-SEQ ID NO:229-SEQ ID NO:230.
  • Embodiment 6 provides the monoclonal antibody of any one of Embodiments 1-5, wherein the VL comprises the amino acid sequence of:
  • VH comprises the amino acid sequence of:
  • Embodiment 7 provides the monoclonal antibody of any one of Embodiments 1-5, wherein the VL comprises the amino acid sequence of:
  • VH comprises the amino acid sequence of:
  • Embodiment 8 provides the monoclonal antibody of any one of Embodiments 1-7, which is humanized.
  • Embodiment 9 provides the monoclonal antibody of any one of Embodiments 1-8, which is labeled.
  • Embodiment 10 provides a pharmaceutical composition comprising the monoclonal antibody of any one of Embodiments 1-9 and at least one pharmaceutical excipient.
  • Embodiment 11 provides an isolated polynucleotide comprising at least one of the nucleic acid sequences of SEQ ID NOs:3, 5, 7, 19, 21, 23, 35, 43, 44, 50, 52, 54, 66, 68, 75, 77, 88, 89, 96, 97, 99, 106, 108, 110, 121, 132, 138, 139, 141, 148, 150, 155, 157, 167, 168, 170, 175, 180, 191, 195, 197, 198, 203, 207, 209, 211, 219, 221, 223, 233, 235, and 237.
  • Embodiment 12 provides the isolated polynucleotide of Embodiment 11, comprising: at least one nucleic acid sequence selected from the group consisting of SEQ ID NOs:3,
  • Embodiment 13 provides the isolated polynucleotide of any of Embodiments 11-12, comprising: at least one nucleic acid sequence group selected from the group consisting of:
  • Embodiment 14 provides a method of treating, ameliorating, and/or preventing a synucleopathic disease in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of at least one isolated monoclonal antibody of any one of Embodiments 1-9.
  • Embodiment 15 provides the method of Embodiment 14, wherein the synucleopathic disease is at least one from the group consisting of Parkinson's disease, Parkinson's disease with dementia, dementia with Lewy bodies, Alzheimer's disease, Down's syndrome, multiple- system atrophy, prion diseases, and other ⁇ -Syn related neurodegenerative disorders.
  • the synucleopathic disease is at least one from the group consisting of Parkinson's disease, Parkinson's disease with dementia, dementia with Lewy bodies, Alzheimer's disease, Down's syndrome, multiple- system atrophy, prion diseases, and other ⁇ -Syn related neurodegenerative disorders.
  • Embodiment 16 provides the method of any one of Embodiments 14-15, wherein the antibody is provided to the subject as a pharmaceutical composition.
  • Embodiment 17 provides the method of any one of Embodiments 14-16, wherein the antibody is administered parenterally to the subject.
  • Embodiment 18 provides a method of detecting a synucleopathic disease in a subject, the method comprising administering to the subject at least one labeled isolated monoclonal antibody of any one of Embodiments 1-9, and detecting presence or absence of a complex of the labeled isolated monoclonal antibody with any ⁇ -Syn fibrils, oligomers, and/or other misfolded ⁇ -Syn species present in the subject, wherein, if the complex is detected, the subject has a synucleopathic disease.
  • Embodiment 19 provides a method of detecting total ⁇ -Syn, ⁇ -Syn fibrils and/or ⁇ - Syn oligomeric species in a sample, the method comprising contacting the sample with at least one labeled isolated monoclonal antibody of any one of Embodiments 1-9, and detecting presence or absence of a complex of the labeled isolated monoclonal antibody with total ⁇ - Syn, ⁇ -Syn monomer, ⁇ -Syn fibrils, and/or ⁇ -Syn oligomeric species present in the sample, wherein, if the complex is detected, total ⁇ -Syn, ⁇ -Syn monomers, ⁇ -Syn fibrils and/or ⁇ -Syn oligomeric species are present in the sample.
  • Embodiment 20 provides the method of Embodiment 19, wherein the sample comprises an in vitro and/or ex vivo sample.
  • Embodiment 21 provides an autonomously replicating or an integrative mammalian cell vector comprising a recombinant nucleic acid encoding an antibody comprising a light chain variable region (VL) and a heavy chain variable region (VH), wherein the VL comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO:27, 46, 70, 114, 126, 185, 213, or 240; a CDR2 region comprising the amino acid sequence of SEQ ID NO:29, 72, 116, 214, or 242; and a CDR3 region comprising the amino acid sequence of SEQ ID NO:31, 85, 118, 129, 152, 205, 216, or 244; and wherein the VH comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO: 11, 58, 92, 101, 144, 160, or 226; a CDR2 region comprising the amino acid sequence of SEQ ID NO: 13, 40, 60, 93, 102
  • Embodiment 22 provides the cell vector of Embodiment 21, which comprises a plasmid or a virus.
  • Embodiment 23 provides the cell vector of any one of Embodiments 21-22, which comprises a mammalian cell expression vector.
  • Embodiment 24 provides the cell vector of any one of Embodiments 21-23, further comprising at least one nucleic acid sequence that directs and/or controls expression of the antibody.
  • Embodiment 25 provides an isolated host cell comprising at least one vector of any one of Embodiments 21-24.
  • Embodiment 26 provides the host cell of Embodiment 25, which is a non-human cell.
  • Embodiment 27 provides the cell vector of any one of Embodiments 25-26, which is mammalian.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present disclosure provides monoclonal antibodies that bind α-Synuclein. In certain aspects, the antibodies preferentially bind to α-Synuclein fibrils over α-Synuclein monomer. In other aspects, the disclosure provides a method of treating, ameliorating, and/or preventing α-Synucleopathic disease in a subject, comprising administering any one of the antibodies of the disclosure to the subject. In yet other aspects, the disclosure provides methods of detecting α-Synuclein fibrils using any one of the antibodies of the disclosure.

Description

TITLE
Anti-Alphα-Synuclein Monoclonal Antibodies, and Methods Using Same
CROSS-REFERENCE TO RELATED APPLICATIONS
This application claims priority under 35 U.S.C. § 119(e) to U.S. Provisional Patent Application No. 62/937,636 filed November 19, 2019, which is hereby incorporated by reference in its entirety herein.
STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR
DEVELOPMENT
This invention was made with government support under grant numbers T32- AG000255, P30-AG10124, P50-NS053488, and R01-NS088322 awarded by National Institutes of Health (NIH). The government has certain rights in the invention.
BACKGROUND OF THE DISCLOSURE
Parkinson's disease (PD) is a progressive neurodegenerative disease that affects 1% of the worldwide population but has no disease-modifying treatments. Even the most efficacious dopamine replacement therapy does not prevent disease progression, including the development of dementia which occurs in up to 80 percent of cases. Motor symptoms that are characteristic of the disease are often preceded by non-motor symptoms, including constipation, sleep disturbances, and olfactory dysfunction, and are often followed by cognitive decline, which can lead to a diagnosis of PD dementia (PDD). Dementia with Lewy bodies (DLB) bears symptom and pathology overlap with PD and PDD, suggesting that these three disorders lie along a spectrum of neurodegenerative diseases collectively known as α-synucleinopathies due to the abnormal accumulation of normally synaptic α-Synuclein protein into neuronal Lewy bodies (LBs) and axonal Lewy neurites (LNs). α-Synuclein is not merely a bystander in these diseases since rare mutations, duplications, and triplications of α- Synuclein lead to familial PD.
The progression of symptoms from manageable to debilitating corresponds with the burden of α-Synuclein pathology in higher cortical regions of the brain. Overexpression of α- Synuclein in mice with or without familial mutations is sufficient to drive the formation of LB-like inclusions and neurodegeneration. Further, reduction in α-Synuclein levels has a beneficial effect in neurotoxin-induced models of PD. Together, these studies suggest that a reduction of α-Synuclein, especially misfolded forms, may be a therapeutic strategy for treatment of PD and related α-synucleinopathies. Because α-Synuclein is primarily localized in the neuronal cytoplasm, it has been assumed that therapeutic molecules would need to cross not only the blood-brain-barrier (BBB), but also the neuronal plasma membrane, to interact with α-Synuclein. However, a number of recent in vitro and in vivo studies suggest that misfolded α-Synuclein species are released by neurons and can be taken up by nearby neurons, inducing the transcellular transmission of pathogenic α-Synuclein. Thus, minimizing the impact of this pool of extracellular, pathogenic α-Synuclein provides a unique and more easily accessed therapeutic opportunity for the treatment of PD, especially if pathological α-Synuclein is also present in the peripheral areas such as the enteric nervous system.
There are a number of potential approaches to inhibit the transmission of α-Synuclein pathology. For example, extracellular α-Synuclein could be targeted for vascular or glymphatic clearance, its uptake could be blocked, or glial cells could be modified to promote clearance of extracellular α-Synuclein. At least some of these possible mechanisms might be facilitated through antibody-mediated immunotherapy. For example, antibodies might block neuronal α-Synuclein uptake while also promoting glymphatic clearance to the periphery or glial clearance through binding to surface Fc receptors. Passive immunotherapy (treatment directly with antibodies, instead of injection of an immunogen) is a particularly attractive option because therapeutic antibodies have been demonstrated to be relatively safe and immunotherapy has been shown to promote clearance of extracellular targets. Sufficient brain levels of the administered antibody have to be achieved to affect disease biology, but antibodies are known to have poor BBB penetration.
There is a need for developing anti-α-Syn antibodies that can be used to investigate neuropathological features of PD and related disorders. In certain embodiments, these antibodies can be used in the treatment of these diseases. This disclosure addresses and meets those needs.
BRIEF SUMMARY OF THE DISCLOSURE The present disclosure provides certain monoclonal antibodies comprising a light chain variable region (VL) and a heavy chain variable region (VH), as defined elsewhere herein. The present disclosure further provides pharmaceutical compositions comprising at least one monoclonal antibody contemplated herein and at least one pharmaceutical excipient. The present disclosure further provides certain isolated polynucleotides comprising at least one of the nucleic acid sequences contemplated herein. The present disclosure further provides autonomously replicating or integrative mammalian cell vectors comprising at least one recombinant nucleic acid encoding at least one antibody comprising a light chain variable region (VL) and a heavy chain variable region (VH), as defined elsewhere herein. The present disclosure further provides isolated host cells comprising any of the vectors contemplated herein.
The present disclosure further provides methods of treating, ameliorating, and/or preventing a synucleopathic disease in a subject. In certain embodiments, the method comprises administering to the subject a therapeutically effective amount of at least one isolated monoclonal antibody contemplated herein.
The present disclosure further provides methods of detecting a synucleopathic disease in a subject. In certain embodiments, the method comprises administering to the subject at least one labeled isolated monoclonal antibody contemplated herein. In certain embodiments, the method comprises detecting presence or absence of a complex of the labeled isolated monoclonal antibody with any α-Syn fibrils, oligomers, and/or other misfolded α-Syn species present in the subject. In certain embodiments, if the complex is detected, the subject has a synucleopathic disease.
The present disclosure further provides methods of detecting total α-Syn, α-Syn fibrils, and/or α-Syn oligomeric species in a sample. In certain embodiments, the method comprises contacting the sample with at least one labeled isolated monoclonal antibody contemplated herein. In certain embodiments, the method comprises detecting presence or absence of a complex of the labeled isolated monoclonal antibody with total α-Syn, α-Syn monomer, α-Syn fibrils, and/or α-Syn oligomeric species present in the sample. In certain embodiments, if the complex is detected, total α-Syn, α-Syn monomers, α-Syn fibrils, and/or α-Syn oligomeric species are present in the sample.
BRIEF DESCRIPTION OF THE DRAWINGS
The following detailed description of specific embodiments of the disclosure will be better understood when read in conjunction with the appended drawings. For the purpose of illustrating the disclosure, the drawings show specific embodiments. It should be understood, however, that the disclosure is not limited to the precise arrangements and instrumentalities of the embodiments shown in the drawings.
FIGs. 1A-1F comprise a passive immunotherapy screen schematic. FIG. 1A: Mice were immunized with α-Synuclein pre-formed fibrils (PFFs) to induce an immune response and production of antibodies against pathogenic α-Synuclein. FIG. IB: Antibody producing B cells were subsequently harvested from the spleen of immunized mice and fused with myeloma cells to produce hybridoma clonal cell lines expressing antibodies against α- Synuclein. FIG. 1C: Hybridomas were separated into individual clonal populations and the antibody-containing supernatant from each clone was passed through a primary screen to identify candidates with preferred properties. To confirm that antibodies would recognize pathogenic human α-Synuclein, antibodies were used in IHC of human tissue. In certain nonlimiting embodiments, candidate antibodies also have a preference for fibrillar α-Synuclein, so they were screened in an indirect ELISA format for monomeric and fibrillar α-Synuclein. Each antibody was epitope mapped and tested for immunogenicity against mouse and human α-Synuclein so it could be utilized in a mouse disease model. Finally, antibodies were screened in a primary neuron immunotherapy assay for their ability to reduce α-Synuclein pathology in cultured neurons. FIG. ID: Prioritized antibodies underwent a further two rounds of subcloning to ensure monoclonality. FIG. IE: Final clones underwent confirmation screening to ensure they maintained optimal properties and to identify a final candidate for the in vivo experiment. FIG. IF: A non-limiting candidate antibody was tested in a mouse model of PD for its ability to reduce α-Synuclein pathology and toxicity. The candidate was tested alongside and IgG control and an α-Synuclein antibody with proven therapeutic efficacy.
FIGs. 2A-2B illustrate non-limiting immunohistochemistry results that reveal antibodies that preferentially bind LBs. FIG. 2A: Sections of amygdala tissue containing abundant Lewy body pathology were stained using undiluted or 1 :3 diluted hybridoma supernatant. Representative staining of Lewy bodies is shown for each of the screened antibody supernatants. Scale bar=50 μm. FIG. 2B: The optical density within Lewy bodies divided by the optical density of a 1 mm2 tissue section containing those Lewy bodies was defined as the Lewy Body Discrimination Index. Antibodies preferentially recognizing Lewy bodies score high on this measure. Most antibodies showed some enhanced recognition of Lewy bodies, with the exception of those antibodies scoring below 1.5, which show little apparent preference for Lewy bodies above neuropil α-Synuclein staining.
FIGs. 3A-3C illustrate non-limiting epitope mapping that ensures that certain antibodies recognize human and mouse α-Synuclein. FIG. 3 A: Schematic of recombinant α- Synuclein fragments used to determine the epitope of the 9000 series antibodies. Full-length (FL) α-Synuclein is 140 amino acids with an internal non-amyloid component (NAC) domain. Constructs used for testing epitopes had truncated N- or C-terminal human α- Synuclein residues. FIG. 3B: Most antibodies recognized both human and mouse α- Synuclein to some extent. Further, all antibodies recognized α-Synuclein with truncated N- termini, suggesting that they all recognize the C-terminus of α-Synuclein. The most extreme of these did not recognize α-Synuclein if even the last 10 amino acids were not included, suggesting that the epitope is between aa 130-140. Many other antibodies recognized 1-130, but not 1-120, suggesting they have an epitope between 120-130. FIG. 3C: Another large batch of antibodies did not recognize 1-110, suggesting they recognize 110-120. Finally, there were several antibodies that recognized all constructs except 1-89, suggesting the epitope lies between amino acids 90-102. *Peptide 1-110 was loaded in the last lane of these gels, thereby shifting the lanes leftward.
FIGs. 4A-4C illustrate a non-limiting sandwich ELISA that identifies antibodies with a preference for misfolded α-Synuclein. Antibodies were assessed for a preference for misfolded α-Synuclein by performing parallel sandwich ELISAs with either human α- Synuclein monomer or α-Synuclein PFFs as the antigen. Syn211 was also used on each plate as a non-selective control antibody. Using this method, three classes of antibodies were distinguished — (FIG. 4A) antibodies that did not bind in this assay and thus did not have a signal for either monomer or PFF; (FIG. 4B) antibodies that are non-selective and have a similar binding to α-Synuclein monomer and PFF; and (FIG. 4C) antibodies that are PFF- selective, showing a markedly higher preference for α-Synuclein PFF than monomer. The histograms shown are representative of the three classes, but all antibodies tested can be classified in one of these categories. Plots represent the means from 3 technical replicates, and error bars represent standard error.
FIGs. 5A-5B illustrate a non-limiting neuron immunotherapy assay that reveals differential potency of α-Synuclein antibodies to prevent LB-like pathology. FIG. 5A: Examples of pS129 α-Synuclein pathology (green) and NeuN (magenta) immunostaining following treatment of primary neurons with α-Synuclein PFFs and the noted representative antibodies. Scale bar=50 μm. FIG. 5B: Quantification of pS 129 α-Synuclein area/neuron number normalized to IgG-treated neurons. Antibodies had varying effects on α-Synuclein pathology and are ranked from least to most effective. Twenty-one of the antibodies showed statistically-significant reductions in pathology (Kruskal-Wallis test with Dunn's multiple comparisons test: *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001). N=6-20/condition.
Error bars represent standard error.
FIGs. 6A-6B comprise a summary of antibody characteristics, shown as a heat map with the scale bars shown at the top of each column. Antibodies are mostly from IgG subclasses. Most antibodies recognize mouse α-Synuclein, and all antibodies recognize human α-Synuclein. The LB discrimination index, derived from immunohistochemistry reflects the ability of antibodies to bind selectively to LB α-Synuclein. The α-Synuclein PFF preference is derived from sandwich ELISA results and spanned over 100-fold differences to allow for selection of antibodies that have a preference for misfolded α-Synuclein (NB = non- binding). Finally, the % inhibition measure, derived from the primary neuron assay, indicates antibody ability to reduce pathology in a cellular system. In certain embodiments, an antibody of interest recognizes both mouse and human α-Synuclein, discriminate LBs from surrounding neuropil, have higher binding affinity for α-Synuclein PFFs than monomer, and inhibit nearly all in vitro neuronal α-Synuclein pathology. Based on these measures,
Syn9048 and Syn9063 were chosen for further subcloning.
FIGs. 7A-7D illustrate non-limiting subclones, which retain properties of parent clones. FIG. 7A: Syn9063 subclones were assayed for PFF preference as previously described to ensure that all subclones showed the same selectivity as the parent clone. All but one of the subclones showed a high preference for α-Synuclein PFFs. FIG. 7B: All Syn9048 subclones showed similar selectivity for α-Synuclein PFFs. Plots in panels (FIG.
7 A) and (FIG. 7B) represent the means from 3 technical replicates, and error bars represent standard error. FIG. 7C: Examples of pS129 α-Synuclein pathology (green) and NeuN (magenta) immunostaining following treatment of primary neurons with α-Synuclein PFFs and the noted molar ratios of purified Syn9048 clone #3 to α-Synuclein monomer. Scale bar=50 μm. FIG. 7D: Quantification of pS129 α-Synuclein area/neuron number normalized to control IgG-treated neurons. Increasing molar ratios of Syn9048 reduced pS129 α- Synuclein pathology in a dose-dependent manner and is fit by a sigmoidal dose curve with an IC50 of 0.006 (R2=0.9539). N=3 /condition. Error bars represent standard error and the shaded area represents the 95% confidence interval of the sigmoidal fit.
FIGs. 8A-8G illustrate that in vivo immunotherapy is well-tolerated and improves dopaminergic tone. FIG. 8 A: Wild-type mice were injected with α-Synuclein PFFs in the dorsal striatum at 2-3 month of age. One week after α-Synuclein PFF injection, mice were injected with 30 mg/kg control IgGl, Syn303 or Syn9048. Mice were injected once weekly thereafter for 6 months, after which mice were sacrificed and assayed for pathology and motor behavior. FIG. 8B: Average weight for mice in each antibody treatment group with standard error represented in shaded bands. Weights increased over time, but were not different by group (Two-way ANOVA: Time p=0.0001; Treatment p=0.7209). N=16/group. Error bars represent standard error. FIG. 8C: Representative images of the SN stained with TH from mice treated with control IgGl, Syn303 or Syn9048. Scale bars = 500 μm. FIG. 8D: Estimated TH+ neurons in the SN following manual quantification of neurons through the SN (C=contralateral; I=ipsilateral). Substantial neuron loss was observed ipsilateral to the injection site for all groups (Two-way ANOVA with Sidak's multiple comparisons test, contra vs. ipsi: IgGl pO.OOOl; Syn303 p<0.0001; Syn9048 pO.OOOl), but was not different between groups (Two-way ANOVA with Sidak's multiple comparisons test Ipsi: IgGl vs. Syn303 p=0.6266, IgGl vs. Syn9048 p=0.3561). N=10-16/group. FIG. 8E: The ratio of neurons remaining on the ipsilateral SN to the contralateral SN similarly showed no difference between groups (One-way ANOVA with Dunnetf s multiple comparison test: IgGl vs. Syn303 p=0.6323, IgGl vs. Syn9048 p=0.9084). FIG. 8F: Dopamine levels measured from the dorsal striatum of injected mice were reduced ipsilateral to the injection site in IgGl -treated animals, but were preserved in Syn9048-treated mice (One-way ANOVA with Dunnetf s multiple comparison test: IgGl vs. Naive p=0.0283; IgGl vs. Syn303 p=0.9791; IgGl vs. Syn9048 p=0.0047). N=7-12/group. FIG. 8G: DOP AC levels were similarly preserved by Syn9048 treatment (One-way ANOVA with Dunnetf s multiple comparison test: IgGl vs. Naive p=0.0469; IgGl vs. Syn303 p=0.9969; IgGl vs. Syn9048 p=0.0049). N=7- 12/group. Error bars represent standard error.
FIGs. 9A-9F illustrate that Syn9048 reduces α-Synuclein pathology in the SN and Amygdala. FIG. 9A: Mice injected with α-Synuclein PFFs accumulate substantial α- Synuclein pathology in the ipsilateral SN, as recognized by the conformation-selective antibody Syn506. Rare pathology is also observed in the contralateral SN at this time point. Scale bars=100 μm. FIG. 9B: Syn506+ area/section was quantified throughout the contralateral SN, and was substantially, albeit not significantly, reduced (One-way ANOVA with Dunnetf s multiple comparison test: IgGl vs. Syn303 p=0.0827; IgGl vs. Syn9048 p=0.0847). N=14-16/group. FIG. 9C: α-Synuclein pathology was also reduced with immunotherapy treatment in the ipsilateral SN (One-way ANOVA with Dunnett's multiple comparison test: IgGl vs. Syn303 p=0.0937; IgGl vs. Syn9048 p=0.0444). N=14-16/group. FIG. 9D: Mice injected with α-Synuclein PFFs accumulate substantial α-Synuclein pathology in the ipsilateral and contralateral amygdala, as recognized by the conformation- selective antibody Syn506. Scale bars= 100 μm. FIG. 9E: Syn506+ area/section was quantified throughout the contralateral amygdala, and was substantially reduced (One-way ANOVA with Dunnett's multiple comparison test: IgGl vs. Syn303 p=0.0521; IgGl vs. Syn9048 p=0.0069). N=14-16/group. FIG. 9F: α-Synuclein pathology was not reduced to the same extent in the ipsilateral amygdala (One-way ANOVA with Dunnett's multiple comparison test: IgGl vs. Syn303 p=0.8694; IgGl vs. Syn9048 p=0.2464). N=14-16/group. All points represent individual mice and error bars represent standard error.
FIG. 10 illustrates non-limiting recognition of b-Synuclein. Most antibodies did not recognize b-Synuclein by Western blot. Syn9030 and Syn9066 had slight reactivity with b- Synuclein, indicating some cross-reactivity of these antibodies. Syn7015 is used as a positive control since this antibody cross-reacts with b-Synuclein.
FIGs. 11 A-11B illustrate a non-limiting sandwich ELISA that identifies non-binding antibodies. Antibodies were assessed for a preference for misfolded α-Synuclein by performing parallel sandwich ELIS As with either α-Synuclein monomer or α-Synuclein PFFs as the antigen. Syn211 was also used on each plate as a non-selective control antibody. This figure displays antibodies which were non-binding in this assay. Plots represent the means from 3 technical replicates, and error bars represent standard error.
FIGs. 12A-12B illustrate a non-limiting sandwich ELISA that identifies non-selective antibodies. Antibodies were assessed for a preference for misfolded α-Synuclein by performing parallel sandwich ELIS As with either α-Synuclein monomer or α-Synuclein PFFs as the antigen. Syn211 was also used on each plate as a non-selective control antibody. This figure displays antibodies which were non-selective in this assay. Plots represent the means from 3 technical replicates, and error bars represent standard error.
FIGs. 13A-13B illustrate a non-limiting sandwich ELISA that identifies α-Synuclein PFF-selective antibodies. Antibodies were assessed for a preference for misfolded α- Synuclein by performing parallel sandwich ELISAs with either α-Synuclein monomer or α- Synuclein PFFs as the antigen. Syn211 was also used on each plate as a non-selective control antibody. This figure displays antibodies which showed a preference for α-Synuclein PFFs in this assay. Plots represent the means from 3 technical replicates, and error bars represent standard error.
FIG. 14 illustrates a non-limiting second sandwich ELISA that confirms α-Synuclein PFF-selective antibodies. Antibodies were assessed for a preference for misfolded α- Synuclein by performing second set of parallel sandwich ELISAs with either α-Synuclein monomer or α-Synuclein PFFs as the antigen and the polyclonal α-Synuclein antibody SNL4. Plots represent the means from 3 technical replicates, and error bars represent standard error.
FIG. 15 illustrates that Syn9048 prevents α-Synuclein pathology induced by mouse α- Synuclein PFFs. Syn9048 was assayed for its ability to prevent α-Synuclein pathology induced by mouse α-Synuclein in neurons. Primary hippocampal neurons were cultured as previously described and treated with mouse α-Synuclein PFFs concurrently with increasing concentrations of Syn9048. Quantification of pS129 α-Synuclein area/neuron number normalized to IgG treatment is shown. Increasing molar ratios of Syn9048 reduced pS129 α- Synuclein pathology in a dose-dependent manner and is fit by a sigmoidal dose curve with an IC50 of 0.004 (R2=0.8026). N=3 /condition. Error bars represent standard error and the shaded area represents the 95% confidence interval of the sigmoidal fit.
DETAILED DESCRIPTION OF THE DISCLOSURE
Definitions
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the disclosure pertains. Although any methods and materials similar or equivalent to those described herein can be used in the practice for testing of the present disclosure, ilustrative materials and methods are described herein. In describing and claiming the present disclosure, the following terminology will be used. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting.
As used herein, each of the following terms has the meaning associated with it in this section.
Unless defined otherwise, all technical and scientific terms used herein generally have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. Generally, the nomenclature used herein and the laboratory procedures in cell culture, molecular genetics, analytical chemistry, immunology, and nucleic acid chemistry and hybridization are those well-known and commonly employed in the art. Standard techniques or modifications thereof are used for chemical syntheses and chemical analyses.
The articles "a" and "an" are used herein to refer to one or to more than one (i.e. to at least one) of the grammatical object of the article. By way of example, "an element" means one element or more than one element.
As used herein, the term "α-Synuclein" or "α-Syn" or "α-syn" refers to a protein that is expressed mainly in brain tissues and is primarily located at the presynpatic terminal of neurons. In certain embodiments, the disclosure contemplates human α-Syn, which has the sequence SEQ ID NO:245:
10 20 30 40 50
MDVFMKGLSK AKEGVVAAAE KTKQGVAEAA GKTKEGVLYV GSKTKEGVVH 60 70 80 90 100
GVATVAEKTK EQVTNVGGAV VTGVTAVAQK TVEGAGSIAA ATGFVKKDQL
110 120 130 140
GKNEEGAPQE GILEDMPVDP DNEAYEMPSE EGYQDYEPEA
As used herein, the term "α-Syn" refers to total α-Syn, α-Syn monomers, α-Syn fibrils, and/or α-Syn oligomers. As used herein, a α-Syn oligomer refers to any multimeric assembly of α-Syn comprising two or more α-Syn monomers.
As used herein, the term "about" will be understood by persons of ordinary skill in the art and will vary to some extent on the context in which it is used. As used herein when referring to a measurable value such as an amount, a concentration, a temporal duration, and the like, the term "about" is meant to encompass variations of ±20% or ±10%, more preferably ±5%, even more preferably ±1%, and still more preferably ±0.1% from the specified value, as such variations are appropriate to perform the disclosed methods.
As used herein, the term "affinity" for a molecule towards another refers to the degree (or tightness) of binding between the two molecules. A higher affinity means tighter binding between the two molecules. Affinity can be quantified in terms of dissociation constant (or Kd), where a Kd value that is lower in magnitude (closer to zero) indicates a higher affinity.
An "amino acid" as used herein is meant to include both natural and synthetic amino acids, and both D and L amino acids. "Standard amino acid" means any of the twenty L- amino acids commonly found in naturally occurring peptides. "Nonstandard amino acid residues" means any amino acid, other than the standard amino acids, regardless of whether it is prepared synthetically or derived from a natural source. As used herein, "synthetic amino acid" also encompasses chemically modified amino acids, including but not limited to salts, amino acid derivatives (such as amides), and substitutions. Amino acids contained within the peptides, and particularly at the carboxy- or amino-terminus, can be modified by methylation, amidation, acetylation or substitution with other chemical groups which can change a peptide's circulating half-life without adversely affecting activity of the peptide.
Additionally, a disulfide linkage may be present or absent in the peptides.
The term "antibody," as used herein, refers to an immunoglobulin molecule able to specifically bind to a specific epitope on an antigen. Antibodies can be intact immunoglobulins derived from natural sources or from recombinant sources and can be immunoreactive portions of intact immunoglobulins. Antibodies are typically tetramers of immunoglobulin molecules. The antibodies in the present disclosure may exist in a variety of forms including, for example, polyclonal antibodies, monoclonal antibodies, intracellular antibodies ("intrabodies"), Fv, Fab and F(ab)2, as well as single chain antibodies (scFv), camelid antibodies and humanized antibodies (Harlow etal. , 1999, Using Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, NY; Harlow et al ., 1989, Antibodies: A Laboratory Manual, Cold Spring Harbor, New York; Houston et al ., 1988, Proc. Natl. Acad. Sci. USA 85:5879-5883; Bird etal., 1988, Science 242:423-426). As used herein, a "neutralizing antibody" is an immunoglobulin molecule that binds to and blocks the biological activity of the antigen.
The term "antigen" or "Ag" as used herein is defined as a molecule that provokes an immune response. This immune response may involve either antibody production, or the activation of specific immunologically-competent cells, or both. The skilled artisan will understand that any macromolecule, including virtually all proteins or peptides, can serve as an antigen. Furthermore, antigens can be derived from recombinant or genomic DNA. A skilled artisan will understand that any DNA, which comprises a nucleotide sequences or a partial nucleotide sequence encoding a protein that elicits an immune response therefore encodes an "antigen" as that term is used herein. Furthermore, one skilled in the art will understand that an antigen need not be encoded solely by a full length nucleotide sequence of a gene. It is readily apparent that the present disclosure includes, but is not limited to, the use of partial nucleotide sequences of more than one gene and that these nucleotide sequences are arranged in various combinations to elicit the desired immune response. Moreover, a skilled artisan will understand that an antigen need not be encoded by a "gene" at all. It is readily apparent that an antigen can be generated or synthesized, or can be derived from a biological sample. Such a biological sample can include, but is not limited to a tissue sample, a tumor sample, a cell or a biological fluid.
A "coding region" of a gene consists of the nucleotide residues of the coding strand of the gene and the nucleotides of the non-coding strand of the gene that are homologous with or complementary to, respectively, the coding region of an mRNA molecule produced by transcription of the gene.
A "coding region" of an mRNA molecule also consists of the nucleotide residues of the mRNA molecule that are matched with an anti-codon region of a transfer RNA molecule during translation of the mRNA molecule or that encode a stop codon. The coding region may thus include nucleotide residues corresponding to amino acid residues not present in the mature protein encoded by the mRNA molecule ( e.g ., amino acid residues in a protein export signal sequence).
"Complementary" as used herein to refer to a nucleic acid, refers to the broad concept of sequence complementarity between regions of two nucleic acid strands or between two regions of the same nucleic acid strand. It is known that an adenine residue of a first nucleic acid region is capable of forming specific hydrogen bonds ("base pairing") with a residue of a second nucleic acid region which is antiparallel to the first region if the residue is thymine or uracil. Similarly, it is known that a cytosine residue of a first nucleic acid strand is capable of base pairing with a residue of a second nucleic acid strand which is antiparallel to the first strand if the residue is guanine. A first region of a nucleic acid is complementary to a second region of the same or a different nucleic acid if, when the two regions are arranged in an antiparallel fashion, at least one nucleotide residue of the first region is capable of base pairing with a residue of the second region. Preferably, the first region comprises a first portion and the second region comprises a second portion, whereby, when the first and second portions are arranged in an antiparallel fashion, at least about 50%, and preferably at least about 75%, at least about 90%, or at least about 95% of the nucleotide residues of the first portion are capable of base pairing with nucleotide residues in the second portion. More preferably, all nucleotide residues of the first portion are capable of base pairing with nucleotide residues in the second portion.
The term "delivery vehicle" is used herein as a generic reference to any delivery vehicle capable of delivering a compound to a subject, including, but not limited to, dermal delivery vehicles and transdermal delivery vehicles.
The term "DNA" as used herein is defined as deoxyribonucleic acid.
"Effective amount" or "therapeutically effective amount" are used interchangeably herein, and refer to an amount of a compound, formulation, material, or composition, as described herein, effective to achieve a particular biological result. Such results may include, but are not limited to, treatment of a disease or condition as determined by any means suitable in the art.
"Encoding" refers to the inherent property of specific sequences of nucleotides in a polynucleotide, such as a gene, a cDNA, or an mRNA, to serve as templates for synthesis of other polymers and macromolecules in biological processes having either a defined sequence of nucleotides (i.e., rRNA, tRNA and mRNA) or a defined sequence of amino acids and the biological properties resulting therefrom. Thus, a gene encodes a protein if transcription and translation of mRNA corresponding to that gene produces the protein in a cell or other biological system. Both the coding strand, the nucleotide sequence of which is identical to the mRNA sequence and is usually provided in sequence listings, and the non-coding strand, used as the template for transcription of a gene or cDNA, can be referred to as encoding the protein or other product of that gene or cDNA.
As used herein, the term "fragment," as applied to a protein or peptide, refers to a subsequence of a larger protein or peptide. A "fragment" of a protein or peptide can be at least about 20 amino acids in length; for example at least about 50 amino acids in length; at least about 100 amino acids in length, at least about 200 amino acids in length, at least about 300 amino acids in length, and at least about 400 amino acids in length (and any integer value in between). As used herein, an antibody fragment refers to active fragments thereof, i.e., fragments having the same characteristics that are used for the definition of an antibody according to the disclosure, in certain embodiments high affinity for α-Syn fibrils (composed of misfolded α-Syn) and low or high binding affinity to α-Syn monomers. For convenience when the term antibody is used, fragments thereof exhibiting the same characteristic are also being considered.
As used herein, the term "fragment," as applied to a nucleic acid, refers to a subsequence of a larger nucleic acid. A "fragment" of a nucleic acid can be at least about 15 nucleotides in length; for example, at least about 50 nucleotides to about 100 nucleotides; at least about 100 to about 500 nucleotides, at least about 500 to about 1000 nucleotides, at least about 1000 nucleotides to about 1500 nucleotides; or about 1500 nucleotides to about 2500 nucleotides; or about 2500 nucleotides (and any integer value in between).
Conventional notation is used herein to describe polynucleotide sequences: the left- hand end of a single-stranded polynucleotide sequence is the 5'-end; the left-hand direction of a double-stranded polynucleotide sequence is referred to as the 5'-direction.
The direction of 5' to 3' addition of nucleotides to nascent RNA transcripts is referred to as the transcription direction. The DNA strand having the same sequence as an mRNA is referred to as the "coding strand"; sequences on the DNA strand which are located 5' to a reference point on the DNA are referred to as "upstream sequences"; sequences on the DNA strand which are 3' to a reference point on the DNA are referred to as "downstream sequences."
An "individual", "patient" or "subject", as that term is used herein, includes a member of any animal species including, but are not limited to, birds, humans and other primates, and other mammals including commercially relevant mammals such as cattle, pigs, horses, sheep, cats, and dogs. Preferably, the subject is a human.
"Instructional material," as that term is used herein, includes a publication, a recording, a diagram, or any other medium of expression which can be used to communicate the usefulness of the composition and/or compound of the disclosure in a kit. The instructional material of the kit may, for example, be affixed to a container that contains the compound and/or composition of the disclosure or be shipped together with a container which contains the compound and/or composition. Alternatively, the instructional material may be shipped separately from the container with the intention that the recipient uses the instructional material and the compound cooperatively. Delivery of the instructional material may be, for example, by physical delivery of the publication or other medium of expression communicating the usefulness of the kit, or may alternatively be achieved by electronic transmission, for example by means of a computer, such as by electronic mail, or download from a website.
"Isolated" means altered or removed from the natural state. For example, a nucleic acid or a peptide naturally present in a living animal is not "isolated," but the same nucleic acid or peptide partially or completely separated from the coexisting materials of its natural state is "isolated." An isolated nucleic acid or protein can exist in substantially purified form, or can exist in a non-native environment such as, for example, a host cell.
An "isolated nucleic acid" refers to a nucleic acid segment or fragment which has been separated from sequences which flank it in a naturally occurring state, i.e., a DNA fragment which has been removed from the sequences which are normally adjacent to the fragment, i.e., the sequences adjacent to the fragment in a genome in which it naturally occurs. The term also applies to nucleic acids which have been substantially purified from other components which naturally accompany the nucleic acid, i.e., RNA or DNA or proteins, which naturally accompany it in the cell. The term therefore includes, for example, a recombinant DNA which is incorporated into a vector, into an autonomously replicating plasmid or virus, or into the genomic DNA of a prokaryote or eukaryote, or which exists as a separate molecule (i.e., as a cDNA or a genomic or cDNA fragment produced by PCR or restriction enzyme digestion) independent of other sequences. It also includes a recombinant DNA which is part of a hybrid gene encoding additional polypeptide sequence.
By "nucleic acid" is meant any nucleic acid, whether composed of deoxyribonucleosides or ribonucleosides, and whether composed of phosphodiester linkages or modified linkages such as phosphotriester, phosphoramidate, siloxane, carbonate, carboxymethylester, acetamidate, carbamate, thioether, bridged phosphoramidate, bridged methylene phosphonate, phosphorothioate, methylphosphonate, phosphorodithioate, bridged phosphorothioate or sulfone linkages, and combinations of such linkages. The term nucleic acid also specifically includes nucleic acids composed of bases other than the five biologically occurring bases (adenine, guanine, thymine, cytosine and uracil). Unless otherwise specified, a "nucleotide sequence encoding an amino acid sequence" includes all nucleotide sequences that are degenerate versions of each other and that encode the same amino acid sequence. The phrase nucleotide sequence that encodes a protein or an RNA may also include introns to the extent that the nucleotide sequence encoding the protein may in some version contain an intron(s).
The term "oligonucleotide" typically refers to short polynucleotides, generally no greater than about 60 nucleotides. It will be understood that when a nucleotide sequence is represented by a DNA sequence (i.e., A, T, G, C), this also includes an RNA sequence (i.e.,
A, U, G, C) in which "U" replaces "T."
As used herein, the term "pharmaceutical composition" refers to a mixture of at least one compound of the disclosure with other chemical components, such as carriers, stabilizers, diluents, dispersing agents, suspending agents, thickening agents, and/or excipients. The pharmaceutical composition facilitates administration of the compound to an organism. Multiple techniques of administering a compound exist in the art including, but not limited to, intravenous, oral, aerosol, parenteral, ophthalmic, pulmonary and topical administration.
"Pharmaceutically acceptable" refers to those properties and/or substances that are acceptable to the patient from a pharmacological/toxicological point of view and to the manufacturing pharmaceutical chemist from a physical/chemical point of view regarding composition, formulation, stability, patient acceptance and bioavailability. "Pharmaceutically acceptable carrier" refers to a medium that does not interfere with the effectiveness of the biological activity of the active ingredient(s) and is not toxic to the host to which it is administered.
The term "polynucleotide" as used herein is defined as a chain of nucleotides. Furthermore, nucleic acids are polymers of nucleotides. Thus, nucleic acids and polynucleotides as used herein are interchangeable. One skilled in the art has the general knowledge that nucleic acids are polynucleotides, which can be hydrolyzed into the monomeric "nucleotides." The monomeric nucleotides can be hydrolyzed into nucleosides. As used herein polynucleotides include, but are not limited to, all nucleic acid sequences which are obtained by any means available in the art, including, without limitation, recombinant means, i.e., the cloning of nucleic acid sequences from a recombinant library or a cell genome, using ordinary cloning technology and PCR™, and the like, and by synthetic means.
As used herein, the terms "protein", "peptide" and "polypeptide" are used interchangeably, and refer to a compound comprised of amino acid residues covalently linked by peptide bonds. The term "peptide bond" means a covalent amide linkage formed by loss of a molecule of water between the carboxyl group of one amino acid and the amino group of a second amino acid. A protein or peptide must contain at least two amino acids, and no limitation is placed on the maximum number of amino acids that may comprise the sequence of a protein or peptide. Polypeptides include any peptide or protein comprising two or more amino acids joined to each other by peptide bonds. As used herein, the term refers to both short chains, which also commonly are referred to in the art as peptides, oligopeptides, and oligomers, for example, and to longer chains, which generally are referred to in the art as proteins, of which there are many types. "Proteins" include, for example, biologically active fragments, substantially homologous proteins, oligopeptides, homodimers, heterodimers, variants of proteins, modified proteins, derivatives, analogs, and fusion proteins, among others. The proteins include natural proteins, recombinant proteins, synthetic proteins, or a combination thereof.
The term "recombinant DNA" as used herein is defined as DNA produced by joining pieces of DNA from different sources.
The term "recombinant polypeptide" as used herein is defined as a polypeptide produced by using recombinant DNA methods.
The term "RNA" as used herein is defined as ribonucleic acid.
The term "therapeutic" as used herein means a treatment and/or prophylaxis.
The term to "treat," as used herein, means reducing the frequency with which symptoms are experienced by a subject or administering an agent or compound to reduce the frequency and/or severity with which symptoms are experienced. As used herein, "alleviate" is used interchangeably with the term "treat."
As used herein, "treating a disease, disorder or condition" means reducing the frequency or severity with which a symptom of the disease, disorder or condition is experienced by a subject. Treating a disease, disorder or condition may or may not include complete eradication or elimination of the symptom.
The following abbreviations are used herein: BBB, blood-brain barrier; CDR, complementary-determining region; DLB, dementia with Lewy bodies; FL, full length; LB, Lewy body; LN, Lewy neurite; MSA, multiple system atrophy; NAC, non-amyloid component; PD, Parkinson's disease; PDD, Parkinson's disease dementia; PFF, pre-formed fibril; VH, heavy chain variable region; VL, light chain variable region.
Ranges: throughout this disclosure, various aspects of the disclosure can be presented in a range format. It should be understood that the description in range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the disclosure. Accordingly, the description of a range should be considered to have specifically disclosed all the possible subranges as well as individual numerical values within that range. For example, description of a range such as from 1 to 6 should be considered to have specifically disclosed subranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6 etc., as well as individual numbers within that range, for example, 1, 2, 2.7, 3, 4, 5, 5.3, and 6. This applies regardless of the breadth of the range.
Description
This disclosure is generally directed to certain monoclonal (mouse) antibodies, or fragments thereof, that recognize certain pathogenic forms of α-Syn, a protein that is misfolded in Parkinson's disease (PD) and related neurodegenerative disorders known as synucleinopathies. PD and dementia with Lewy bodies (DLB) are progressive neurodegenerative diseases for which there is no disease-modifying treatment. PD and DLB are characterized by aggregation of the synaptic protein α-Synuclein, and there is compelling evidence to suggest that progression of these diseases is associated with the transcellular spread of pathogenic α-Synuclein through the brains of afflicted individuals. Therapies targeting extracellular, pathogenic α-Synuclein may therefore hold promise for slowing or halting disease progression.
At the onset of this investigation, it was unclear what the preferred properties are for a therapeutic α-Synuclein antibody. For example, targeting all α-Synuclein species with a pan- α-Synuclein antibody can have deleterious effects in the central nervous system or in the blood, where α-Synuclein is abundant in red blood cells. Moreover, the binding of a pan-α- Synuclein antibody to non-pathogenic forms of the protein would reduce the antibody available for binding to misfolded species.
Previous research has identified several antibodies that are effective in animal models of PD at reducing α-Synuclein aggregates. These antibodies had differing selectivity profiles (α-Synuclein oligomers, C-terminal truncated α-Synuclein, or fibrillar α-Synuclein) and it is currently unclear whether antibodies directed against certain epitopes will be more efficacious than others. As it is generally acknowledged that only -0.1% of administered antibody passes the BBB, there are likely to be benefits to utilizing α-Synuclein antibodies that preferentially bind to pathogenic species and not the α-Synuclein monomer that is present in the brain. This would increase the effective concentration of antibody that could target the α-Synuclein that promotes disease progression, without loss of antibody in non- productive binding to monomers.
In a non-limiting aspect, the present studies were directed to identifying an antibody with high selectivity for pathogenic, misfolded α-Synuclein. After first immunizing mice with misfolded α-Synuclein and creating a library of B-cell hybridomas, antibodies produced by clonal hybridoma cultures were passed through a series of screening assays to select for antibodies that show high selectivity for misfolded α-Synuclein and are able to inhibit the formation of LB-like structures in a primary neuron model of α-synucleinopathy. An illustrative candidate antibody, Syn9048, was tested for efficacy in a wildtype mouse model of pathological α-Synuclein transmission. Chronic 6-month administration of Syn9048 was well-tolerated by mice, and Syn9048 was able to preserve striatal dopamine levels and reduce α-Synuclein pathology, especially in areas where α-Synuclein inclusions likely resulted from transcellular spread of pathogenic α-Synuclein. In all measures, Syn9048 showed improved efficacy over a previously validated α-Synuclein antibody (Tran, etal. , 2014, Cell Reports 7:2054-2065), indicating that Syn9048 has desirable properties for treating, ameliorating, and/or preventing the diseases contemplated herein. This study highlights the therapeutic potential of α-Synuclein immunotherapy for the treatment of PD and DLB, and provides a framework for screening of α-Synuclein antibodies to identify those with desirable properties.
In certain embodiments, the antibodies of the disclosure are highly selective towards pathogenic forms of α-Synuclein and can be administered as therapeutic agents targeting those pathogenic protein forms. In certain embodiments, the antibodies of the disclosure recognize a conformational epitope comprising amino acids 110-120 and/or 120-130 in combination with another region of α-Syn.
In certain embodiments, the antibodies of the disclosure show preferential binding towards the pathological form of α-Syn (i.e., fibrils and/or oligomers) compared to the native (i.e., monomeric) form. In other embodiments, the antibodies of the disclosure reduce formation of pathological α-Syn inclusions/fibrils that normally form in cultured neurons that are exposed to recombinant α-Syn fibrils. In yet other embodiments, the antibodies of the disclosure detect pathological α-Syn fibrils. In yet other embodiments, the antibodies of the disclosure are used as therapeutics for decreasing the development/spread of pathological α- Syn fibrils and/or oligomers in synucleinopathies. In yet other embodiments, the antibodies of the disclosure do not cross-react with Tau and/or betα-amyloid protein.
In certain embodiments, the antibodies of the disclosure bind to α-Syn fibrils and/or oligomers with a dissociation constant Kd equal to or less than about 10-6 M, about 10-7 M, about 10-8 M, about 10-9 M, about 10-10 M, or about 10-11 M. In other embodiments, the antibodies of the disclosure bind to α-Syn monomers with an affinity that at least about 10 times, 30 times, 100 times, 300 times, or 1000 times lower than the affinity of the antibodies for α-Syn fibrils. In yet other embodiments, the antibodies of the disclosure bind to α-Syn monomers with a dissociation constant Kd equal to or higher than about 10-10 M, about 10-9 M, about 10-8 M, about 10-7 M, about 10-6 M, about 10-5 M, about 10-4 M, or about 10-3 M. In yet other embodiments, the antibodies of the disclosure bind with nearly equal affinity to α- Syn fibrils and monomers. In yet other embodiments, the antibodies of the disclosure bind with nearly equal affinity to α-Syn fibrils, oligomers and monomers, with a dissociation constant Kd equal to or less than about 10-7 M, about 10-8 M, about 10-9 M, about 10-10 M, or about 10-11 M. Binding affinities of the antibodies can be determined by using a variety of methods recognized in the art, including methods described elsewhere herein, such as but not limited to isothermal calorimetry, surface plasmon resonance, immunoassays such as ELISA or RIAs, and the like.
Compositions Comprising Antibodies
In one aspect, the disclosure comprises isolated monoclonal antibodies that selectively bind α-Syn in the fibrillar and/or oligomeric conformation, and/or bind both soluble, oligomeric, and fibrillar α-Syn with high affinity. In certain embodiments, the antibody comprises a heavy chain. In other embodiments, the heavy chain comprises three complementary-determining regions (CDR), namely CDR1, CDR2, and CDR3. In yet other embodiments, the light chain comprises three complementary-determining regions (CDR), namely CDR1, CDR2, and CDR3.
In certain embodiments, the monoclonal antibody (named 9003 herein) comprises light and heavy variable chains having the sequences shown below:
Heavy chain: DNA sequence (414 bp)
Signal seauence-FRl-CDRl-FR2-CDR2-FR3-CDR3-FR4
SEQ ID NO: 1 — SEQ ID NO:2 — SEP ID NO:3 — SEQ ID NO:4 — SEP ID NO: 5 — SEQ ID NO:6 — SEP ID NO: 7 — SEQ ID NO:8
ATGCTGTTGGGGCTGAAGTGGGTTTTCTTTGTTGTTTTTTATCAAGGTGTGCATTGTGAGGTGCAGC
TTGTTGAGTCTGGTGGAGGATTGGTGCAACCTAAAGGGTCATTGAAACTCTCATGTGCAGCCTCTGG
ATTCACCTTCAATACCTACGCCATGCACTGGGTCCGCCAGGCTCCAGGAAAGGGTTTGGAATGGGTT
GCTCGCATAAGAAGTGAAAGTAATAATTTTGCAACATATTATGCCGATTCAGTGAAAGACAGTTTCA
CCATCTCCAGAGATGATTCACAAAGCATGC TC TATC TGCAAATGAACAAC TTGAAAAC TGAGGACAC AGCCGTATATTACTGTGTGAGAGGGGGGTTATCTCCCTTTGACTACTGGGGCCAAGGCACCACTCTC
ACAGTCTCCTCA
Heavy chain: Amino acid sequence (138 aa)
Signal peptide-FRl-CDRl-FR2-CDR2-FR3-CDR3-FR4
SEQ ID NO:9 — SEQ ID NO:10 — SEP ID NO: 11 — SEQ ID NO:12 — SEP ID NO: 13
— SEQ ID NO: 14 — SEP ID NO: 15 — SEQ ID NO: 16
MLLGLKWVFFVVFYQGVHCEVQLVESGGGLVQPKGSLKLSCAASGFTFNTYAMHWVRQAPGKGLEWV
ARIRSESNNFATYYADSVKDSFTISRDDSQSMLYLQMNNLKTEDTAVYYCVRGGLSPFDYWGQGTTL
TVSS
Light chain: DNA sequence (384 bp)
Signal seauence-FRl-CDRl-FR2-CDR2-FR3-CDR3-FR4
SEQ ID NO: 17 — SEQ ID NO: 18 — SEP ID NO: 19 — SEQ ID NO:20 — SEO ID NO:21
— SEQ ID NO:22 — SEP ID NO:23 — SEQ ID NO:24
ATGGATTTTCAAGTGCAGATTTTCAGCTTCCTGCTAATCAGTGCCTCAGTCATAATATCCAGAGGAC
AAATTGTTCTCACCCAGTCTCCAGCAATCATGTCTGCATCTCCAGGGGAGAAGGTCACCATGACCTG
CAGTGCCAGCTCAAGTGTAAGTTACATGCACTGGTACCAACAGAAGTCAGGCACCTCCCCCAAAAGA
TGGATTTATGACACTTCCAAACTGGCTTCTGGAGTCCCTGCTCGCTTCAGTGGCAGTGGGTCTGGGA
CCTCTTACTCTCTCACAATCAACAGCATGGAGGCTGAAGATGCTGCCACTTATTACTGCCAGCAGTG
GAGTAGAAATCCACCCACGTTCGGAGGGGGGACCAAGCTGGAAATAAAA
Light chain: Amino acid sequence (128 aa)
Signal peptide-FRl-CDRl-FR2-CDR2-FR3-CDR3-FR4
SEQ ID NO:25 — SEQ ID NO:26 — SEP ID NO:27 — SEQ ID NO:28 — SEP ID NO:29
— SEQ ID NO:30 — SEO ID NO:31 — SEQ ID NO:32
MDFQVQIFSFLLISASVIISRGQIVLTQSPAIMSASPGEKVTMTCSASSSVSYMHWYQQKSGTSPKR WIYDTSKLASGVPARFSGSGSGTSYSLTINSMEAEDAATYYCQQWSRNPPTFGGGTKLEIK
In certain embodiments, the monoclonal antibody (named 9004 herein) comprises light and heavy variable chains having the sequences shown below:
Heavy chain: DNA sequence (426 bp)
Signal seauence-FRl-CDRl-FR2-CDR2-FR3-CDR3-FR4
SEQ ID N0 33 — SEQ ID NO:34 — SEP ID NO:3 — SEQ ID NO:4 — SEP ID NO :35 — SEQ ID NO:36 — SEP ID NO:7 — SEQ ID NO:37
ATGACATTGAACGTGCTGTTGGGGCTGAAGTGGGTTTTCTTTGTTGTTTTTTATCAAGGTGTGCATT
GTGAGGTGCACCTTGTTGAGTCTGGTGGAGGATTGGTGCAGCCTAAAGGGTCATTGAAACTCTCATG
TGCAGCCTCTGGATTCACCTTCAATACCTACGCCATGCACTGGGTCCGCCAGGCTCCAGGAAAGGGT TTGGAATGGGTTGCTCGCATAAGAAGTAAAAGTAATAATTATGCAACATATTATGCCGATTCAGTGA
AAGAC AGGTTCACCATCTCCAGAGATGATTCACAAAGCATGC TC TATC TGCAAATGAACAAC TTGAA AACTGAGGACACAGCCATGTATTACTGTGTGAGAGGGGGGTTATCTCCCTTTGACTACTGGGGCCAA GGCACCACACTCACAGTCTCCTCA Heavy chain: Amino acid sequence (142 aa)
Signal peptide-FRl-CDRl-FR2-CDR2-FR3-CDR3-FR4
SEQ ID NO:38 — SEQ ID NO:39 — SEP ID NO: 11 — SEQ ID NO:12 — SEP ID NQ:40 — SEQ ID NO:41 — SEP ID NO: 15 — SEQ ID NO:16
MTLNVLLGLKWVFFVVFYQGVHCEVHLVESGGGLVQPKGSLKLSCAASGFTFNTYAMHWVRQAPGKG LEWVARIRSKSNNYATYYADSVKDRFTI SRDD SQSMLYLQMNNLKTED TAMY Y CVRGGLSPFDYWGQ GTTLTVSS
Light chain: DNA sequence (384 bp)
Signal seauence-FRl-CDRl-FR2-CDR2-FR3-CDR3-FR4
SEQ ID NO: 17 — SEQ ID NO: 18 — SEP ID NO: 19 — SEQ ID NO:42 — SEP ID NO:43 — SEP ID NO:22 — SEP ID N0 44 — SEP ID NO:45
ATGGATTTTCAAGTGCAGATTTTCAGCTTCCTGCTAATCAGTGCCTCAGTCATAATATCCAGAGGAC
AAATTGTTCTCACCCAGTCTCCAGCAATCATGTCTGCATCTCCAGGGGAGAAGGTCACCATGACCTG CAGTGCCAGCTCAAGTGTAACTTACATGCACTGGTACCAGCAGAAGTCAGGCACCTCCCCCAAAAGA TGGATTTATGACACATCCAAACTGGCTTCTGGAGTCCCTGCTCGCTTCAGTGGCAGTGGGTCTGGGA CCTCTTACTCTCTCACAATCAGCAGCATGGAGGCTGAAGATGCTGCCACTTATTACTGCCAGCAGTG GAGTAGTAACCCACCCACGTTCGGAGGGGGGACCAAGCTGGAAATAAGA Light chain: Amino acid sequence (128 aa)
Signal peptide-FRl-CDRl-FR2-CDR2-FR3-CDR3-FR4
SEQ ID NO:25 — SEQ ID NO:26 — SEP ID NO:46 — SEQ ID NO:28 — SEP ID NO:29 — SEQ ID NO:30 — SEO ID NO:31 — SEQ ID NO:47
MDFQVQIFSFLLISASVIIS RGQIVLTQSPAIMSASPGEKVTMTCSASSSVTYMHWYQQKSGTSPKR WIYDTSKLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCQQWSSNPPTFGGGTKLEIR
In certain embodiments, the monoclonal antibody (named 9005 herein) comprises light and heavy variable chains having the sequences shown below:
Heavy chain: DNA sequence (414 bp)
Signal seauence-FRl-CDRl-FR2-CDR2-FR3-CDR3-FR4
SEQ ID NO:48 — SEQ ID NO:49 — SEQ ID NO:50 — SEQ ID NO:51 — SEP ID NO: 52 — SEQ ID NO:53 — SEP ID NO: 54 — SEQ ID NO:55 ATGAACTTCGGGCTCAGCTTGATTTTCCTTGTCCTTGTTTTAAAAGGTGTCCAGTGTGAAGTGATGC
TGGTGGAGTCTGGGGGAGGCTTAGTGAAGTCTGGAGGGTCCCTAAAACTCTCCTGTGCAGCCTCTGG ATTCACTTTCAGTAGCTATGCCATGTCTTGGGTTCGCCAGACTCCGGAGAAGAGGCTGGAATGGGTC
GCAACTATTAGTACTGGTGGTGGTTACACCTACTATCCAGACAGTGTGAAGGGGCGATTCACCATCT
CCAGAGACAATGCCAAGAACACCCTGTACCTGCAAATGAGCAGTCTGAGGTCTGAGGACACGGCCAT
GTATTATTGTGTAAGAAGGGGGACGGCTAGAGGGTACTTCGATGTCTGGGGCGCAGGGACCACGGTC
ACCGTCTCCTCA
Heavy chain: Amino acid sequence (138 aa)
Signal peptide-FRl-CDRl-FR2-CDR2-FR3-CDR3-FR4
SEQ ID NO:56 — SEQ ID NO:57 — SEO ID NO:58 — SEQ ID NO:59 — SEP ID NO: 60
— SEQ ID NO:61 — SEP ID NO: 62 — SEQ ID NO:63
MNFGLSLIFLVLVLKGVQCEVMLVESGGGLVKSGGSLKLSCAASGFTFSSYAMSWVRQTPEKRLEWV ATISTGGGYTYYPDSVKGRFTISRDNAKNTLYLQMSSLRSEDTAMYYCVRRGTARGYFDVWGAGTTV TVSS
Light chain: DNA sequence (384 bp)
Signal seauence-FRl-CDRl-FR2-CDR2-FR3-CDR3-FR4
SEQ ID NO:64 — SEQ ID NO: 18 — SEP ID NO: 19 — SEQ ID NO:65 — SEP ID NO: 66
— SEQ ID NO:67 — SEP ID NO: 68 — SEQ ID NO:24
ATGGATTTTCAAGTGCAGATTTTCAGCTTCCTGCTAATCAGTGCCTCAGTCATACTGTCCAGAGGAC
AAATTGTTCTCACCCAGTCTCCAGCAATCATGTCTGCATCTCCAGGGGAGAAGGTCACCATGACCTG
CAGTGCCAGCTCAAGTGTAAGTTACATGTACTGGTACCAGCAGAAGCCAGAATCCTCCCCCAGACTC
CTGATTTATGACACATCCAACCTGGCTTCTGGAGTCCCTGTTCGCTTCAGTGGCAGTGGGTCTGGGA
CCTCTTATTTTCTCACAATCAGCCGAATGGAGGCTGAAGATGCTGCCACTTATTACTGCCAGCAGTG
GAAGACTTACCCACCCACGTTCGGAGGGGGGACCAAGCTGGAAATAAAA
Light chain: Amino acid sequence (128 aa)
Signal peptide-FRl-CDRl-FR2-CDR2-FR3-CDR3-FR4
SEQ ID NO:69 — SEQ ID NO:26 — SEP ID NO: 70 — SEQ ID NO:71 — SEP ID NO: 72
— SEQ ID NO:73 — SEO ID NO:85 — SEQ ID NO:32
MDFQVQIFSFLLISASVILSRGQIVLTQSPAIMSASPGEKVTMTCSASSSVSYMYWYQQKPESSPRL LIYDTSNLASGVPVRFSGSGSGTSYFLTISRMEAEDAATYYCQQWKTYPPTFGGGTKLEIK
In certain embodiments, the monoclonal antibody (named 9009 herein) comprises light and heavy variable chains having the sequences shown below:
Heavy chain: DNA sequence (414 bp)
Signal seauence-FRl-CDRl-FR2-CDR2-FR3-CDR3-FR4
SEQ ID NO: 1 — SEQ ID NO:2 — SEP ID NO:3 — SEQ ID NO:4 — SEP ID NO: 5 — SEQ ID NO:6 — SEP ID NO: 7 — SEQ ID NO:8
ATGCTGTTGGGGCTGAAGTGGGTTTTCTTTGTTGTTTTTTATCAAGGTGTGCATTGTGAGGTGCAGC TTGTTGAGTCTGGTGGAGGATTGGTGCAACCTAAAGGGTCATTGAAACTCTCATGTGCAGCCTCTGG
ATTCACCTTCAATACCTACGCCATGCACTGGGTCCGCCAGGCTCCAGGAAAGGGTTTGGAATGGGTT
GCTCGCATAAGAAGTGAAAGTAATAATTTTGCAACATATTATGCCGATTCAGTGAAAGACAGTTTCA
CCATCTCCAGAGATGATTCACAAAGCATGCTCTATCTGCAAATGAACAACTTGAAAACTGAGGACAC AGCCGTATATTACTGTGTGAGAGGGGGGTTATCTCCCTTTGACTACTGGGGCCAAGGCACCACTCTC ACAGTCTCCTCA
Heavy chain: Amino acid sequence (138 aa)
Signal peptide-FRl-CDRl-FR2-CDR2-FR3-CDR3-FR4
SEQ ID NO:9 — SEQ ID NO:10 — SEP ID NO: 11 — SEQ ID NO:12 — SEP ID NO: 13
— SEQ ID NO: 14 — SEP ID NO: 15 — SEQ ID NO: 16
MLLGLKWVFFVVFYQGVHCEVQLVESGGGLVQPKGSLKLSCAASGFTFNTYAMHWVRQAPGKGLEWV
ARIRSESNNFATYYADSVKDSFTISRDDSQSMLYLQMNNLKTEDTAVYYCVRGGLSPFDYWGQGTTL
TVSS
Light chain: DNA sequence (384 bp)
Signal seauence-FRl-CDRl-FR2-CDR2-FR3-CDR3-FR4
SEQ ID NO: 17 — SEQ ID NO: 18 — SEP ID NO: 19 — SEQ ID NO:20 — SEO ID NO:21
— SEQ ID NO:22 — SEP ID NO:23 — SEQ ID NO:24
ATGGATTTTCAAGTGCAGATTTTCAGCTTCCTGCTAATCAGTGCCTCAGTCATAATATCCAGAGGAC
AAATTGTTCTCACCCAGTCTCCAGCAATCATGTCTGCATCTCCAGGGGAGAAGGTCACCATGACCTG
CAGTGCCAGCTCAAGTGTAAGTTACATGCACTGGTACCAACAGAAGTCAGGCACCTCCCCCAAAAGA
TGGATTTATGACACTTCCAAACTGGCTTCTGGAGTCCCTGCTCGCTTCAGTGGCAGTGGGTCTGGGA
CCTCTTACTCTCTCACAATCAACAGCATGGAGGCTGAAGATGCTGCCACTTATTACTGCCAGCAGTG
GAGTAGAAATCCACCCACGTTCGGAGGGGGGACCAAGCTGGAAATAAAA
Light chain: Amino acid sequence (128 aa)
Signal peptide-FRl-CDRl-FR2-CDR2-FR3-CDR3-FR4
SEQ ID NO:25 — SEQ ID NO:26 — SEP ID NO:27 — SEQ ID NO:28 — SEP ID NO:29
— SEQ ID NO:30 — SEO ID NO:31 — SEQ ID NO:32
MDFQVQIFSFLLISASVIISRGQIVLTQSPAIMSASPGEKVTMTCSASSSVSYMHWYQQKSGTSPKR WIYDTSKLASGVPARFSGSGSGTSYSLTINSMEAEDAATYYCQQWSRNPPTFGGGTKLEIK
In certain embodiments, the monoclonal antibody (named 9014 herein) comprises light and heavy variable chains having the sequences shown below:
Heavy chain: DNA sequence (414 bp)
Signal seauence-FRl-CDRl-FR2-CDR2-FR3-CDR3-FR4
SEQ ID NO: 1 — SEQ ID NO:2 — SEP ID NO:3 — SEQ ID NO:4 — SEP ID NO: 5 — SEQ ID NO:6 — SEP ID NO: 7 — SEQ ID NO:8
ATGCTGTTGGGGCTGAAGTGGGTTTTCTTTGTTGTTTTTTATCAAGGTGTGCATTGTGAGGTGCAGC
TTGTTGAGTCTGGTGGAGGATTGGTGCAACCTAAAGGGTCATTGAAACTCTCATGTGCAGCCTCTGG ATTCACCTTCAATACCTACGCCATGCACTGGGTCCGCCAGGCTCCAGGAAAGGGTTTGGAATGGGTT GCTCGCATAAGAAGTGAAAGTAATAATTTTGCAACATATTATGCCGATTCAGTGAAAGACAGTTTCA CCATCTCCAGAGATGATTCACAAAGCATGCTCTATCTGCAAATGAACAACTTGAAAACTGAGGACAC AGCCGTATATTACTGTGTGAGAGGGGGGTTATCTCCCTTTGACTACTGGGGCCAAGGCACCACTCTC ACAGTCTCCTCA
Heavy chain: Amino acid sequence (138 aa)
Signal peptide-FRl-CDRl-FR2-CDR2-FR3-CDR3-FR4
SEQ ID NO:9 — SEQ ID NO:10 — SEP ID NO: 11 — SEQ ID NO:12 — SEP ID NO: 13
— SEQ ID NO: 14 — SEP ID NO: 15 — SEQ ID NO: 16
MLLGLKWVFFVVFYQGVHCEVQLVESGGGLVQPKGSLKLSCAASGFTFNTYAMHWVRQAPGKGLEWV
ARIRSESNNFATYYADSVKDSFTISRDDSQSMLYLQMNNLKTEDTAVYYCVRGGLSPFDYWGQGTTL
TVSS
Light chain: DNA sequence (384 bp)
Signal seauence-FRl-CDRl-FR2-CDR2-FR3-CDR3-FR4
SEQ ID NO: 17 — SEQ ID NO: 18 — SEP ID NO: 19 — SEQ ID NO:20 — SEO ID NO:21
— SEQ ID NO:22 — SEP ID NO:23 — SEQ ID NO:24
ATGGATTTTCAAGTGCAGATTTTCAGCTTCCTGCTAATCAGTGCCTCAGTCATAATATCCAGAGGAC
AAATTGTTCTCACCCAGTCTCCAGCAATCATGTCTGCATCTCCAGGGGAGAAGGTCACCATGACCTG
CAGTGCCAGCTCAAGTGTAAGTTACATGCACTGGTACCAACAGAAGTCAGGCACCTCCCCCAAAAGA
TGGATTTATGACACTTCCAAACTGGCTTCTGGAGTCCCTGCTCGCTTCAGTGGCAGTGGGTCTGGGA
CCTCTTACTCTCTCACAATCAACAGCATGGAGGCTGAAGATGCTGCCACTTATTACTGCCAGCAGTG
GAGTAGAAATCCACCCACGTTCGGAGGGGGGACCAAGCTGGAAATAAAA
Light chain: Amino acid sequence (128 aa)
Signal peptide-FRl-CDRl-FR2-CDR2-FR3-CDR3-FR4
SEQ ID NO:25 — SEQ ID NO:26 — SEP ID NO:27 — SEQ ID NO:28 — SEP ID NO:29
— SEQ ID NO:30 — SEO ID NO:31 — SEQ ID NO:32
MDFQVQIFSFLLISASVIISRGQIVLTQSPAIMSASPGEKVTMTCSASSSVSYMHWYQQKSGTSPKR WIYDTSKLASGVPARFSGSGSGTSYSLTINSMEAEDAATYYCQQWSRNPPTFGGGTKLEIK
In certain embodiments, the monoclonal antibody (named 9018 herein) comprises light and heavy variable chains having the sequences shown below:
Heavy chain: DNA sequence (414 bp)
Signal seauence-FRl-CDRl-FR2-CDR2-FR3-CDR3-FR4 SEQ ID NO:48 — SEQ ID NO:74 — SEQ ID NO:50 — SEQ ID NO:51 — SEP ID NO: 75
— SEQ ID NO:76 — SEP ID NO: 77 — SEQ ID NO:78
ATGAACTTCGGGCTCAGCTTGATTTTCCTTGTCCTTGTTTTAAAAGGTGTCCAGTGTGAAGTGATGC
TGGTGGAGTCTGGGGGAGGCTTAGTGAAGCCTGGAGGGTCCCTGAAACTCTCCTGTGCAGCCTCTGG
ATTCACTTTCAGTAGCTATGCCATGTCTTGGGTTCGCCAGACTCCGGAGAAGAGGCTGGAATGGGTC
GCAACCATTAGTACTGGTGGTGGTTACACCTACTATCCAGACAGTGTGAAGGGGCGATTCACCGTCT
CCAGAGACAATGCCAAGAACACCCTGTACCTGCAAATGAGCAGTCTGAGGTCTGAGGACACGGCCAT
GTATTACTGTGCAAGAAGGGGGACGTCTAGAGGGTACTTCGATGTCTGGGGCGCAGGGACTACGGTC
ACCGTCTCCTCA
Heavy chain: Amino acid sequence (138 aa)
Signal peptide-FRl-CDRl-FR2-CDR2-FR3-CDR3-FR4
SEQ ID NO:56 — SEQ ID NO:79 — SEO ID NO:58 — SEQ ID NO:59 — SEP ID NO: 60
— SEQ ID NO:80 — SEO ID NO:81 — SEQ ID NO:63
MNFGLSLIFLVLVLKGVQCEVMLVESGGGLVKPGGSLKLSCAASGFTFSSYAMSWVRQTPEKRLEWV ATISTGGGYTYYPDSVKGRFTVSRDNAKNTLYLQMSSLRSEDTAMYYCARRGTSRGYFDVWGAGTTV TVSS
Light chain: DNA sequence (384 bp)
Signal seauence-FRl-CDRl-FR2-CDR2-FR3-CDR3-FR4
SEQ ID NO:64 — SEQ ID NO:82 — SEP ID NO: 19 — SEQ ID NO:65 — SEP ID NO: 66
— SEQ ID NO:67 — SEP ID NO: 68 — SEQ ID NO:83
ATGGATTTTCAAGTGCAGATTTTCAGCTTCCTGCTAATCAGTGCCTCAGTCATACTGTCCAGAGGAC
AAATTATTCTCACCCAGTCTCCAGCAATCATGTCTGCATCTCCAGGGGAGAAGGTCACCATGACCTG
CAGTGCCAGCTCAAGTGTAAGTTACATGTACTGGTACCAGCAGAAGCCAGAATCCTCCCCCAGACTC
CTGATTTATGACACATCCAACCTGGCTTCTGGAGTCCCTGTTCGCTTCAGTGGCAGTGGGTCTGGGA
CCTCTTATTTTCTCACAATCAGCCGAATGGAGGCTGAAGATGCTGCCACTTATTACTGCCAGCAGTG
GAAGACTTACCCACCCACGTTCGGAGGGGGGACCAGGCTGGAAATAAAA
Light chain: Amino acid sequence (128 aa)
Signal peptide-FRl-CDRl-FR2-CDR2-FR3-CDR3-FR4
SEQ ID NO:69 — SEQ ID NO:84 — SEP ID NO: 70 — SEQ ID NO:71 — SEP ID NO: 72
— SEQ ID NO:73 — SEO ID NO:85 — SEQ ID NO:86
MDFQVQIFSFLLISASVILSRGQIILTQSPAIMSASPGEKVTMTCSASSSVSYMYWYQQKPESSPRL LIYDTSNLASGVPVRFSGSGSGTSYFLTISRMEAEDAATYYCQQWKTYPPTFGGGTRLEIK
In certain embodiments, the monoclonal antibody (named 9021 herein) comprises light and heavy variable chains having the sequences shown below:
Heavy chain: DNA sequence (414 bp) Signal seauence-FRl-CDRl-FR2-CDR2-FR3-CDR3-FR4
SEQ ID NO:48 — SEQ ID NO:87 — SEO ID NO:88 — SEQ ID NO:51 — SEP ID NO: 89
— SEQ ID NO:90 — SEP ID NO: 54 — SEQ ID NO:55
ATGAACTTCGGGCTCAGCTTGATTTTCCTTGTCCTTGTTTTAAAAGGTGTCCAGTGTGAAGTGATGA
TGGTGGAGTCTGGGGGAGGCTTAGTGAAGCCTGGAGGGTCCCTGAAACTCTCCTGTGCAGCCTCTGG
ATTCACTTTCAGTAACTATGCCATGTCTTGGGTTCGCCAGACTCCGGAGAAGAGGCTGGAATGGGTC
GCAACGATTAGTACTGGTGGTGGTTACACCTACTATCCAGACAGTATGAAGGGGCGATTCACCATCT
CCAGAGACAATGCCAAGAACACCCTGTACCTGCAAATGAGCAGTCTGAGGTCTGAGGACACGGCCAT
GTATTACTGTGCAAGAAGGGGGACGGCTAGAGGGTACTTCGATGTCTGGGGCGCAGGGACCACGGTC
ACCGTCTCCTCA
Heavy chain: Amino acid sequence (138 aa)
Signal peptide-FRl-CDRl-FR2-CDR2-FR3-CDR3-FR4
SEQ ID NO:56 — SEQ ID NO:91 — SEP ID NO: 92 — SEQ ID NO:59 — SEP ID NO: 93
— SEQ ID NO:94 — SEP ID NO: 62 — SEQ ID NO:63
MNFGLSLIFLVLVLKGVQCEVMMVESGGGLVKPGGSLKLSCAASGFTFSNYAMSWVRQTPEKRLEWV ATISTGGGYTYYPDSMKGRFTISRDNAKNTLYLQMSSLRSEDTAMYYCARRGTARGYFDVWGAGTTV TVSS
Light chain: DNA sequence (384 bp)
Signal seauence-FRl-CDRl-FR2-CDR2-FR3-CDR3-FR4
SEQ ID NO:64 — SEQ ID NO: 18 — SEP ID NO: 19 — SEQ ID NO:65 — SEP ID NO: 66
— SEQ ID NO:95 — SEP ID NO: 96 — SEQ ID NO:24
ATGGATTTTCAAGTGCAGATTTTCAGCTTCCTGCTAATCAGTGCCTCAGTCATACTGTCCAGAGGAC
AAATTGTTCTCACCCAGTCTCCAGCAATCATGTCTGCATCTCCAGGGGAGAAGGTCACCATGACCTG
CAGTGCCAGCTCAAGTGTAAGTTACATGTACTGGTACCAGCAGAAGCCAGAATCCTCCCCCAGACTC
CTGATTTATGACACATCCAACCTGGCTTCTGGAGTCCCTGTTCGCTTCAGTGGCAGTGGGTCTGGGA
CCTCTTATTTTCTCACAATCAGCCGAATGGAGGCTGAAGATGCTGCCACTTATTATTGCCAACAGTG
GAAGACTTACCCACCCACGTTCGGAGGGGGGACCAAGCTGGAAATAAAA
Light chain: Amino acid sequence (128 aa)
Signal peptide-FRl-CDRl-FR2-CDR2-FR3-CDR3-FR4
SEQ ID NO:69 — SEQ ID NO:26 — SEP ID NO: 70 — SEQ ID NO:71 — SEP ID NO: 72
— SEQ ID NO:73 — SEO ID NO:85 — SEQ ID NO:32
MDFQVQIFSFLLISASVILSRGQIVLTQSPAIMSASPGEKVTMTCSASSSVSYMYWYQQKPESSPRL LIYDTSNLASGVPVRFSGSGSGTSYFLTISRMEAEDAATYYCQQWKTYPPTFGGGTKLEIK
In certain embodiments, the monoclonal antibody (named 9023 herein) comprises light and heavy variable chains having the sequences shown below: Individual positive clones with correct VH and VL insert sizes were sequenced, one kind of VH DNA sequence and Two kinds ofVLDNA sequences were obtained in the trial.
Heavy chain: DNA sequence (414 bp)
Signal seauence-FRl-CDRl-FR2-CDR2-FR3-CDR3-FR4
SEQ ID NO:48 — SEQ ID NO:74 — SEP ID NO: 97 — SEQ ID NO:98 — SEP ID NO: 99 — SEQ ID NO: 100 — SEP ID NO: 54 — SEQ ID NO:55
ATGAACTTCGGGCTCAGCTTGATTTTCCTTGTCCTTGTTTTAAAAGGTGTCCAGTGTGAAGTGATGC
TGGTGGAGTCTGGGGGAGGCTTAGTGAAGCCTGGAGGGTCCCTGAAACTCTCCTGTGCAGCCTCTGG
ATTCACTTTCAGTCGCTATGCCATGTCTTGGGTTCGACAGACTCCGGAGAAGAGGCTGGAGTGGGTC
GCAACCACTAGTATTGGTGGTGGTTACACCTACTATCTTGACAGTGTGAAGGGGCGATTCACCATCT
CCAGAGACAATGTCGAGAATACCCTATACCTGCAAATGACCAGTCTGAGGTCTGAGGACACGGCCAT
GTATTTCTGTACAAGAAGGGGGACGGCTAGAGGGTACTTCGATGTCTGGGGCGCAGGGACCACGGTC
ACCGTCTCCTCA
Heavy chain: Amino acid sequence (138 aa)
Signal peptide-FRl-CDRl-FR2-CDR2-FR3-CDR3-FR4
SEQ ID NO:56 — SEQ ID NO:79 — SEP ID NO: 101 — SEQ ID NO:59 — SEP ID NO: 102 — SEQ ID NO:103 — SEP ID NO: 62 — SEQ ID NO:63
MNFGLSLIFLVLVLKGVQCEVMLVESGGGLVKPGGSLKLSCAASGFTFSRYAMSWVRQTPEKRLEWV ATTSIGGGYTYYLDSVKGRFTISRDNVENTLYLQMTSLRSEDTAMYFCTRRGTARGYFDVWGAGTTV TVSS
Light chain 1: DNA sequence (381 bp)
Signal seauence-FRl-CDRl-FR2-CDR2-FR3-CDR3-FR4
SEQ ID NO: 104 — SEQ ID NO: 105 — SEP ID NO: 106 — SEQ ID NO: 107 — SEP ID NO: 108 — SEQ ID NO:109 — SEP ID NO: 110 — SEQ ID NO:lll
ATGGAGACACATTCTCAGGTCTTTGTATACATGTTGCTGTGGTTGTCTGGTGTTGAAGGAGACATTG
TGATGACCCAGTCTCACAAATTCATGTCCACATCAGTAGGAGACAGGGTCAGCATCACCTGCAAGGC
CAGTCAGGATGTGGGTACTGCTGTAGCCTGGTATCAACAGAAACCAGGGCAATCTCCTAAACTACTG
ATTTACTGGGCATCCACCCGGCACACTGGAGTCCCTGATCGCTTCACAGGCAGTGGATCTGGGACAG
ATTTCACTCTCACCATTAGCAATGTGCAGTCTGAAGACTTGGCAGATTATTTCTGTCAGCAATATAG
CAGCTATCCTCTCACGTTCGGTGCTGGGACCAAGCTGGAGCTGAAA
Light chain 1: Amino acid sequence (127 aa)
Signal peptide-FRl-CDRl-FR2-CDR2-FR3-CDR3-FR4
SEQ ID NO: 112 — SEQ ID NO:113 — SEP ID NO: 114 — SEQ ID NO:115 — SEP ID NO:116 — SEQ ID NO:117 — SEP ID NO: 118 — SEQ ID NO:119
METHSQVFVYMLLWLSGVEGDIVMTQSHKFMSTSVGDRVSITCKASQDVGTAVAWYQQKPGQSPKLL IYWASTRHTGVPDRFTGSGSGTDFTLTISNVQSEDLADYFCQQYSSYPLTFGAGTKLELK
Light chain 2: DNA sequence (384 bp)
Signal seauence-FRl-CDRl-FR2-CDR2-FR3-CDR3-FR4
SEQ ID NO:64 — SEQ ID NO:120 — SEP ID NO: 121 — SEQ ID NO:122 — SEP ID NO: 66 — SEQ ID NO: 123 — SEP ID NO: 68 — SEQ ID NO: 124
ATGGATTTTCAAGTGCAGATTTTCAGCTTCCTGCTAATCAGTGCCTCAGTCATACTGTCCAGAGGAC
AAATTGTTCTCACCCAGTCTCCAGCAATCATGTCTGCATCTCCAGGGGACAAGGTCACCATGACCTG
CAGTGCCACCTCAAGTGTAAGTTACATGTACTGGTACCAGCAGAAGCCAGGATCCTCCCCCAGACTC
CTGATTTATGACACATCCAACCTGGCTTCTGGAGTCCCTGTTCGCTTCAGTGGCAGTGGGTCTGGGA
CCTCTTACTCTCTCACAATCAGCCGAATGGAGCCTGAAGATGCTGCCTCTTATTACTGCCAGCAGTG
GAAGAGTTACCCACCCACGTTCGGCTCGGGGACAAAGTTGGAAATAAAA
Light chain 2: Amino acid sequence (128 aa)
Signal peptide-FRl-CDRl-FR2-CDR2-FR3-CDR3-FR4
SEQ ID NO:69 — SEQ ID NO:125 — SEP ID NO: 126 — SEQ ID NO:127 — SEP ID NO: 72 — SEQ ID NO: 128 — SEP ID NO: 129 — SEQ ID NO: 130
MDFQVQIFSFLLISASVILSRGQIVLTQSPAIMSASPGDKVTMTCSATSSVSYMYWYQQKPGSSPRL LIYDTSNLASGVPVRFSGSGSGTSYSLTISRMEPEDAASYYCQQWKSYPPTFGSGTKLEIK
In certain embodiments, the monoclonal antibody (named 9060 herein) comprises light and heavy variable chains having the sequences shown below:
Heavy chain: DNA sequence (426 bp)
Signal seauence-FRl-CDRl-FR2-CDR2-FR3-CDR3-FR4
SEQ ID N0 33 — SEQ ID NO: 131 — SEP ID NO:3 — SEQ ID NO:4 — SEP ID NO: 132 — SEQ ID NO: 133 — SEP ID NO:7 — SEQ ID NO:37
ATGACATTGAACGTGCTGTTGGGGCTGAAGTGGGTTTTCTTTGTTGTTTTTTATCAAGGTGTGCATT
GTGAGGTACACCTTGTTGAGTCTGGTGGAGGATTGGTGCAGCCTAAAGGGTCATTGAAACTCTCATG
TGCAGCCTCTGGATTCACCTTCAATACCTACGCCATGCACTGGGTCCGCCAGGCTCCAGGAAAGGGT
TTGGAATGGGTTGCTCGCATAAGAAATAAAAGTAATAATTATGCAACATATTATGCCGATTCAGTGA
AAGACAGGTTCACCATCTCCAGAGATGATTCACAAAGCATGCTCTTTCTGCAAATGGACAACTTGAA
AACTGAGGACACAGCCATATATTACTGTGTGAGAGGGGGGTTATCTCCCTTTGACTACTGGGGCCAA
GGCACCACACTCACAGTCTCCTCA
Heavy chain: Amino acid sequence (142 aa)
Signal peptide-FRl-CDRl-FR2-CDR2-FR3-CDR3-FR4
SEQ ID N0 38 — SEQ ID NO:39 — SEP ID NO: 11 — SEQ ID NO:12 — SEP ID NO:134 — SEQ ID NO: 135 — SEP ID NO: 15 — SEQ ID NO: 16 MTLNVLLGLKWVFFVVFYQGVHCEVHLVESGGGLVQPKGSLKLSCAASGFTFNTYAMHWVRQAPGKG
LEWVARIRNKSNNYATYYADSVKDRFTISRDDSQSMLFLQMDNLKTEDTAIYYCVRGGLSPFDYWGQ
GTTLTVSS
Light chain: DNA sequence (384 bp)
Signal seauence-FRl-CDRl-FR2-CDR2-FR3-CDR3-FR4
SEQ ID NO: 17 — SEQ ID NO: 18 — SEP ID NO: 19 — SEQ ID NO:42 — SEP ID NO:43
— SEQ ID NO:22 — SEP ID NO:44 — SEQ ID NO:45
ATGGATTTTCAAGTGCAGATTTTCAGCTTCCTGCTAATCAGTGCCTCAGTCATAATATCCAGAGGAC
AAATTGTTCTCACCCAGTCTCCAGCAATCATGTCTGCATCTCCAGGGGAGAAGGTCACCATGACCTG
CAGTGCCAGCTCAAGTGTAACTTACATGCACTGGTACCAGCAGAAGTCAGGCACCTCCCCCAAAAGA
TGGATTTATGACACATCCAAACTGGCTTCTGGAGTCCCTGCTCGCTTCAGTGGCAGTGGGTCTGGGA
CCTCTTACTCTCTCACAATCAGCAGCATGGAGGCTGAAGATGCTGCCACTTATTACTGCCAGCAGTG
GAGTAGTAACCCACCCACGTTCGGAGGGGGGACCAAGCTGGAAATAAGA
Light chain: Amino acid sequence (128 aa)
Signal peptide-FRl-CDRl-FR2-CDR2-FR3-CDR3-FR4
SEQ ID NO:25 — SEQ ID NO:26 — SEP ID NO:46 — SEQ ID NO:28 — SEP ID NO:29
— SEQ ID NO:30 — SEO ID NO:31 — SEQ ID NO:47
MDFQVQIFSFLLISASVIISRGQIVLTQSPAIMSASPGEKVTMTCSASSSVTYMHWYQQKSGTSPKR WIYDTSKLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCQQWSSNPPTFGGGTKLEIR
In certain embodiments, the monoclonal antibody (named 9064 herein) comprises light and heavy variable chains having the sequences shown below:
Heavy chain: DNA sequence (426 bp)
Signal seauence-FRl-CDRl-FR2-CDR2-FR3-CDR3-FR4
SEQ ID N0 33 — SEQ ID NO: 131 — SEP ID NO:3 — SEQ ID NO:4 — SEP ID NO: 132
— SEQ ID NO: 133 — SEP ID NO:7 — SEQ ID NO:37
ATGACATTGAACGTGCTGTTGGGGCTGAAGTGGGTTTTCTTTGTTGTTTTTTATCAAGGTGTGCATT
GTGAGGTACACCTTGTTGAGTCTGGTGGAGGATTGGTGCAGCCTAAAGGGTCATTGAAACTCTCATG
TGCAGCCTCTGGATTCACCTTCAATACCTACGCCATGCACTGGGTCCGCCAGGCTCCAGGAAAGGGT
TTGGAATGGGTTGCTCGCATAAGAAATAAAAGTAATAATTATGCAACATATTATGCCGATTCAGTGA
AAGACAGGTTCACCATCTCCAGAGATGATTCACAAAGCATGCTCTTTCTGCAAATGGACAACTTGAA
AACTGAGGACACAGCCATATATTACTGTGTGAGAGGGGGGTTATCTCCCTTTGACTACTGGGGCCAA
GGCACCACACTCACAGTCTCCTCA
Heavy chain: Amino acid sequence (142 aa)
Signal peptide-FRl-CDRl-FR2-CDR2-FR3-CDR3-FR4
SEQ ID N0 38 — SEQ ID NO:39 — SEP ID NO: 11 — SEQ ID NO:12 — SEP ID NO:134 — SEQ ID NO: 135 — SEP ID NO: 15 — SEQ ID NO: 16
MTLNVLLGLKWVFFVVFYQGVHCEVHLVESGGGLVQPKGSLKLSCAASGFTFNTYAMHWVRQAPGKG
LEWVARIRNKSNNYATYYADSVKDRFTISRDDSQSMLFLQMDNLKTEDTAIYYCVRGGLSPFDYWGQ
GTTLTVSS
Light chain: DNA sequence (384 bp)
Signal seauence-FRl-CDRl-FR2-CDR2-FR3-CDR3-FR4
SEQ ID NO: 17 — SEQ ID NO: 18 — SEP ID NO: 19 — SEQ ID NO:42 — SEP ID NO:43
— SEQ ID NO:22 — SEP ID NO:44 — SEQ ID NO:45
ATGGATTTTCAAGTGCAGATTTTCAGCTTCCTGCTAATCAGTGCCTCAGTCATAATATCCAGAGGAC
AAATTGTTCTCACCCAGTCTCCAGCAATCATGTCTGCATCTCCAGGGGAGAAGGTCACCATGACCTG
CAGTGCCAGCTCAAGTGTAACTTACATGCACTGGTACCAGCAGAAGTCAGGCACCTCCCCCAAAAGA
TGGATTTATGACACATCCAAACTGGCTTCTGGAGTCCCTGCTCGCTTCAGTGGCAGTGGGTCTGGGA
CCTCTTACTCTCTCACAATCAGCAGCATGGAGGCTGAAGATGCTGCCACTTATTACTGCCAGCAGTG
GAGTAGTAACCCACCCACGTTCGGAGGGGGGACCAAGCTGGAAATAAGA
Light chain: Amino acid sequence (128 aa)
Signal peptide-FRl-CDRl-FR2-CDR2-FR3-CDR3-FR4
SEQ ID NO:25 — SEQ ID NO:26 — SEP ID NO:46 — SEQ ID NO:28 — SEP ID NO:29
— SEQ ID NO:30 — SEO ID NO:31 — SEQ ID NO:47
MDFQVQIFSFLLISASVIISRGQIVLTQSPAIMSASPGEKVTMTCSASSSVTYMHWYQQKSGTSPKR WIYDTSKLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCQQWSSNPPTFGGGTKLEIR
In certain embodiments, the monoclonal antibody (named 9071 herein) comprises light and heavy variable chains having the sequences shown below:
Heavy chain: DNA sequence (426 bp)
Signal seauence-FRl-CDRl-FR2-CDR2-FR3-CDR3-FR4
SEQ ID N0 33 — SEQ ID NO: 131 — SEP ID NO:3 — SEQ ID NO:4 — SEP ID NO: 132
— SEQ ID NO: 133 — SEP ID NO:7 — SEQ ID NO:37
ATGACATTGAACGTGCTGTTGGGGCTGAAGTGGGTTTTCTTTGTTGTTTTTTATCAAGGTGTGCATT
GTGAGGTACACCTTGTTGAGTCTGGTGGAGGATTGGTGCAGCCTAAAGGGTCATTGAAACTCTCATG
TGCAGCCTCTGGATTCACCTTCAATACCTACGCCATGCACTGGGTCCGCCAGGCTCCAGGAAAGGGT
TTGGAATGGGTTGCTCGCATAAGAAATAAAAGTAATAATTATGCAACATATTATGCCGATTCAGTGA
AAGACAGGTTCACCATCTCCAGAGATGATTCACAAAGCATGCTCTTTCTGCAAATGGACAACTTGAA
AACTGAGGACACAGCCATATATTACTGTGTGAGAGGGGGGTTATCTCCCTTTGACTACTGGGGCCAA
GGCACCACACTCACAGTCTCCTCA
Heavy chain: Amino acid sequence (142 aa)
Signal peptide-FRl-CDRl-FR2-CDR2-FR3-CDR3-FR4 SEQ ID N0 38 — SEQ ID NO:39 — SEP ID NO: 11 — SEQ ID NO:12 — SEP ID NO:134 — SEQ ID NO: 135 — SEP ID NO: 15 — SEQ ID NO: 16
MTLNVLLGLKWVFFVVFYQGVHCEVHLVESGGGLVQPKGSLKLSCAASGFTFNTYAMHWVRQAPGKG
LEWVARIRNKSNNYATYYADSVKDRFTISRDDSQSMLFLQMDNLKTEDTAIYYCVRGGLSPFDYWGQ
GTTLTVSS
Light chain: DNA sequence (384 bp)
Signal seauence-FRl-CDRl-FR2-CDR2-FR3-CDR3-FR4
SEQ ID NO: 17 — SEQ ID NO: 18 — SEP ID NO: 19 — SEQ ID NO:42 — SEP ID NO:43
— SEQ ID NO:22 — SEP ID NO:44 — SEQ ID NO:45
ATGGATTTTCAAGTGCAGATTTTCAGCTTCCTGCTAATCAGTGCCTCAGTCATAATATCCAGAGGAC
AAATTGTTCTCACCCAGTCTCCAGCAATCATGTCTGCATCTCCAGGGGAGAAGGTCACCATGACCTG
CAGTGCCAGCTCAAGTGTAACTTACATGCACTGGTACCAGCAGAAGTCAGGCACCTCCCCCAAAAGA
TGGATTTATGACACATCCAAACTGGCTTCTGGAGTCCCTGCTCGCTTCAGTGGCAGTGGGTCTGGGA
CCTCTTACTCTCTCACAATCAGCAGCATGGAGGCTGAAGATGCTGCCACTTATTACTGCCAGCAGTG
GAGTAGTAACCCACCCACGTTCGGAGGGGGGACCAAGCTGGAAATAAGA
Light chain: Amino acid sequence (128 aa)
Signal peptide-FRl-CDRl-FR2-CDR2-FR3-CDR3-FR4
SEQ ID NO:25 — SEQ ID NO:26 — SEP ID NO:46 — SEQ ID NO:28 — SEP ID NO:29
— SEQ ID NO:30 — SEO ID NO:31 — SEQ ID NO:47
MDFQVQIFSFLLISASVIISRGQIVLTQSPAIMSASPGEKVTMTCSASSSVTYMHWYQQKSGTSPKR WIYDTSKLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCQQWSSNPPTFGGGTKLEIR
In certain embodiments, the monoclonal antibody (named 9096 herein) comprises light and heavy variable chains having the sequences shown below:
Heavy chain: DNA sequence (414 bp)
Signal seauence-FRl-CDRl-FR2-CDR2-FR3-CDR3-FR4
SEQ ID NO: 136 — SEQ ID NO:137 — SEP ID NO: 138 — SEQ ID NO:51 — SEP ID NO:139 — SEQ ID NO:140 — SEP ID NO: 141 — SEQ ID NO:8
ATGAACTTTGTGCTCAGCTTGATTTTCCTTGCCCTCATTTTAAAAGGTGTCCAGTGTGAAGTGCAGC
TGGTGGAGTCTGGGGGAGGCTTAGTGAAGCCTGGAGGGTCCCTGAAACTCTCCTGTGCAGCCTCTGG
ATTCACTTTCAGTGGGTATGCCATGTCTTGGGTTCGCCAGACTCCGGAGAAGAGGCTGGAGTGGGTC
GCAACCATTAGTAATGGTGGTAGTTACACCTACTATCCAGACAGTGTGAAGGGTCGATTCACCATCT
CCAGAGACAATGCCAAGAAGACCCTGTACCTGCAAATGAGCAGTCTGAGGTCTGAGGACACGGCCAT
GTATTACTGTACAAGACGGGCTGCTACGAGGGGATACTTTGACTACTGGGGCCAAGGCACCACTCTC
ACAGTCTCCTCA
Heavy chain: Amino acid sequence (138 aa) Signal peptide-FRl-CDRl-FR2-CDR2-FR3-CDR3-FR4
SEQ ID NO: 142 — SEQ ID NO: 143 — SEP ID NO: 144 — SEQ ID NO:59 — SEP ID NO: 145 — SEQ ID NO: 146 — SEP ID NO: 147 — SEQ ID NO: 16
MNFVLSLIFLALILKGVQCEVQLVESGGGLVKPGGSLKLSCAASGFTFSGYAMSWVRQTPEKRLEWV ATISNGGSYTYYPDSVKGRFTISRDNAKKTLYLQMSSLRSEDTAMYYCTRRAATRGYFDYWGQGTTL TVSS
Light chain: DNA sequence (384 bp)
Signal seauence-FRl-CDRl-FR2-CDR2-FR3-CDR3-FR4
SEQ ID NO:64 — SEQ ID NO:18 — SEP ID NO: 19 — SEQ ID NO:122 — SEP ID NO: 148 — SEQ ID NO:149 — SEP ID NO: 150 — SEQ ID NO:lll
ATGGATTTTCAAGTGCAGATTTTCAGCTTCCTGCTAATCAGTGCCTCAGTCATACTGTCCAGAGGAC
AAATTGTTCTCACCCAGTCTCCAGCAATCATGTCTGCATCTCCAGGGGAGAAGGTCACCATGACCTG
CAGTGCCAGCTCAAGTGTAAGTTACATGTACTGGTACCAGCAGAAGCCAGGATCCTCCCCCAGACTC
CTGATTTATGACACATCCAAGCTGGCTTCTGGCGTCCCTGTTCGCTTCAGTGGCAGTGGGTCTGGGA
CCTCTTACTCTCTCACAATCAGCCGAATGGAGGCTGAAGATGCTGCCACTTATTACTGCCAGCAGTG
GAGAAGTTACCCACCCACGTTCGGTGCTGGGACCAAGCTGGAGCTGAAA
Light chain: Amino acid sequence (128 aa)
Signal peptide-FRl-CDRl-FR2-CDR2-FR3-CDR3-FR4
SEQ ID NO:69 — SEQ ID NO:26 — SEP ID NO: 70 — SEQ ID NO:127 — SEP ID NO:29 — SEQ ID NO:151 — SEP ID NO: 152 — SEQ ID NO:119
MDFQVQIFSFLLISASVILSRGQIVLTQSPAIMSASPGEKVTMTCSASSSVSYMYWYQQKPGSSPRL LIYDTSKLASGVPVRFSGSGSGTSYSLTISRMEAEDAATYYCQQWRSYPPTFGAGTKLELK
In certain embodiments, the monoclonal antibody (named 9110 herein) comprises light and heavy variable chains having the sequences shown below:
Heavy chain: DNA sequence (426 bp)
Signal seauence-FRl-CDRl-FR2-CDR2-FR3-CDR3-FR4
SEQ ID N0 33 — SEQ ID NO: 131 — SEP ID NO:3 — SEQ ID NO:4 — SEP ID NO: 132 — SEQ ID NO: 133 — SEP ID NO:7 — SEQ ID NO:37
ATGACATTGAACGTGCTGTTGGGGCTGAAGTGGGTTTTCTTTGTTGTTTTTTATCAAGGTGTGCATT
GTGAGGTACACCTTGTTGAGTCTGGTGGAGGATTGGTGCAGCCTAAAGGGTCATTGAAACTCTCATG TGCAGCCTCTGGATTCACCTTCAATACCTACGCCATGCACTGGGTCCGCCAGGCTCCAGGAAAGGGT TTGGAATGGGTTGCTCGCATAAGAAATAAAAGTAATAATTATGCAACATATTATGCCGATTCAGTGA AAGACAGGTTCACCATCTCCAGAGATGATTCACAAAGCATGCTCTTTCTGCAAATGGACAACTTGAA AACTGAGGACACAGCCATATATTACTGTGTGAGAGGGGGGTTATCTCCCTTTGACTACTGGGGCCAA
GGCACCACACTCACAGTCTCCTCA Heavy chain: Amino acid sequence (142 aa)
Signal peptide-FRl-CDRl-FR2-CDR2-FR3-CDR3-FR4
SEQ ID N0 38 — SEQ ID NO:39 — SEP ID NO: 11 — SEQ ID NO:12 — SEP ID NO:134 — SEQ ID NO: 135 — SEP ID NO: 15 — SEQ ID NO: 16
MTLNVLLGLKWVFFVVFYQGVHCEVHLVESGGGLVQPKGSLKLSCAASGFTFNTYAMHWVRQAPGKG
LEWVARIRNKSNNYATYYADSVKDRFTISRDDSQSMLFLQMDNLKTEDTAIYYCVRGGLSPFDYWGQ
GTTLTVSS
Light chain: DNA sequence (384 bp)
Signal seauence-FRl-CDRl-FR2-CDR2-FR3-CDR3-FR4
SEQ ID NO: 17 — SEQ ID NO: 18 — SEP ID NO: 19 — SEQ ID NO:42 — SEP ID NO:43
— SEQ ID NO:22 — SEP ID NO:44 — SEQ ID NO:45
ATGGATTTTCAAGTGCAGATTTTCAGCTTCCTGCTAATCAGTGCCTCAGTCATAATATCCAGAGGAC
AAATTGTTCTCACCCAGTCTCCAGCAATCATGTCTGCATCTCCAGGGGAGAAGGTCACCATGACCTG
CAGTGCCAGCTCAAGTGTAACTTACATGCACTGGTACCAGCAGAAGTCAGGCACCTCCCCCAAAAGA
TGGATTTATGACACATCCAAACTGGCTTCTGGAGTCCCTGCTCGCTTCAGTGGCAGTGGGTCTGGGA
CCTCTTACTCTCTCACAATCAGCAGCATGGAGGCTGAAGATGCTGCCACTTATTACTGCCAGCAGTG
GAGTAGTAACCCACCCACGTTCGGAGGGGGGACCAAGCTGGAAATAAGA
Light chain: Amino acid sequence (128 aa)
Signal peptide-FRl-CDRl-FR2-CDR2-FR3-CDR3-FR4
SEQ ID NO:25 — SEQ ID NO:26 — SEP ID NO:46 — SEQ ID NO:28 — SEP ID NO:29
— SEQ ID NO:30 — SEO ID NO:31 — SEQ ID NO:47
MDFQVQIFSFLLISASVIISRGQIVLTQSPAIMSASPGEKVTMTCSASSSVTYMHWYQQKSGTSPKR WIYDTSKLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCQQWSSNPPTFGGGTKLEIR
In certain embodiments, the monoclonal antibody (named 9035 herein) comprises light and heavy variable chains having the sequences shown below:
Heavy chain: DNA sequence (414 bp)
Signal seauence-FRl-CDRl-FR2-CDR2-FR3-CDR3-FR4
SEQ ID NO: 136 — SEQ ID NO:153 — SEO ID NO:5Q — SEQ ID NO:154 — SEP ID NO:155 — SEQ ID NO: 156 — SEP ID NO: 157 — SEQ ID NO: 158
ATGAACTTTGTGCTCAGCTTGATTTTCCTTGCCCTCATTTTAAAAGGTGTCCAGTGTGAAGTGCAGC
TGGTGGAGTCTGGGGGAGGCTTAGTGAAGCCTGGAGGGTCCCTGAAACTCTCCTGTGGAGCCTCTGG
ATTCACTTTCAGTAGCTTTGCCATGTCTTGGGTTCGCCAGACTCCGGAAAAGAGGCTGGAGTGGGTC
GCAACCATTAGTAATGGTGGCAGTTACACCTACTATCCAGACAGTGTGCAGGGTCGATTCACCATCT
CCAGAGACAATGCCAAGAACACCCTGTACCTGCGCATGAGCAGTCTGCGGTCTGAGGACACGGCCAT GTATTACTGTGCAAGACGGAGTAGTACGAGGGGCTTCTTTGACTACTGGGGCCACGGCACCACTCTC
ACAGTCTCCTCA
Heavy chain: Amino acid sequence (138 aa)
Signal peptide-FRl-CDRl-FR2-CDR2-FR3-CDR3-FR4
SEQ ID NO: 142 — SEQ ID NO: 159 — SEP ID NO: 160 — SEQ ID NO:59 — SEP ID NO:161 — SEQ ID NO: 162 — SEP ID NO: 163 — SEQ ID NO: 164
MNFVLSLIFLALILKGVQCEVQLVESGGGLVKPGGSLKLSCGASGFTFSSFAMSWVRQTPEKRLEWV ATISNGGSYTYYPDSVQGRFTISRDNAKNTLYLRMSSLRSEDTAMYYCARRSSTRGFFDYWGHGTTL TVSS
Light chain: DNA sequence (384 bp)
Signal seauence-FRl-CDRl-FR2-CDR2-FR3-CDR3-FR4
SEQ ID NO: 165 — SEQ ID NO: 166 — SEP ID NO: 167 — SEQ ID NO: 122 — SEP ID NO: 168 — SEQ ID NO:169 — SEP ID NO: 170 — SEQ ID NO:lll
ATGGATTTTCAAGTGCAGATTTTCAGCTTCCTGCTAATCAGTGCCTCAGTCATACTGTCCCGAGGAC
AAATTTTTCTCACCCAGTCTCCAGCAATCATGTCTGCATCTCCAGGGGAGAAGGTCACCATGACCTG
CAGTGCCAGCTCAAGTGTTAGTTACATGTACTGGTACCAGCAGAAGCCAGGATCCTCCCCCAGACTC
CTGATTTATGACTCATCCAAGCTGGCTTCTGGAGTCCCTGTTCAGTTCAGCGGCAGTGGGTCTGGGA
CCTCTTACTCTCTCACAATCAGCCGAATGGAGGCTGAAGATGCTGCCACTTATTACTGCCAGCAGTG
GAGGAGTTACCCACCCACGTTCGGTGCTGGGACCAAGCTGGAGCTGAAA
Light chain: Amino acid sequence (128 aa)
Signal peptide-FRl-CDRl-FR2-CDR2-FR3-CDR3-FR4
SEQ ID NO:69 — SEQ ID NO:171 — SEP ID NO: 70 — SEQ ID NO:127 — SEP ID NO:29 — SEQ ID NO: 172 — SEP ID NO: 152 — SEQ ID NO: 119
MDFQVQIFSFLLISASVILSRGQIFLTQSPAIMSASPGEKVTMTCSASSSVSYMYWYQQKPGSSPRL LIYDSSKLASGVPVQFSGSGSGTSYSLTISRMEAEDAATYYCQQWRSYPPTFGAGTKLELK
In certain embodiments, the monoclonal antibody (named 9047 herein) comprises light and heavy variable chains having the sequences shown below:
Heavy chain: DNA sequence (414 bp)
Signal seauence-FRl-CDRl-FR2-CDR2-FR3-CDR3-FR4
SEQ ID NO: 173 — SEQ ID NO: 153 — SEO ID NO:5Q — SEQ ID NO: 154 — SEP ID NO:139 — SEQ ID NO: 174 — SEP ID NO: 175 — SEQ ID NO: 176
ATGAACTTTGTGCTCAGTTTGATTTTCCTTGCCCTCATTTTAAAAGGTGTCCAGTGTGAAGTGCAGC
TGGTGGAGTCTGGGGGAGGCTTAGTGAAGCCTGGAGGGTCCCTGAAACTCTCCTGTGGAGCCTCTGG
ATTCACTTTCAGTAGCTTTGCCATGTCTTGGGTTCGCCAGACTCCGGAAAAGAGGCTGGAGTGGGTC GCAACCATTAGTAATGGTGGTAGTTACACCTACTATCCAGACAGTGTGAAGGGTCGATTCACCATCT
CCAGAGACAATGCCAAGAACACCCTGTACCTGCGCATGAGCAGTCTGCGGTCTGAGGACACGGCCCT
GTATTACTGTACAAGACGGAGTTCTACGAGGGGCTTCTTTGACTACTGGGGCCCCGGCACCACTCTC
ACAGTCTCCTCA
Heavy chain: Amino acid sequence (138 aa)
Signal peptide-FRl-CDRl-FR2-CDR2-FR3-CDR3-FR4
SEQ ID NO: 142 — SEQ ID NO: 159 — SEP ID NO: 160 — SEQ ID NO:59 — SEP ID NO: 145 — SEQ ID NO: 177 — SEP ID NO: 163 — SEQ ID NO: 178
MNFVLSLIFLALILKGVQCEVQLVESGGGLVKPGGSLKLSCGASGFTFSSFAMSWVRQTPEKRLEWV ATISNGGSYTYYPDSVKGRFTISRDNAKNTLYLRMSSLRSEDTALYYCTRRSSTRGFFDYWGPGTTL TVSS
Light chain: DNA sequence (384 bp)
Signal seauence-FRl-CDRl-FR2-CDR2-FR3-CDR3-FR4
SEQ ID NO: 179 — SEQ ID NO: 166 — SEP ID NO: 180 — SEQ ID NO: 181 — SEP ID NO: 168 — SEQ ID NO: 182 — SEP ID NO: 68 — SEQ ID NO: 183
ATGGATTTTCAAGTGCAGATTTTCAGCTTCCTGCTAATCAGTGCCTCAGTCTTACTGTCCCGAGGAC
AAATTTTTCTCACCCAGTCTCCAGCAATCATGTCTGCATCTCCAGGGGAGAAGGTCACCATGACCTG
CAGTGCCAGCTCAAGTGTTACTTACATGTACTGGTACCAGCAGAATCCAGGATCCTCCCCCAGACTC
CTGATTTATGACTCATCCAAGCTGGCTTCTGGAGTCCCTGTTCGGTTCAGCGGCAGTGGGTCTGGGA
CCTCTTACTCTCTCACAATCAGCCGAATGGAGGCTGAAGATGCTACCACTTATTACTGCCAGCAGTG
GAAGAGTTACCCACCCACGTTCGGTACTGGGACCAAGCTGGACCTGAAA
Light chain: Amino acid sequence (128 aa)
Signal peptide-FRl-CDRl-FR2-CDR2-FR3-CDR3-FR4
SEQ ID NO: 184 — SEQ ID NO: 171 — SEP ID NO: 185 — SEQ ID NO: 186 — SEP ID NO:29 — SEQ ID NO: 187 — SEP ID NO: 129 — SEQ ID NO: 188
MDFQVQIFSFLLISASVLLSRGQIFLTQSPAIMSASPGEKVTMTCSASSSVTYMYWYQQNPGSSPRL LIYDSSKLASGVPVRFSGSGSGTSYSLTISRMEAEDATTYYCQQWKSYPPTFGTGTKLDLK
In certain embodiments, the monoclonal antibody (named 9052 herein) comprises light and heavy variable chains having the sequences shown below:
Heavy chain: DNA sequence (414 bp)
Signal seauence-FRl-CDRl-FR2-CDR2-FR3-CDR3-FR4
SEQ ID NO: 136 — SEQ ID NO:189 — SEO ID NO:5Q — SEQ ID NO:154 — SEP ID NO:139 — SEQ ID NO:190 — SEP ID NO: 191 — SEQ ID NO:8
ATGAACTTTGTGCTCAGCTTGATTTTCCTTGCCCTCATTTTAAAAGGTGTCCAGTGTGAAGTGCAGC TGGTGGAGTCTGGGGGAGTCTTAGTGAAGCCTGGAGGGTCCCTGAAACTCTCCTGTGCAGCCTCTGG
ATTCACTTTCAGTAGCTTTGCCATGTCTTGGGTTCGCCAGACTCCGGAAAAGAGGCTGGAGTGGGTC
GCAACCATTAGTAATGGTGGTAGTTACACCTACTATCCAGACAGTGTGAAGGGTCGATTCACCATCT
CCAGAGACAATGCCAAGAACACCCTGTACCTGCGAATGAGCAGTCTGCGGTCTGAGGACACGGCCAT
GTATTACTGTGTAAGACGGGCTACTACGAGGGGCTACTTTGACTACTGGGGCCAAGGCACCACTCTC
ACAGTCTCCTCA
Heavy chain: Amino acid sequence (138 aa)
Signal peptide-FRl-CDRl-FR2-CDR2-FR3-CDR3-FR4
SEQ ID NO: 142 — SEQ ID NO: 192 — SEP ID NO: 160 — SEQ ID NO:59 — SEP ID NO: 145 — SEQ ID NO: 193 — SEP ID NO: 194 — SEQ ID NO: 16
MNFVLSLIFLALILKGVQCEVQLVESGGVLVKPGGSLKLSCAASGFTFSSFAMSWVRQTPEKRLEWV ATISNGGSYTYYPDSVKGRFTISRDNAKNTLYLRMSSLRSEDTAMYYCVRRATTRGYFDYWGQGTTL TVSS
Light chain: DNA sequence (384 bp)
Signal seauence-FRl-CDRl-FR2-CDR2-FR3-CDR3-FR4
SEQ ID NO: 165 — SEQ ID NO: 166 — SEP ID NO: 167 — SEQ ID NO: 122 — SEP ID NO: 168 — SEQ ID NO:169 — SEP ID NO: 195 — SEQ ID NO:lll
ATGGATTTTCAAGTGCAGATTTTCAGCTTCCTGCTAATCAGTGCCTCAGTCATACTGTCCCGAGGAC
AAATTTTTCTCACCCAGTCTCCAGCAATCATGTCTGCATCTCCAGGGGAGAAGGTCACCATGACCTG
CAGTGCCAGCTCAAGTGTTAGTTACATGTACTGGTACCAGCAGAAGCCAGGATCTTCCCCCAGACTC
CTGATTTATGACTCATCCAAGCTGGCTTCTGGAGTCCCTGTTCAGTTCAGCGGCAGTGGGTCTGGGA
CCTCTTACTCTCTCACAATCAGCCGAATGGAGGCTGAAGATGCTGCCACTTATTACTGCCAGCAGTG
GAGGAGTTATCCACCCACGTTCGGTGCTGGGACCAAGCTGGAGCTGAAA
Light chain: Amino acid sequence (128 aa)
Signal peptide-FRl-CDRl-FR2-CDR2-FR3-CDR3-FR4
SEQ ID NO:69 — SEQ ID NO:171 — SEP ID NO: 70 — SEQ ID NO:127 — SEP ID NO:29 — SEQ ID NO: 172 — SEP ID NO: 152 — SEQ ID NO: 119
MDFQVQIFSFLLISASVILSRGQIFLTQSPAIMSASPGEKVTMTCSASSSVSYMYWYQQKPGSSPRL LIYDSSKLASGVPVQFSGSGSGTSYSLTISRMEAEDAATYYCQQWRSYPPTFGAGTKLELK
In certain embodiments, the monoclonal antibody (named 9061 herein) comprises light and heavy variable chains having the sequences shown below:
Individual positive clones with correct VH and VL insert sizes were sequenced, one kind of VH DNA sequence and Two kinds ofVLDNA sequences were obtained in the trial.
Heavy chain: DNA sequence (414 bp) Signal seauence-FRl-CDRl-FR2-CDR2-FR3-CDR3-FR4
SEQ ID NO: 136 — SEQ ID NO:196 — SEO ID NO:5Q — SEQ ID NO:51 — SEP ID NO: 197 — SEQ ID NO:90 — SEP ID NO: 198 — SEQ ID NO:8
ATGAACTTTGTGCTCAGCTTGATTTTCCTTGCCCTCATTTTAAAAGGTGTCCAGTGTGAAGTGCAGC
TGGTGGAGTCTGGGAGAGGCTTAGTGAAGCCTGGCGGGTCCCTGAAACTCTCCTGTGCAGCCTCTGG
ATTCACTTTCAGTAGCTATGCCATGTCTTGGGTTCGCCAGACTCCGGAGAAGAGGCTGGAGTGGGTC
GCAACCATTAGTACTGGTGGTAGTTACACCTACTATCCAGACAGTGTGAAGGGTCGATTCACCATCT
CCAGAGACAATGCCAAGAACACCCTGTACCTGCAAATGAGCAGTCTGAGGTCTGAGGACACGGCCAT
GTATTACTGTGCAAGACGGGGTACTACGAGGGGATACTTTGACTACTGGGGCCAAGGCACCACTCTC
ACAGTCTCCTCA
Heavy chain: Amino acid sequence (138 aa)
Signal peptide-FRl-CDRl-FR2-CDR2-FR3-CDR3-FR4
SEQ ID NO: 142 — SEQ ID NO: 199 — SEO ID NO:58 — SEQ ID NO:59 — SEP ID NO:2QO — SEQ ID NO:94 — SEO ID NO:2Ql — SEQ ID NO: 16
MNFVLSLIFLALILKGVQCEVQLVESGRGLVKPGGSLKLSCAASGFTFSSYAMSWVRQTPEKRLEWV ATISTGGSYTYYPDSVKGRFTISRDNAKNTLYLQMSSLRSEDTAMYYCARRGTTRGYFDYWGQGTTL TVSS
Light chain 1: DNA sequence (384 bp)
Signal seauence-FRl-CDRl-FR2-CDR2-FR3-CDR3-FR4
SEQ ID NO:64 — SEQ ID NO:18 — SEP ID NO: 19 — SEQ ID NO:122 — SEP ID NO: 66 — SEQ ID NO:202 — SEP ID NO:2Q3 — SEQ ID NO: 111
ATGGATTTTCAAGTGCAGATTTTCAGCTTCCTGCTAATCAGTGCCTCAGTCATACTGTCCAGAGGAC
AAATTGTTCTCACCCAGTCTCCAGCAATCATGTCTGCATCTCCAGGGGAGAAGGTCACCATGACCTG
CAGTGCCAGCTCAAGTGTAAGTTACATGTACTGGTACCAGCAGAAGCCAGGATCCTCCCCCAGACTC
CTGATTTATGACACATCCAACCTGGCTTCTGGAGTCCCTGTTCGCTTCAGTGGCAGTGGGTCTGGGA
CCTCTTACTCTCTCACAATCAGCCGAATGGAGGCTGAAGATGCTGCCACTTATTCCTGCCAGCAGTG
GAGTAGTTACCCACCCACGTTCGGTGCTGGGACCAAGCTGGAGCTGAAA
Light chain 1: Amino acid sequence (128 aa)
Signal peptide-FRl-CDRl-FR2-CDR2-FR3-CDR3-FR4
SEQ ID NO:69 — SEQ ID NO:26 — SEP ID NO: 70 — SEQ ID NO:127 — SEP ID NO: 72 — SEQ ID NO:204 — SEP ID NO:2Q5 — SEQ ID NO: 119
MDFQVQIFSFLLISASVILSRGQIVLTQSPAIMSASPGEKVTMTCSASSSVSYMYWYQQKPGSSPRL LIYDTSNLASGVPVRFSGSGSGTSYSLTISRMEAEDAATYSCQQWSSYPPTFGAGTKLELK Light chain 2: DNA sequence (381 bp)
Signal seauence-FRl-CDRl-FR2-CDR2-FR3-CDR3-FR4 SEQ ID NO:206 — SEQ ID NO: 105 — SEP ID NO:2Q7 — SEQ ID NO:208 — SEP ID NP:209 — SEQ ID NO:210 — SEP ID NP:211 — SEQ ID NO:24
ATGGAGTCACAGATTCAGGTCTTTGTATTCGTGTTTCTCTGGTTGTCTGGTGTTGACGGAGACATTG
TGATGACCCAGTCTCACAAATTCATGTCCACATCAGTAGGAGACAGGGTCAGCATCACCTGCAAGGC
CAGTCAGGATGTGAGTACTGCTGTAGCCTGGTATCAACAGAAACCAGGACAATCTCCTAAACTACTG
ATTTACTCGGCATCCTACCGGTACACTGGAGTCCCTGATCGCTTCACTGGCAGTGGATCTGGGACGG
ATTTCACTTTCACCATCAGCAGTGTGCAGGCTGAAGACCTGGCAGTTTATTACTGTCAGCAACATTA
TAGTACTCCGTACACGTTCGGAGGGGGGACCAAGCTGGAAATAAAA
Light chain 2: Amino acid sequence (127 aa)
Signal peptide-FRl-CDRl-FR2-CDR2-FR3-CDR3-FR4
SEQ ID NQ 212 — SEQ ID NO:113 — SEO ID NQ:213 — SEQ ID NO:115 — SEP ID NO:214 — SEQ ID NO:215 — SEO ID NQ:216 — SEQ ID NO:32
MESQIQVFVFVFLWLSGVDGDIVMTQSHKFMSTSVGDRVSITCKASQDVSTAVAWYQQKPGQSPKLL
IYSASYRYTGVPDRFTGSGSGTDFTFTISSVQAEDIJAVYYCQQHYSTPYTFGGGTKLEIK
In certain embodiments, the monoclonal antibody (named 9092 herein) comprises light and heavy variable chains having the sequences shown below:
Heavy chain: DNA sequence (405 bp)
Signal seauence-FRl-CDRl-FR2-CDR2-FR3-CDR3-FR4
SEQ ID NO:217 — SEQ ID NO:218 — SEQ ID NQ:219 — SEQ ID NO:220 — SEQ ID NO:221 — SEQ ID NO:222 — SEQ ID NQ:223 — SEQ ID NO:8
ATGGGATGGAGCCGGATCTTTCTCTTCCTCCTGTCAATAATTGCAGGTGTCCATTGCCAGGTCCAGC
TGCAGCAGTCTGGACCTGAGCTGGTGAAGCCTGGGGCTTCAGTGCGGATATCCTGCAAGGCTTCTGG CTACACCTTCACAACCTTCTATTTACACTGGGTGAAGCAGAGGCCTGGACAGGGACTTGAGTGGATT GGATGGATTTATCCTGTAAATGTTAAAATTAAGTACAGTGAGAGGTTCAAGGGCAAGGCCACAC TGA CTGCAGACAAATCCTCCAGCACAGCCTACATGCAGCTCGGCAGCCTGACCTCTGAGGACTCTGCGGT CTATTTCTGTGTAAGAGGGGGGAGGGGACTTGACTACTGGGGCCAAGGCACCACTCTCACAGTCTCC TCA
Heavy chain: Amino acid sequence (135 aa)
Signal peptide-FRl-CDRl-FR2-CDR2-FR3-CDR3-FR4
SEQ ID NO:224 — SEQ ID NO:225 — SEP ID NO:226 — SEQ ID NO:227 — SEP ID NQ:228 — SEQ ID NO:229 — SEQ ID NQ:230 — SEQ ID NO: 16
MG W SRI FLFLLSII AG VH CQVQLQQS GPELVKPGASVRI S CKAS GY TFTT F Y L HWVKQRPGQGLEWI GWIYPVNVKIKY SERFKGKATLTADKSSSTAYMQLGSLTSEDSAVYFCVRGGRGLDYWGQGTTLTVS S
Light chain: DNA sequence (396 bp) Signal seauence-FRl-CDRl-FR2-CDR2-FR3-CDR3-FR4
SEQ ID NO:231 — SEQ ID NO:232 — SEP ID NO:233 — SEQ ID NO:234 — SEP ID NP:235 — SEQ ID NO:236 — SEP ID NP:237 — SEQ ID NO: 124
ATGGAATCACAGACTCAGGTCTTCCTCTCCCTGCTGCTCTGGGTATCTGGTACCTGTGGGAACATTA
TGATGACACAGTCGCCATCATCTCTGGCTGTGTCTGCAGGAGAAAAGGTCACTATGAGCTGTAAGTC
CAGTCAAAGTGTTTTATACAGTTCAAATCAGAAGAACTACTTGGCCTGGTACCAGCAGAAACCAGGG
CAGTCTCCTAAAATGCTGATCTACTGGGCATCCTTTAGGGAATCTGGTGTCCCTGATCGCTTCACAG GCAGTGGATCTGGGACAGATTTTACTCTTACCATCAGCAGTGTACAAGCTGAAGACCTGGCAGTTTA TTACTGTCATCAATACCTCTCCTTATTCACGTTCGGCTCGGGGACAAAGTTGGAAATAAAA Light chain: Amino acid sequence (132 aa)
Signal peptide-FRl-CDRl-FR2-CDR2-FR3-CDR3-FR4
SEQ ID NO:238 — SEQ ID NO:239 — SEP ID NO:24Q — SEQ ID NO:241 — SEP ID NO:242 — SEQ ID NO:243 — SEO ID NO:244 — SEQ ID NO: 130
MESQTQVFLSLLLWVSGTCGNIMMTQSPSSLAVSAGEKVTMSCKSSQSVLYSSNQKNYLAWYQQKPG QSPKMLIYWASFRESGVPDRFTGSGSGTDFTLTISSVQAEDLAVYYCHQYLSLFTFGSGTKLEIK
In certain embodiments, the monoclonal antibody (named 9099 herein) comprises light and heavy variable chains having the sequences shown below:
Heavy chain: DNA sequence (414 bp)
Signal seauence-FRl-CDRl-FR2-CDR2-FR3-CDR3-FR4
SEQ ID NO: 136 — SEQ ID NO:189 — SEO ID NO:5Q — SEQ ID NO:154 — SEP ID NO:139 — SEQ ID NO:190 — SEP ID NO: 191 — SEQ ID NO:8
ATGAACTTTGTGCTCAGCTTGATTTTCCTTGCCCTCATTTTAAAAGGTGTCCAGTGTGAAGTGCAGC
TGGTGGAGTCTGGGGGAGTCTTAGTGAAGCCTGGAGGGTCCCTGAAACTCTCCTGTGCAGCCTCTGG
ATTCACTTTCAGTAGCTTTGCCATGTCTTGGGTTCGCCAGACTCCGGAAAAGAGGCTGGAGTGGGTC
GCAACCATTAGTAATGGTGGTAGTTACACCTACTATCCAGACAGTGTGAAGGGTCGATTCACCATCT
CCAGAGACAATGCCAAGAACACCCTGTACCTGCGAATGAGCAGTCTGCGGTCTGAGGACACGGCCAT
GTATTACTGTGTAAGACGGGCTACTACGAGGGGCTACTTTGACTACTGGGGCCAAGGCACCACTCTC
ACAGTCTCCTCA
Heavy chain: Amino acid sequence (138 aa)
Signal peptide-FRl-CDRl-FR2-CDR2-FR3-CDR3-FR4
SEQ ID NO: 142 — SEQ ID NO: 192 — SEP ID NO: 160 — SEQ ID NO:59 — SEP ID NO: 145 — SEQ ID NO: 193 — SEP ID NO: 194 — SEQ ID NO: 16
MNFVLSLIFLALILKGVQCEVQLVESGGVLVKPGGSLKLSCAASGFTFSSFAMSWVRQTPEKRLEWV ATISNGGSYTYYPDSVKGRFTISRDNAKNTLYLRMSSLRSEDTAMYYCVRRATTRGYFDYWGQGTTL
TVSS Light chain: DNA sequence (384 bp)
Signal seauence-FRl-CDRl-FR2-CDR2-FR3-CDR3-FR4
SEQ ID NO: 165 — SEQ ID NO: 166 — SEP ID NO: 167 — SEQ ID NO: 122 — SEP ID NO: 168 — SEQ ID NO:169 — SEP ID NO: 195 — SEQ ID NO:lll
ATGGATTTTCAAGTGCAGATTTTCAGCTTCCTGCTAATCAGTGCCTCAGTCATACTGTCCCGAGGAC
AAATTTTTCTCACCCAGTCTCCAGCAATCATGTCTGCATCTCCAGGGGAGAAGGTCACCATGACCTG
CAGTGCCAGCTCAAGTGTTAGTTACATGTACTGGTACCAGCAGAAGCCAGGATCTTCCCCCAGACTC
CTGATTTATGACTCATCCAAGCTGGCTTCTGGAGTCCCTGTTCAGTTCAGCGGCAGTGGGTCTGGGA
CCTCTTACTCTCTCACAATCAGCCGAATGGAGGCTGAAGATGCTGCCACTTATTACTGCCAGCAGTG
GAGGAGTTATCCACCCACGTTCGGTGCTGGGACCAAGCTGGAGCTGAAA
Light chain: Amino acid sequence (128 aa)
Signal peptide-FRl-CDRl-FR2-CDR2-FR3-CDR3-FR4
SEQ ID NO:69 — SEQ ID NO:171 — SEP ID NO: 70 — SEQ ID NO:127 — SEP ID NO:29 — SEQ ID NO: 172 — SEP ID NO: 152 — SEQ ID NO: 119
MDFQVQIFSFLLISASVILSRGQIFLTQSPAIMSASPGEKVTMTCSASSSVSYMYWYQQKPGSSPRL LIYDSSKLASGVPVQFSGSGSGTSYSLTISRMEAEDAATYYCQQWRSYPPTFGAGTKLELK
In certain embodiments, the monoclonal antibody (named 9100 herein) comprises light and heavy variable chains having the sequences shown below:
Heavy chain: DNA sequence (414 bp)
Signal seauence-FRl-CDRl-FR2-CDR2-FR3-CDR3-FR4
SEQ ID NO: 136 — SEQ ID NO:189 — SEO ID NO:5Q — SEQ ID NO:154 — SEP ID NO:139 — SEQ ID NO:190 — SEP ID NO: 191 — SEQ ID NO:8
ATGAACTTTGTGCTCAGCTTGATTTTCCTTGCCCTCATTTTAAAAGGTGTCCAGTGTGAAGTGCAGC
TGGTGGAGTCTGGGGGAGTCTTAGTGAAGCCTGGAGGGTCCCTGAAACTCTCCTGTGCAGCCTCTGG
ATTCACTTTCAGTAGCTTTGCCATGTCTTGGGTTCGCCAGACTCCGGAAAAGAGGCTGGAGTGGGTC
GCAACCATTAGTAATGGTGGTAGTTACACCTACTATCCAGACAGTGTGAAGGGTCGATTCACCATCT
CCAGAGACAATGCCAAGAACACCCTGTACCTGCGAATGAGCAGTCTGCGGTCTGAGGACACGGCCAT
GTATTACTGTGTAAGACGGGCTACTACGAGGGGCTACTTTGACTACTGGGGCCAAGGCACCACTCTC
ACAGTCTCCTCA
Heavy chain: Amino acid sequence (138 aa)
Signal peptide-FRl-CDRl-FR2-CDR2-FR3-CDR3-FR4
SEQ ID NO: 142 — SEQ ID NO: 192 — SEP ID NO: 160 — SEQ ID NO:59 — SEP ID NO: 145 — SEQ ID NO: 193 — SEP ID NO: 194 — SEQ ID NO: 16
MNFVLSLIFLALILKGVQCEVQLVESGGVLVKPGGSLKLSCAASGFTFSSFAMSWVRQTPEKRLEWV ATISNGGSYTYYPDSVKGRFTISRDNAKNTLYLRMSSLRSEDTAMYYCVRRATTRGYFDYWGQGTTL TVSS
Light chain: DNA sequence (384 bp)
Signal seauence-FRl-CDRl-FR2-CDR2-FR3-CDR3-FR4
SEQ ID NO: 165 — SEQ ID NO: 166 — SEP ID NO: 167 — SEQ ID NO: 122 — SEP ID NO: 168 — SEQ ID NO:169 — SEP ID NO: 195 — SEQ ID NO:lll
ATGGATTTTCAAGTGCAGATTTTCAGCTTCCTGCTAATCAGTGCCTCAGTCATACTGTCCCGAGGAC
AAATTTTTCTCACCCAGTCTCCAGCAATCATGTCTGCATCTCCAGGGGAGAAGGTCACCATGACCTG
CAGTGCCAGCTCAAGTGTTAGTTACATGTACTGGTACCAGCAGAAGCCAGGATCTTCCCCCAGACTC
CTGATTTATGACTCATCCAAGCTGGCTTCTGGAGTCCCTGTTCAGTTCAGCGGCAGTGGGTCTGGGA
CCTCTTACTCTCTCACAATCAGCCGAATGGAGGCTGAAGATGCTGCCACTTATTACTGCCAGCAGTG
GAGGAGTTATCCACCCACGTTCGGTGCTGGGACCAAGCTGGAGCTGAAA
Light chain: Amino acid sequence (128 aa)
Signal peptide-FRl-CDRl-FR2-CDR2-FR3-CDR3-FR4
SEQ ID NO:69 — SEQ ID NO:171 — SEP ID NO: 70 — SEQ ID NO:127 — SEP ID NO:29 — SEQ ID NO: 172 — SEP ID NO: 152 — SEQ ID NO: 119
MDFQVQIFSFLLISASVILSRGQIFLTQSPAIMSASPGEKVTMTCSASSSVSYMYWYQQKPGSSPRL LIYDSSKLASGVPVQFSGSGSGTSYSLTISRMEAEDAATYYCQQWRSYPPTFGAGTKLELK
In certain embodiments, the isolated monoclonal antibody comprises a light chain variable region (VL) and a heavy chain variable region (VH). In certain embodiments, the VL comprises a CDR1 region comprising the amino acid sequence of SEQ ID NO:27, 46, 70, 114, 126, 185, 213, or 240. In certain embodiments, the VL comprises a CDR2 region comprising the amino acid sequence of SEQ ID NO:29, 72, 116, 214, or 242. In certain embodiments, the VL comprises a CDR3 region comprising the amino acid sequence of SEQ ID NQ:31, 85, 118, 129, 152, 205, 216, or 244. In certain embodiments, the VH comprises a CDR1 region comprising the amino acid sequence of SEQ ID NQ: 11, 58, 92, 101, 144, 160, or 226. In certain embodiments, the VH comprises a CDR2 region comprising the amino acid sequence of SEQ ID NQ:13, 40, 60, 93, 102, 134, 145, 161, 200, or 228. In certain embodiments, the VH comprises a CDR3 region comprising the amino acid sequence of SEQ ID NO: 15, 62, 81, 147, 163, 194, 201, or 230.
In certain embodiments, the VL comprises a CDR1 region comprising the amino acid sequence of SEQ ID NO:27, 46, 70, 114, or 126.
In certain embodiments, the VL comprises a CDR2 region comprising the amino acid sequence of SEQ ID NO:29, 72, or 116. In certain embodiments, the VL comprises a CDR3 region comprising the amino acid sequence of SEQ ID NO:31, 85, 118, 129, or 152.
In certain embodiments, the VL comprises a CDR1 region comprising the amino acid sequence of SEQ ID NO:70, 185, 213, or 240.
In certain embodiments, the VL comprises a CDR2 region comprising the amino acid sequence of SEQ ID NO:29, 72, 214, or 242.
In certain embodiments, the VL comprises a CDR3 region comprising the amino acid sequence of SEQ ID NO: 152, 129, 205, 216, or 244.
In certain embodiments, the VL comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO:27; a CDR2 region comprising the amino acid sequence of SEQ ID NO:29; and a CDR3 region comprising the amino acid sequence of SEQ ID NO:31.
In certain embodiments, the VL comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO:46; a CDR2 region comprising the amino acid sequence of SEQ ID NO:29; and a CDR3 region comprising the amino acid sequence of SEQ ID NO:31.
In certain embodiments, the VL comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO:70; a CDR2 region comprising the amino acid sequence of SEQ ID NO:29; and a CDR3 region comprising the amino acid sequence of SEQ ID NO:152.
In certain embodiments, the VL comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO:70; a CDR2 region comprising the amino acid sequence of SEQ ID NO:72; and a CDR3 region comprising the amino acid sequence of SEQ ID NO:85.
In certain embodiments, the VL comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO:70; a CDR2 region comprising the amino acid sequence of SEQ ID NO:72; and a CDR3 region comprising the amino acid sequence of SEQ ID NO:205.
In certain embodiments, the VL comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO: 114; a CDR2 region comprising the amino acid sequence of SEQ ID NO: 116; and a CDR3 region comprising the amino acid sequence of SEQ ID NO:118.
In certain embodiments, the VL comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO: 126; a CDR2 region comprising the amino acid sequence of SEQ ID NO:72; and a CDR3 region comprising the amino acid sequence of SEQ ID NO: 129.
In certain embodiments, the VL comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO: 185; a CDR2 region comprising the amino acid sequence of SEQ ID NO:29; and a CDR3 region comprising the amino acid sequence of SEQ ID NO: 129.
In certain embodiments, the VL comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO:213; a CDR2 region comprising the amino acid sequence of SEQ ID NO:214; and a CDR3 region comprising the amino acid sequence of SEQ ID NO:216.
In certain embodiments, the VL comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO:240; a CDR2 region comprising the amino acid sequence of SEQ ID NO:242; and a CDR3 region comprising the amino acid sequence of SEQ ID NO:244.
In certain embodiments, the VH comprises a CDR1 region comprising the amino acid sequence of SEQ ID NO: 11, 58, 92, 101, or 144.
In certain embodiments, the VH comprises a CDR2 region comprising the amino acid sequence of SEQ ID NO: 13, 40, 60, 93, 102, 134, or 145.
In certain embodiments, the VH comprises a CDR3 region comprising the amino acid sequence of SEQ ID NO: 15, 62, 81, or 147.
In certain embodiments, the VH comprises a CDR1 region comprising the amino acid sequence of SEQ ID NO: 160, 58, or 226.
In certain embodiments, the VH comprises a CDR2 region comprising the amino acid sequence of SEQ ID NO: 161, 145, 200, or 228.
In certain embodiments, the VH comprises a CDR3 region comprising the amino acid sequence of SEQ ID NO: 163, 194, 201, or 230.
In certain embodiments, the VH comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO: 11; a CDR2 region comprising the amino acid sequence of SEQ ID NO:13; and a CDR3 region comprising the amino acid sequence of SEQ ID NO:15;
In certain embodiments, the VH comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO: 11; a CDR2 region comprising the amino acid sequence of SEQ ID NO:40; and a CDR3 region comprising the amino acid sequence of SEQ ID NO: 15.
In certain embodiments, the VH comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO: 11; a CDR2 region comprising the amino acid sequence of SEQ ID NO: 134; and a CDR3 region comprising the amino acid sequence of SEQ ID NO:15.
In certain embodiments, the VH comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO:58; a CDR2 region comprising the amino acid sequence of SEQ ID NO:60; and a CDR3 region comprising the amino acid sequence of SEQ ID NO:62.
In certain embodiments, the VH comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO:58; a CDR2 region comprising the amino acid sequence of SEQ ID NO:60; and a CDR3 region comprising the amino acid sequence of SEQ ID NO:81.
In certain embodiments, the VH comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO:58; a CDR2 region comprising the amino acid sequence of SEQ ID NO:200; and a CDR3 region comprising the amino acid sequence of SEQ ID NO:201.
In certain embodiments, the VH comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO:92; a CDR2 region comprising the amino acid sequence of SEQ ID NO:93; and a CDR3 region comprising the amino acid sequence of SEQ ID NO:62.
In certain embodiments, the VH comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO: 101; a CDR2 region comprising the amino acid sequence of SEQ ID NO: 102; and a CDR3 region comprising the amino acid sequence of SEQ ID NO:62.
In certain embodiments, the VH comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO: 144; a CDR2 region comprising the amino acid sequence of SEQ ID NO: 145; and a CDR3 region comprising the amino acid sequence of SEQ ID NO: 147.
In certain embodiments, the VH comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO: 160; a CDR2 region comprising the amino acid sequence of SEQ ID NO: 145; and a CDR3 region comprising the amino acid sequence of SEQ ID NO:163.
In certain embodiments, the VH comprises a CDR1 region comprising the amino acid sequence of SEQ ID NO: 160; a CDR2 region comprising the amino acid sequence of SEQ ID NO: 145; and a CDR3 region comprising the amino acid sequence of SEQ ID NO: 194.
In certain embodiments, the VH comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO: 160; a CDR2 region comprising the amino acid sequence of SEQ ID NO: 161; and a CDR3 region comprising the amino acid sequence of SEQ ID NO:163.
In certain embodiments, the VH comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO:226; a CDR2 region comprising the amino acid sequence of SEQ ID NO:228; and a CDR3 region comprising the amino acid sequence of SEQ ID NO:230.
In certain embodiments, the VL comprises the amino acid sequence of SEQ ID NO:27-SEQ ID NO:28-SEQ ID NO:29-SEQ ID NO:30-SEQ ID NO:31,
SEQ ID NO:46-SEQ ID NO:28-SEQ ID NO:29-SEQ ID NO:30-SEQ ID NO:31,
SEQ ID NO:70-SEQ ID NO:71-SEQ ID NO:72-SEQ ID NO:73-SEQ ID NO:85,
SEQ ID NO:70-SEQ ID NO:127-SEQ ID NO:29-SEQ ID NO:151-SEQ ID NO: 152,
SEQ ID NO:70-SEQ ID NO:127-SEQ ID NO:29-SEQ ID NO:172-SEQ ID NO: 152,
SEQ ID NO:70-SEQ ID NO: 127-SEQ ID NO:72-SEQ ID NO:204-SEQ ID NO:205,
SEQ ID NO: 114-SEQ ID NO: 115-SEQ ID NO: 116-SEQ ID NO: 117-SEQ ID NO: 118, SEQ ID NO: 126-SEQ ID NO: 127-SEQ ID NO:72-SEQ ID NO: 128-SEQ ID NO: 129, SEQ ID NO:185-SEQ ID NO:186-SEQ ID NO:29-SEQ ID NO:187-SEQ ID NO: 129, SEQ ID NO:213-SEQ ID NO: 115-SEQ ID NO:214-SEQ ID NO:215-SEQ ID NO:216, or SEQ ID NO:240-SEQ ID NO:241-SEQ ID NO:242-SEQ ID NO:243-SEQ ID NO:244.
In certain embodiments, the VH comprises the amino acid sequence of SEQ ID NO: 11-SEQ ID NO: 12-SEQ ID NO: 13-SEQ ID NO: 14-SEQ ID NO: 15,
SEQ ID NO: 11-SEQ ID NO: 12-SEQ ID NO:40-SEQ ID NO:41-SEQ ID NO: 15,
SEQ ID NO: 11-SEQ ID NO: 12-SEQ ID NO:134-SEQ ID NO:135-SEQ ID NO: 15,
SEQ ID NO:58-SEQ ID NO:59-SEQ ID NO:60-SEQ ID NO:61-SEQ ID NO:62,
SEQ ID NO:58-SEQ ID NO:59-SEQ ID NO:60-SEQ ID NO:80-SEQ ID NO:81,
SEQ ID NO:58-SEQ ID NO:59-SEQ ID N0:200-SEQ ID NO:94-SEQ ID NO:201,
SEQ ID NO:92-SEQ ID NO:59-SEQ ID NO:93-SEQ ID NO:94-SEQ ID NO:62,
SEQ ID NO:101-SEQ ID NO:59-SEQ ID NO:102-SEQ ID NO:103-SEQ ID NO:62,
SEQ ID NO: 144-SEQ ID NO:59-SEQ ID NO: 145-SEQ ID NO: 146-SEQ ID NO: 147, SEQ ID NO:160-SEQ ID NO:59-SEQ ID NO: 145-SEQ ID NO:177-SEQ ID NO: 163, SEQ ID NO:160-SEQ ID NO:59-SEQ ID NO: 145-SEQ ID NO:193-SEQ ID NO: 194, SEQ ID NO:160-SEQ ID NO:59-SEQ ID NO:161-SEQ ID NO:162-SEQ ID NO: 163, or SEQ ID NO:226-SEQ ID NO:227-SEQ ID NO:228-SEQ ID NO:229-SEQ ID NO:230.
In certain embodiments, the VL comprises the amino acid sequence of:
SEQ ID NO:27-SEQ ID NO:28-SEQ ID NO:29-SEQ ID NO:30-SEQ ID NO:31,
SEQ ID NO:46-SEQ ID NO:28-SEQ ID NO:29-SEQ ID NO:30-SEQ ID NO:31,
SEQ ID NO:70-SEQ ID NO:71-SEQ ID NO:72-SEQ ID NO:73-SEQ ID NO:85,
SEQ ID NO:70-SEQ ID NO: 127-SEQ ID NO:29-SEQ ID NO: 151-SEQ ID NO: 152.
SEQ ID NO: 114-SEQ ID NO: 115-SEQ ID NO: 116-SEQ ID NO: 117-SEQ ID NO: 118, or SEQ ID NO: 126-SEQ ID NO: 127-SEQ ID NO:72-SEQ ID NO: 128-SEQ ID NO: 129. In certain embodiments, the VH comprises the amino acid sequence of:
SEQ ID NO: 11-SEQ ID NO: 12-SEQ ID NO: 13-SEQ ID NO: 14-SEQ ID NO: 15,
SEQ ID NO: 11-SEQ ID NO: 12-SEQ ID NO:40-SEQ ID NO:41-SEQ ID NO: 15,
SEQ ID NO: 11-SEQ ID NO: 12-SEQ ID NO:134-SEQ ID NO:135-SEQ ID NO: 15,
SEQ ID NO:58-SEQ ID NO:59-SEQ ID NO:60-SEQ ID NO:61-SEQ ID NO:62,
SEQ ID NO:58-SEQ ID NO:59-SEQ ID NO:60-SEQ ID NO:80-SEQ ID NO:81,
SEQ ID NO:92-SEQ ID NO:59-SEQ ID NO:93-SEQ ID NO:94-SEQ ID NO:62,
SEQ ID NO:101-SEQ ID NO:59-SEQ ID NO:102-SEQ ID NO:103-SEQ ID NO:62, or SEQ ID NO: 144-SEQ ID NO:59-SEQ ID NO: 145-SEQ ID NO: 146-SEQ ID NO: 147.
In certain embodiments, the VL comprises the amino acid sequence of:
SEQ ID NO:70-SEQ ID NO:127-SEQ ID NO:29-SEQ ID NO:172-SEQ ID NO: 152,
SEQ ID NO:70-SEQ ID NO: 127-SEQ ID NO:72-SEQ ID NO:204-SEQ ID NO:205,
SEQ ID NO:185-SEQ ID NO:186-SEQ ID NO:29-SEQ ID NO:187-SEQ ID NO: 129,
SEQ ID NO:213-SEQ ID NO:l 15-SEQ ID NO:214-SEQ ID NO:215-SEQ ID NO:216, or SEQ ID NO:240-SEQ ID NO:241-SEQ ID NO:242-SEQ ID NO:243-SEQ ID NO:244.
In certain embodiments, the VH comprises the amino acid sequence of:
SEQ ID NO:58-SEQ ID NO:59-SEQ ID NO:200-SEQ ID NO:94-SEQ ID NO:201,
SEQ ID NO:160-SEQ ID NO:59-SEQ ID NO: 145-SEQ ID NO:177-SEQ ID NO: 163,
SEQ ID NO:160-SEQ ID NO:59-SEQ ID NO: 145-SEQ ID NO:193-SEQ ID NO: 194,
SEQ ID NO:160-SEQ ID NO:59-SEQ ID NO:161-SEQ ID NO:162-SEQ ID NO: 163, or SEQ ID NO:226-SEQ ID NO:227-SEQ ID NO:228-SEQ ID NO:229-SEQ ID NO:230.
In certain embodiments, the monoclonal antibody is humanized.
In certain embodiments, the monoclonal antibody is labeled.
In certain embodiments, the antibody of the disclosure is capable of crossing the blood-brain barrier (BBB). In certain embodiments, the antibody of the disclosure is bispecific, being IgG-like or non-IgG-like. The antibody can bind to alphα-synuclein, as described elsewhere herein and using any of the CDR sequences recited herein, and can also bind to a BBB target receptor that allows for transport of the antibody through the BBB (in a non-limiting example, through receptor-mediated transcytosis). A non-limiting example of such BBB target receptor is transferrin receptor, which activates a molecular channel that normally imports iron into the brain. Anti-human transferrin receptor antibodies contemplated within the invention include those recited in US20160369001, which is incorporated herein in its entirety by reference. Other non-limiting examples of such BBB target receptors are low-density lipoprotein (LDL) receptor and insulin receptor. In certain embodiments, the antibodies of the disclosure comprise a single-chain anti-BBB target receptor antibody. In certain embodiments, the antibodies of the disclosure have an Fc fragment engineered to be capable of binding to a BBB target receptor. Approaches contemplated in the present disclosure are described in Pulgar, Front. Neurosci., January 2019, Vol. 12, Article 2019, and Kariolis, et al ., Science Translational Medicine 12(545), eaayl359, which are incorporated herein in their entireties by reference.
The disclosure further provides isolated polynucleotides (including RNA and/or DNA) encoding the antibodies or antigen binding fragments thereof, for example a nucleic acid encoding for one or more CDRs, or a variable heavy chain or variable light chain region of the α-Syn antibodies of the disclosure. Nucleic acid includes DNA and RNA.
In certain embodiments, the disclosure provides an isolated polynucleotide comprising the nucleic acid sequence of SEQ ID NOs:3, 5, 7, 19, 21, 23, 35, 43, 44, 50, 52,
54, 66, 68, 75, 77, 88, 89, 96, 97, 99, 106, 108, 110, 121, 132, 138, 139, 141, 148, 150, 155, 157, 167, 168, 170, 175, 180, 191, 195, 197, 198, 203, 207, 209, 211, 219, 221, 223, 233,
235, and 237.
In certain embodiments, the disclosure provides an isolated polynucleotide comprising at least one nucleic acid sequence selected from the group consisting of SEQ ID
NOs:3, 5, 7, 35, 50, 52, 54, 75, 77, 88, 89, 97, 99, 132, 138, 139, 141, 155, 157, 175, 191, 197, 198, 219, 221, and 223.
In certain embodiments, the disclosure provides an isolated polynucleotide comprising at least one nucleic acid sequence selected from the group consisting of SEQ ID NOs:19, 21, 23, 43, 44, 66, 68, 96, 106, 108, 110, 121, 148, 150, 167, 168, 170, 180, 195, 203, 207, 209, 211, 233, 235, and 237.
In certain embodiments, the antibody has a VL encoded by a nucleic acid sequence group comprising a nucleic acid sequence set selected from the group consisting of: SEQ ID NOs: 19, 21, 23; SEQ ID NOs: 19, 43, 44; SEQ ID NOs: 19, 66, 68; SEQ ID NOs: 19, 66, 96;
SEQ ID NOs:19, 66, 203; SEQ ID NOs:19, 148, 150; SEQ ID NOs:106, 108, 110; SEQ ID N0s:121, 66, 68; SEQ ID NOs: 167, 168, 170; SEQ ID NOs: 167, 168, 195; SEQ ID NOs:180, 168, 68; SEQ ID NOs:213, 214, 216; and SEQ ID NOs:233, 235, 237.
In certain embodiments, the antibody has a VH encoded by a nucleic acid sequence group comprising a nucleic acid sequence set selected from the group consisting of: SEQ ID NOs:3, 5, 7; SEQ ID NOs:3, 35, 7; SEQ ID NOs:3, 132, 7; SEQ ID NOs:50, 52, 54; SEQ ID NOs:50, 75, 77; SEQ ID NOs:50, 139, 175; SEQ ID NOs:50, 139, 191; SEQ ID NOs:50, 155, 157; SEQ ID NOs:50, 197, 198; SEQ ID NOs:88, 89, 54; SEQ ID NOs:97, 99, 54; SEQ ID NOs:138, 139, 141; and SEQ ID NOs:219, 221, 223.
In certain embodiments, the disclosure provides an autonomously replicating or an integrative mammalian cell vector comprising a recombinant nucleic acid of the disclosure.
In other embodiments, the disclosure provides a vector comprising a recombinant nucleic acid of the disclosure. In yet other embodiments, the recombinant nucleic acid of the disclosure encodes an antibody comprising a light chain variable region (VL) and a heavy chain variable region (VH). In certain embodiments, the VL comprises a CDR1 region comprising the amino acid sequence of SEQ ID NO:27, 46, 70, 114, 126, 185, 213, or 240.
In certain embodiments, the VL comprises a CDR2 region comprising the amino acid sequence of SEQ ID NO:29, 72, 116, 214, or 242. In certain embodiments, the VL comprises a CDR3 region comprising the amino acid sequence of SEQ ID NO:31, 85, 118, 129, 152, 205, 216, or 244. In certain embodiments, the VH comprises a CDR1 region comprising the amino acid sequence of SEQ ID NO: 11, 58, 92, 101, 144, 160, or 226. In certain embodiments, the VH comprises a CDR2 region comprising the amino acid sequence of SEQ ID NO: 13, 40, 60, 93, 102, 134, 145, 161, 200, or 228. In certain embodiments, the VH comprises a CDR3 region comprising the amino acid sequence of SEQ ID NO: 15, 62, 81, 62, 147, 163, 194, 201, or 230. In yet other embodiments, the vector comprises a plasmid or virus. In yet other embodiments, the vector comprises a mammalian cell expression vector. The expression vector can comprise nucleic acid sequences that direct and/or control expression of the inserted polynucleotide. Such nucleic acid sequences can include regulatory sequence, including promoter sequences, terminator sequences, polyadenylation sequences, and enhancer sequences. Systems for cloning and expression of a polypeptide in a variety of cells are well known in the art.
The disclosure further provides a host cell comprising the expression vector of the disclosure. In certain embodiments, the host cell is isolated. In other embodiments, the host cell is a non-human cell. In yet other embodiments, the host cell is mammalian.
The antibody of the disclosure can be a mammalian antibody, such as primate, human, rodent, rabbit, ovine, porcine or equine antibody. The antibody can be any class or isotype antibody, for example IgM or IgG. In certain embodiments, the antibody is IgG.
The disclosure further provides a kit comprising an antibody of the disclosure. The antibody may be an intact immunoglobulin molecule or fragment thereof such as Fab, F(ab)2 or Fv fragment. The antibody can be labelled as described elsewhere herein. The kit can be for use in a method of determining whether a subject has a neurodegenerative disease, and/or for treating, ameliorating, and/or preventing a subject afflicted or thought to be afflicted with a neurodegenerative disease. The kit can further any other reagent or instrument that is required to implement a method of the disclosure, such as a buffer, an applicator, and the like.
The following table illustrates the relationship between the SEQ ID NOs: used in the priority document (U.S. Provisional Patent Application No. 62/937,636) and the SEQ ID NOs: used in the present disclosure
Figure imgf000050_0001
Figure imgf000051_0001
Figure imgf000052_0001
Figure imgf000053_0001
Figure imgf000054_0001
Figure imgf000055_0001
The non-limiting generation of these antibodies is illustrated in the Examples and Figures provided herein. In certain embodiments, the disclosure comprises pharmaceutical compositions comprising each of these antibodies in combination with one or more pharmaceutically acceptable excipients. In some embodiments the pharmaceutical composition is formulated for parenteral delivery. In other embodiments, the antibodies are humanized.
Method of Treating, Ameliorating, and/or Preventing a Synucleopathic Disease In one aspect, the disclosure provides a method of treating, ameliorating, and/or preventing a synucleopathic disease comprising administering a therapeutically effective amount of an isolated monoclonal antibody of the disclosure to a patient. In another aspect, the disclosure provides an isolated monoclonal antibody of the disclosure for use as a medicament for treating, ameliorating, and/or preventing a synucleopathic disease. In yet another aspect, the disclosure provides use of an isolated monoclonal antibody of the disclosure in the manufacture of a medicament for the treatment, amelioration, and/or prevention of a synucleopathic disease. In yet another aspect, the disclosure provides an isolated monoclonal antibody of the disclosure for use in a method for treating, ameliorating, and/or preventing a synucleopathic disease. In certain embodiments, the antibody is humanized. In other embodiments, the antibody is administered as a pharmaceutical composition.
The monoclonal antibodies described above may be used to treat, ameliorate, and/or prevent a synucleopathic disease by reducing α-Syn pathology in neurons induced by α-Syn fibrils and/or oligomers. In certain embodiments, the neurodegenerative disorders associated with α-Syn include but are not limited to Parkinson's disease, dementia (such as Parkinson's disease with dementia and/or dementia with Lewy bodies), Alzheimer's disease, Down's syndrome, multiple-system atrophy, prion diseases, and other α-Syn related neurodegenerative disorders. The antibody can be administered systemically or directly to the site where α-Syn fibrils, e.g. a Lewy body, are observed or thought to be present. In a non-limiting example, the antibody can be administered by injection into a blood vessel supplying the brain or into the brain itself. The subject can be a mammal, such as a human or a non-human mammal.
Methods of Detecting a Synucleopathic Disease
In yet another aspect, the disclosure provides methods of detecting synucleopathic disease in a patient. In other embodiments, the antibodies of the disclosure can be used as diagnostic tools for neurodegenerative disorders associated with α-Syn, including but not limited to Parkinson's disease, dementia (such as Parkinson's disease with dementia and/or dementia with Lewy bodies), Alzheimer's disease, Down's syndrome, multiple-system atrophy, prion diseases, and other α-Syn related neurodegenerative disorders. In certain embodiments, the methods are performed in vitro. In certain embodiments, the methods are performed ex vivo.
In certain embodiments, the method of detecting a synucleopathic disease in a subject comprises the steps of administering a labeled, isolated monoclonal antibody of the disclosure to the subject, and detecting the presence of absence of a complex between any α- Syn fibrils and/or oligomers in the subject and the antibody. If the complex is present, that indicates that α-Syn fibrils and/or oligomers exist in the subject. In certain embodiments, if α-Syn fibrils and/or oligomers are present in the subject, the subject has a neurodegenerative disease. In other embodiments, if α-Syn fibrils or oligomers are not present in the subject, the subject does not have a neurodegenerative disease. In yet other embodiments, if the subject has a neurodegenerative disease, the individual is counseled to undergo therapy and/or pharmacological treatment for the neurodegenerative disease. In yet other embodiments, if the subject has a neurodegenerative disease, the individual is provided therapy and/or pharmacological treatment for the neurodegenerative disease.
In certain embodiments, the method further comprises comparing the level of antibody/α-Syn fibrils and/or oligomer complexes formed in the subject with the level of antibody/α-Syn fibrils and/or oligomer complexes formed in a reference subject. The reference subject can be a subject known not to have α-Syn fibrils and/or oligomers, a subject known to have detectable α-Syn fibrils and/or oligomers, and/or a subject known to have a certain level of α-Syn fibrils and/or oligomers. The reference subject can further be the same subject being treated or evaluated, but corresponding to an earlier α-Syn fibrils and/or oligomers detection experiment, as a way to evaluate disease progression and/or treatment efficacy in the subject.
In yet another aspect, the disclosure provides methods of detecting α-Syn fibrils in a sample. In certain embodiments, the antibodies of the disclosure can be used as diagnostic tools for detecting the presence of α-Syn fibrils, oligomers or other misfolded α-Syn species in a sample.
In certain embodiments, the method of detecting α-Syn fibrils, oligomers, or other misfolded α-Syn species in a sample (for example, from a subject) comprises the steps of contacting the sample with a labeled, isolated monoclonal antibody of the disclosure, and detecting the presence or absence of a complex between any α-Syn fibrils, oligomers, or other misfolded α-Syn species in the sample and the antibody. If the complex is detected, that indicates the presence of α-Syn fibrils, oligomers, or other misfolded α-Syn species in the sample. The sample can be, in non-limiting examples, cerebrospinal fluid (CSF), blood, urine, saliva, or tissues from brain, gut, colon, skin, or salivary gland. In certain embodiments, the sample is a CSF sample and/or a brain tissue sample. In other embodiments, the sample is used as is after being removed from the subject. In other embodiments, the sample is pre-treated being used within the present methods.
In certain embodiments, the method further comprises comparing the level of antibody-α-Syn fibril s/oligomers or other antibody-misfolded α-Syn complexes formed in the sample with the level of antibody-α-Syn fibril s/oligomers or other antibody-misfolded α-Syn complexes formed in a reference sample. The reference sample can be from a subject known not to have α-Syn fibril s/oligomers or other misfolded α-Syn species, a subject known to have detectable α-Syn fibrils/oligomers or other misfolded α-Syn species, and/or a subject known to have a certain level of α-Syn fibril s/oligomers or other misfolded α-Syn species.
The reference sample can further be from the same subject being treated or evaluated, but corresponding to an earlier α-Syn fibrils/oligomers or other misfolded α-Syn species detection, as a way to evaluate disease progression and/or treatment efficacy in the subject.
In certain embodiments, the level of α-Syn fibril s/oligomers or other misfolded α-Syn species detected in a subject or in a sample from a subject correlates with severity or progression of a neurodegenerative disease in the subject. In other embodiments, the methods of the disclosure can be used to monitor severity or progression of a neurodegenerative disease in the subject. In yet other embodiments, the methods of the disclosure can be used to monitor effectiveness of a therapy and/or pharmacological intervention in a subject afflicted or believed to be afflicted with a neurodegenerative disease.
In certain embodiments, the sample comprises or is an in vitro sample. In certain embodiments, the sample comprises or is an ex vivo sample.
Methods for detecting formation of a complex between the antibody and α-Syn fibrils/oligomers or other misfolded α-Syn species comprise, but are not limited to, radioimmunoassay, enzyme-linked immunosorbant assay (ELISA), sandwich immunoassay, fluorescent immunoassay, precipitation reaction, gel immunodiffusion assay, agglutination assay, protein A immunoassay, immunoelectrophoresis assay, electrophoresis, western blotting, or any other technique known in the art.
In certain embodiments, the antibodies of the disclosure can be combined with a label and used to detect over α-Syn levels in a patient or in a sample. In other embodiments, the antibodies of the disclosure can be combined with a label and used to detect α-Syn fibrils/oligomers or other misfolded α-Syn species in a patient or in a sample. Methods of labeling antibodies are known in the art and a variety of approaches may be employed. In certain embodiments the label is a radiolabel, such as but not limited to F18, 1123, In111, 1131, C14, H3, Tc99m, P32, 1125, Ga68 and the like. In other embodiments, the label is a fluorescent label, such as but not limited to fluorescein, rhodamine and the like. In yet other embodiments, the label is a contrast agent, such as but not limited to gadolinium (Gd), dysprosium and iron, magnetic agents, and the like. Other labels include nuclear magnetic resonance active labels, positron emitting isotopes detectable by a PET scanner, chemiluminescent and enzymatic markers. Non-limiting imaging techniques include electron microscopy, confocal microscopy, light microscopy, positron emission tomography (PET), gammα-scintigraphy, magnetic resonance imaging (MRI), functional magnetic resonance imaging (FMRI), magnetoencephalography (MEG), and single photon emission computerized tomography (SPECT). In yet other embodiments, the label is on a secondary antibody that binds a primary antibody comprising the above described sequences.
Administration/Dosage/Formulations
Administration of the compounds and/or compositions of the present disclosure to a patient, preferably a mammal, more preferably a human, may be carried out using known procedures, at dosages and for periods of time effective to perform a therapeutic and/or imaging method contemplated in the disclosure. An effective amount of the compound necessary for adequate therapeutic treatment and/or imaging signal may vary according to factors such as the state of a disease or disorder in the patient; the age, sex, and weight of the patient; and/or the equipment used to detect the compound of the disclosure. One of ordinary skill in the art would be able to study the relevant factors and make the determination regarding the effective amount of the therapeutic and/or imaging compound without undue experimentation.
Actual dosage levels of the active ingredients in the pharmaceutical compositions of this disclosure may be varied so as to obtain an amount of the active ingredient that is effective to achieve successful therapy and/or imaging for a particular patient, composition, and mode of administration, without being toxic to the patient.
In certain embodiments, the compositions of the disclosure are formulated using one or more pharmaceutically acceptable excipients or carriers. In certain embodiments, the pharmaceutical compositions of the disclosure comprise an effective amount of a compound of the disclosure and a pharmaceutically acceptable carrier.
The carrier may be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetable oils. The proper fluidity may be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms may be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it is preferable to include isotonic agents, for example, sugars, sodium chloride, or polyalcohols such as mannitol and sorbitol, in the composition. Prolonged absorption of the injectable compositions may be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate or gelatin.
Formulations may be employed in admixtures with conventional excipients, i.e., pharmaceutically acceptable organic or inorganic carrier substances suitable for oral, parenteral, nasal, intravenous, subcutaneous, enteral, or any other suitable mode of administration, known to the art. The pharmaceutical preparations may be sterilized and if desired mixed with auxiliary agents, e.g. , lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure buffers, coloring, flavoring and/or aromatic substances and the like. Routes of administration of any of the compositions of the disclosure include oral, nasal, rectal, intravaginal, parenteral, buccal, sublingual or topical. The compounds for use in the disclosure may be formulated for administration by any suitable route, such as for oral or parenteral, for example, transdermal, transmucosal ( e.g ., sublingual, lingual, (trans) buccal, (trans)urethral, vaginal (e.g., trans- and perivaginally), (intra)nasal and (trans)rectal), intravesical, intrapulmonary, intraduodenal, intragastrical, intrathecal, subcutaneous, intramuscular, intradermal, intrα-arterial, intravenous, intrabronchial, inhalation, and topical administration.
Suitable compositions and dosage forms include, for example, tablets, capsules, caplets, pills, gel caps, troches, dispersions, suspensions, solutions, syrups, granules, beads, transdermal patches, gels, powders, pellets, magmas, lozenges, creams, pastes, plasters, lotions, discs, suppositories, liquid sprays for nasal or oral administration, dry powder or aerosolized formulations for inhalation, compositions and formulations for intravesical administration and the like. It should be understood that the formulations and compositions that would be useful in the present disclosure are not limited to the particular formulations and compositions that are described herein.
Parenteral Administration
As used herein, "parenteral administration" of a pharmaceutical composition includes any route of administration characterized by physical breaching of a tissue of a subject and administration of the pharmaceutical composition through the breach in the tissue. Parenteral administration thus includes, but is not limited to, administration of a pharmaceutical composition by injection of the composition, by application of the composition through a surgical incision, by application of the composition through a tissue-penetrating non-surgical wound, and the like. In particular, parenteral administration is contemplated to include, but is not limited to, subcutaneous, intravenous, intraperitoneal, intramuscular, intrastemal injection, and kidney dialytic infusion techniques.
Formulations of a pharmaceutical composition suitable for parenteral administration comprise the active ingredient combined with a pharmaceutically acceptable carrier, such as sterile water or sterile isotonic saline. Such formulations may be prepared, packaged, or sold in a form suitable for bolus administration or for continuous administration. Injectable formulations may be prepared, packaged, or sold in unit dosage form, such as in ampules or in multidose containers containing a preservative. Formulations for parenteral administration include, but are not limited to, suspensions, solutions, emulsions in oily or aqueous vehicles, pastes, and implantable sustained-release or biodegradable formulations. Such formulations may further comprise one or more additional ingredients including, but not limited to, suspending, stabilizing, or dispersing agents. In certain embodiments of a formulation for parenteral administration, the active ingredient is provided in dry (i.e., powder or granular) form for reconstitution with a suitable vehicle ( e.g ., sterile pyrogen free water) prior to parenteral administration of the reconstituted composition.
The pharmaceutical compositions may be prepared, packaged, or sold in the form of a sterile injectable aqueous or oily suspension or solution. This suspension or solution may be formulated according to the known art, and may comprise, in addition to the active ingredient, additional ingredients such as the dispersing agents, wetting agents, or suspending agents described herein. Such sterile injectable formulations may be prepared using a nontoxic parenterally-acceptable diluent or solvent, such as water or 1,3-butanediol, for example. Other acceptable diluents and solvents include, but are not limited to, Ringer's solution, isotonic sodium chloride solution, and fixed oils such as synthetic mono- or di-glycerides. Other parentally-administrable formulations which are useful include those which comprise the active ingredient in microcrystalline form, in a liposomal preparation, or as a component of a biodegradable polymer system. Compositions for sustained release or implantation may comprise pharmaceutically acceptable polymeric or hydrophobic materials such as an emulsion, an ion exchange resin, a sparingly soluble polymer, or a sparingly soluble salt. Additional Administration Forms
Additional dosage forms of this disclosure include dosage forms as described in U.S. Patents Nos. 6,340,475; 6,488,962; 6,451,808; 5,972,389; 5,582,837; and 5,007,790. Additional dosage forms of this disclosure also include dosage forms as described in U.S. Patent Applications Nos. 2003/0147952; 2003/0104062; 2003/0104053; 2003/0044466; 2003/0039688; and 2002/0051820. Additional dosage forms of this disclosure also include dosage forms as described in PCT Applications Nos. WO 03/35041; WO 03/35040; WO 03/35029; WO 03/35177; WO 03/35039; WO 02/96404; WO 02/32416; WO 01/97783; WO 01/56544; WO 01/32217; WO 98/55107; WO 98/11879; WO 97/47285; WO 93/18755; and WO 90/11757.
EXPERIMENTAL EXAMPLES
The disclosure is further described in detail by reference to the following experimental examples. These examples are provided for purposes of illustration only, and are not intended to be limiting unless otherwise specified. Thus, the disclosure should in no way be construed as being limited to the following examples, but rather, should be construed to encompass any and all variations which become evident as a result of the teaching provided herein.
Without further description, it is believed that one of ordinary skill in the art can, using the preceding description and the following illustrative examples, practice the claimed methods of the present disclosure. The following working examples therefore, specifically point out the preferred embodiments of the present disclosure, and are not to be construed as limiting in any way the remainder of the disclosure.
Animals
Mice used for antibody generation were Balb/c; mice used for primary neuron culture were CD-1 (Charles River, Cat# CRL:22, RRID:IMSR_CRL:22), and mice used for in vivo studies were B6C3F1 (Charles River, Cat# CRL:31, RRID:IMSR_CRL:31).
Primary Hippocampal Neuron Cultures
Primary hippocampal neuron cultures were prepared as previously described (Henderson, et al. , 2017, JNeurosci.; Henderson, et al. , 2018, Acta Neuropathologica Comm. 6:45) from embryonic day (E) 16-18 CD1 embryos. Dissociated hippocampal neurons were plated at 17,500 cells/well (96-well plate) in neuron media (Neurobasal medium (ThermoFisher 21103049) supplemented with B27 (ThermoFisher 17504044), 2 mM GlutaMax (ThermoFisher 35050061), and 100 U/mL penicillin/streptomycin (ThermoFisher 15140122). α-Synuclein PFFs
Purification of recombinant α-Synuclein and generation of α-Synuclein PFFs was conducted as described elsewhere (Luk, etal. , 2009, Proc Natl Acad Sci U S A 106:20051- 20056; Volpicelli-Daley, etal, 2014, Nature Protocols 9:2135-2146). The pRK172 plasmid containing the gene of interest was transformed into BL21 (DE3) RIL-competent E. coli (Agilent Technologies Cat#230245). A single colony from this transformation was expanded in Terrific Broth (12 g/L of Bacto-tryptone, 24 g/L of yeast extract 4% (vol/vol) glycerol, 17 mM KH2PO4 and 72 mM KH2PO4) with ampicillin. Bacterial pellets from the growth were sonicated and sample was boiled to precipitate undesired proteins. The supernatant was dialyzed with 10 mM Tris, pH 7.6, 50 mM NaCl, 1 mM EDTA overnight. Protein was filtered with a 0.22 μm filter and concentrated using Amicon Ultrα-15 centrifugal filter units (Millipore Sigma Cat# UFC901008). Protein was then loaded onto a Superdex 200 column and 1 mL fractions were collected. Fractions were run on SDS-PAGE and stained with Coomassie blue to select fractions that were highly enriched in α-Synuclein. These fractions were combined and dialyzed in 10 mM Tris, pH 7.6, 50 mM NaCl, 1 mM EDTA overnight. Dialyzed fractions were applied to the MonoQ column (GE Health, HiTrap Q HP 645932) and run using a linear gradient from 25 mM NaCl to 1 M NaCl. Collected fractions were run on SDS-PAGE and stained with Coomassie blue. Fractions that were highly enriched in α- Synuclein were collected and dialyzed into DPBS. Protein was filtered through a 0.22 μm filter and concentrated to 5 mg/mL with Amicon Ultrα- 15 centrifugal filter units (Millipore Sigma Cat# UFC901008). Monomer was aliquoted and frozen at -80°C. For preparation of α-Synuclein PFFs, α-Synuclein monomer was shaken at 1,000 rpm for 7 days. Conversion to PFFs was validated by sedimentation at 100,000 x g for 60 minutes and by Thioflavin T fluorescence. α-Synuclein PFF Treatments
Primary Neurons
For treatment of neurons, mouse α-Synuclein PFFs, which were generated at a concentration of 5 mg/mL, were vortexed and diluted with Dulbecco's phosphate-buffered saline (DPBS, Corning Cat#21-031-CV) to 100 μg/mL. They were then sonicated on high for 10 cycles of 30 seconds on, 30 seconds off (Diagenode Biorupter UCD-300 bath sonicator). α-Synuclein PFFs were then diluted in neuron media to 5 μg/mL and added to neuron cultures at the noted concentrations.
Mice
Mouse α-Synuclein PFFs, which were generated at a concentration of 5 mg/mL were vortexed and diluted with DPBS to 2 mg/mL. They were then sonicated on high for 10 cycles of 30 seconds on, 30 seconds off (Diagenode Biorupter UCD-300 bath sonicator). Mice were injected when 3 months old. Mice were injected unilaterally by insertion of a single needle into the right forebrain (coordinates: +0.2 mm relative to Bregma, +2.0 mm from midline) targeting the dorsal striatum (2.6 mm beneath the dura) with 5 μg α-Synuclein PFFs (2.5 μL). Injections were performed using a 10 μL syringe (Hamilton, NV) at a rate of 0.4 μL/minute. After 6 months, mice were perfused transcardially with PBS, brains were removed and underwent overnight fixation in 70% ethanol in 150 mM NaCl, pH 7.4.
Antibody Production Murine monoclonal antibodies were raised as described previously (Gibbons, et al. , 2018, Neuropathol Exp Neurol 77:216-228) against sonicated, human α-Synuclein PFFs emulsified with complete Freund's adjuvant (0.05 mg α-Synuclein /mouse) followed by 2 subsequent boosts of 0.025 mg α-Synuclein emulsified with incomplete Freund's adjuvant 3 and 6 weeks following the initial injections. Nine weeks after initial antigen injection, mice received an intravenous boost of 0.025 mg/mouse. Four days after intravenous injection, spleens were dissociated into single cell suspensions and fused with SP2 cells by 1 -minute treatment with a mixture of 50% polyethylene glycol and 5% DMSO. Hybridoma cells were selected for 7 days in medium containing 5.7 mM azaserine-10; 100 pM hypoxanthine (Sigma Cat# A9666) and cultured in Kennetfs HY (90% DMEM, 10% NCTC135, 4.15 g/L glucose, 3.55 g/L NaHCO3 ), supplemented with 20% fetal bovine serum (FBS; Atlanta Biological Cat# E0118), 100 U/mL penicillin/100 μg/mL streptomycin (Gibco Cat# 15140-122); 2 mM L-glutamine (Coming Cat# 25-005-Cl) and OPI media supplement (1 mM oxoloacetate, 0.45 mM pyruvate, 0.2 U/mL insulin; Sigma Cat# 05003). Monoclonal populations were isolated by limiting dilution to 0.3 cells/well in 96-well plates. Antibodies were further characterized as described below. Hybridomas with selectivity for pathological misfolded α-syn were expanded and subcloned at least twice.
Epitope Mapping
Recombinant α-Synuclein constructs were produced in E. coli as previously established (Volpicelli-Daley, et al. , 2014, Nature Protocols 9:2135-2146). Total protein concentration in each sample was determined by a bicinchoninic acid colorimetric assay (Fisher Cat#23223 and 23224), using bovine serum albumin as a standard (Thermo Fisher Cat#23210). Protein was resolved on 5-20% gradient polyacrylamide gels using equal protein loading (250 ng α-Synuclein/well). Proteins were transferred to 0.2 μm nitrocellulose membranes and detected with primary antibodies (1 : 1000). Primary antibodies were detected using IRDye 800 (LI-COR 925-32210) or IRDye 680 (LI-COR 925-68071) secondary antibodies, scanned on a LI-COR Odyssey Imaging System and analyzed using Image Studio software.
Primary Neuron Immunotherapy Assay
Neurons were treated using a modified version of the procedure previously described (Tran, et al. , 2014, Cell Reports 7:2054-2065). Neurons were fed every three days after plating until 10 DIV. At that point, 125 μL of media was removed from each well, and sterile α-Synuclein antibodies were added in 20 μL of fresh neuron media at incubated at 37°C for 30 minutes. 125 μg of freshly sonicated PFFs were added in an additional 20 μL of neuron media. Neurons were fed at 1 and 4 DPT and fixed and stained at 7-days post transduction as described previously (Tran, et al. , 2014, Cell Reports 7:2054-2065). Data are reported as the normalized pS129 α-Synuclein area divided by NeuN count. For initial clone selection, antibodies were included at a 1:1 molar ratio to α-Synuclein PFFs. For more detailed characterization of high priority clones, antibodies were included at molar ratios ranging from 2:1 to 0.0003:1 (antibody: PFFs).
Immunocytochemistry
Primary neuron or cell line cultures were fixed with 4% paraformaldehyde, 4% sucrose in phosphate-buffered saline and washed five times in PBS. Immunostaining of neuronal cultures was carried out as described previously (Henderson, etal. , 2018, Acta Neuropathologica Comm. 6:45). Cells were permeabilized in 3% BSA + 0.3% TX-100 in PBS for 15 minutes at room temperature. After a PBS wash, cells were blocked for 50 minutes with 3% BSA in PBS prior to incubation with primary antibodies for 2 hours at room temperature. Primary antibodies used were targeting pS129 α-Synuclein (81 A, CNDR,
1 :5,000) and NeuN (Millipore Cat#MAB377, 1 : 1,500). Cells were washed 5x with PBS and incubated with secondary antibodies for 1 hour at room temperature. After 5x wash with PBS, cells were incubated in DAPI (ThermoFisher Cat#D21490, 1 : 10,000) in PBS. 96-well plates were imaged on In Cell Analyzer 2200 (GE Healthcare) and analyzed in the accompanying software. A standard intensity-based threshold was applied to the pS129 α- Synuclein channel equally across plates and positive area was quantified. For NeuN quantification, an object-based analysis was applied to identify objects of specified size and intensity. All quantification was optimized and applied equally across all conditions.
Sandwich ELISA
A 384-well Maxisorp clear plate (Thermo Fisher Scientific, Cat# 12565347) was coated with 30 μL per well (50 ng) of antibody in Takeda coating buffer, then plate was spun at 1000 x g for 1 minute and incubated overnight at 4°C. The plate was washed 4 times with PBST (PBS with 0.05% Tween) and blocked using Block Ace blocking solution (95 μL per well) (AbD Serotec) overnight at 4°C. Serial double dilutions of human wild-type α- Synuclein fibrils and monomer were made in Buffer C (0.02 M sodium phosphate buffer, 2 mM EDTA, 0.4 M NaCl, 1% BSA, 0.005% thimerisol) starting at 256 μg/mL of monomer and 25.6 μg/mL of fibrils. Fibrils were then sonicated on high for 10 cycles of 30 seconds on, 30 seconds off (Diagenode Biorupter UCD-300 bath sonicator) prior to dilutions. Dilutions were added to each well (30 μL per well) and incubated overnight at 4°C. The plate was washed 4 times with PBST. 30 μL of MJF-R1 (1:3,000, Abeam Cat# abl38501) in Buffer C was added to each well and the plate was incubated for 4 hours at 37°C. After washing with PBST 4 times, 1 : 10k diluted goat-anti-rabbit IgG-HRP conjugate (Cell Signaling Technology) was added to the plate and the plate was incubated for 1 hour at 37°C. Following washing with PBST 4 times the plate was developed for 10-15 minutes using 30 μL per well of room temperature 1-Step Ultra TMB-ELISA Substrate Solution (Thermo Fisher Scientific, Cat# 34029) and the reaction was quenched using 10% phosphoric acid (30 μL per well). Plates were read on 384-450 nm on the SpectraMax M5 plate reader (Molecular Devices).
Antibody Purification (Small Preparation)
Small amounts of antibodies for in vitro experiments were purified using the DynaBead magnetic system (Invitrogen, Cat#10003D) using 1 mL of Protein A and 1 mL of Protein G beads per 50 mL of supernatant. The beads were first washed 3 times with PBS, with 10 minutes of wash time on a rotator. The supernatant was added and incubated with the beads for 4 hours at room temperature or overnight at 4°C. The supernatant was removed and the beads were washed 3 times with PBS. Elution buffer (100 mM glycine, pH 2.8) was added to beads for 30 seconds and immediately neutralized with 1.5 M Tris-base. Buffer solution was removed and put into 50 kD filter Eppendorf tubes and a buffer exchange was completed 3 times spinning according to the manufacturer's protocol. Antibodies were stored at 1 mg/mL.
Antibody Purification (Large Preparation)
For large preparations of hybridoma supernatant, antibodies were purified using a HiTrap MabSelect SuRe column (GE Healthcare Life Sciences, Cat# 11003494) on an AKTA Pure FPLC system (GE Healthcare Life Sciences). Supernatant was sterile filtered with a 0.2 μm filter and loaded on the column. After washing, antibodies were eluted with 100 mM glycine, 150 mM NaCl, pH 3.0. Eluate was immediately neutralized with 1 M Tris- base, pH 9.0. The UV trace was used to select and pool fractions containing antibody. Antibody was concentrated using Amicon Ultrα- 15 50 K centrifugal filter units (Millipore Sigma, Cat# UFC905024) and dialyzed into phosphate-buffered saline, pH 7.2. Antibodies were then sterile filtered with a 0.2 μm filter, protein concentration in each sample was determined by a bicinchoninic acid colorimetric assay (Fisher Cat# 23223 and 23224), using bovine serum albumin as a standard (Thermo Fisher Cat# 23210). Samples were run on a 15% SDS-PAGE gel and coomassie stained to ensure presence of heavy and light changes and protein purity. After purification from hybridoma supernatant, antibodies were frozen in 1 mL aliquots and stored at -20°C.
In Vivo Antibody Administration
Immediately prior to use, antibodies were thawed and kept on ice until administration. Mice were weighed and antibodies were administered intraperitoneally to a final concentration of 30 mg/kg body weight. Injection side was alternated between injections, and mice were monitored for adverse events related to injection.
Striatal Dopamine/DOPAC Detection
Following transcardial perfusion, a 1 mm coronal section was removed from the rostral brain between approximately Bregma and Bregma + 1 mm. The dorsal striatum was manually dissected from both the right (ipsilateral) and left (contralateral) side of the brain and flash frozen on dry ice for liquid chromatography-mass spectrometry (LC-MS) analysis of dopamine (DA) and dihydroxyphenylacetic acid (DOPAC). Frozen tissue was suspended in 10 μL Milli-Q water/mg tissue and sonicated at power level 1.5 using 15-20 short pulses (QSONICA MICROSON™ XL-2000) until solution was homogenous. Lysate was briefly spun down and 30 μL was transferred to a new tube containing 30 μL 0.4 M perchloric acid. Remaining lysate was suspended in 2x RIPA buffer with protease inhibitors for assay of protein levels. Perchlorate sample were spun at 3000 x g and 4°C for 15 minutes. Two volumes of 0.4 M sodium acetate was added to supernatant and spin filtered through a 0.65 μm filter. DA and DOPAC were subsequently quantitated using a Waters Acquity UPLC- TQD LC-MS system. Ten microliters of each sample were injected onto a Waters Acquity HSS T3, C18, 1.8 μm, 2.1 x 100 mm column at 35°C and 0.4 mL/min. Mobile phase B was held at 0% B for 1 minute post injection and gradient separated from 0 to 25% B between 2 and 3 minutes followed by wash and equilibration steps (A: 0.1% (v/v) formic acid in water; B: acetonitrile with 0.1% (v/v) formic acid). Compounds were detected using multiple reaction monitoring of their specific collision-induced ion transitions (Dopamine, ES+ 154>137; 3,4-Dihydrophenylacetic acid, ES- 167>123). Peak areas were quantitated using Waters QuaLynx software against standard curves analyzed concurrently (Dopamine Hydrochloride (DA), Sigma Cat# H8502-5G; 3,4-Dihydrophenylacetic acid (DOPAC),
Sigma Cat# 850217-1G) and normalized to total protein level.
Immunohistochemistry
After perfusion and fixation, brains were embedded in paraffin blocks, cut into 6 μm sections, and mounted on glass slides. Slides were then stained using standard immunohistochemistry as described elsewhere herein. Slides were deparaffmized with 2 sequential 5-minute washes in xylenes, followed by 1 -minute washes in a descending series of ethanols: 100%, 100%, 95%, 80%, 70%. Slides were then incubated in deionized water for one minute prior to antigen retrieval as noted. After antigen retrieval, slides were incubated in 5% hydrogen peroxide in methanol to quench endogenous peroxidase activity. Slides were washed for 10 minutes in running tap water, 5 minutes in 0.1 M Tris, then blocked in 0.1 M Tris/2% fetal bovine serum (FBS). Slides were incubated in primary antibodies overnight. The following primary antibodies were used. For misfolded α- Synuclein, Syn506 was used at 0.4 ug/mL final concentration with microwave antigen retrieval (95°C for 15 minutes with citric acid based antigen unmasking solution (Vector H- 3300). To stain midbrain dopaminergic neurons, Tyrosine hydroxylase (TH-16; Sigmα- Aldrich T2928, RRID:AB_477569) was used at 1:5,000 with formic acid antigen retrieval.
Primary antibody was rinsed off with 0.1 M Tris for 5 minutes, then incubated with goat anti-rabbit (Vector BA1000, RRID: AB 2313606) or horse anti-mouse (Vector BA2000, RRID:AB_2313581) biotinylated IgGin 0.1 M Tris/2% FBS 1:1000 for 1 hour. Biotinylated antibody was rinsed off with 0.1 M Tris for 5 minutes, then incubated with avidin-biotin solution (Vector PK-6100, RRID:AB_2336819) for 1 hour. Slides were then rinsed for 5 minutes with 0.1 M Tris, then developed with ImmPACT DAB peroxidase substrate (Vector SK-4105, RRID:AB_2336520) and counterstained briefly with Harris Hematoxylin (Fisher 67-650-01). Slides were washed in running tap water for 5 minutes, dehydrated in ascending ethanol for 1 minute each: 70%, 80%, 95%, 100%, 100%, then washed twice in xylenes for 5 minutes and coversliped in Cytoseal Mounting Media (Fisher 23-244-256). Digitized slides were then used for quantitative pathology.
Quantitative Histology
To assay for antibody binding to Lewy body α-Synuclein, undiluted hybridoma supernatant or supernatant diluted 1:3 in PBS was directly added to sections of human amygdala tissue with abundant Lewy bodies. Tissue was processed and developed in DAB reagent in parallel. A similar 1 mm2 section from each piece of tissue was then used to assay the ability of the antibody to preferentially bind Lewy bodies. Staining intensity was manually thresholded to only highlight Lewy bodies blind to antibody treatment and analyzed for mean optical density. Mean optical density for the whole section was then assayed using a standardized cutoff. The mean optical density of Lewy body staining divided by the mean optical density of the piece of tissue was calculated and is reported at the Lewy body discrimination index.
For mice, all section selection, annotation and quantification was done blinded to treatment group. All quantitation was performed in HALO quantitative pathology software (Indica Labs). Every 10th slide through the midbrain was stained with tyrosine hydroxylase (TH). TH-stained sections were used to annotate the SN, and cell counting was performed manually in a blinded manner for all sections. The sum of all sections was multiplied by 10 to estimate the total count that would be obtained by counting every section. The SN annotations drawn onto the TH-stained sections were then transferred to sequential sections that had been stained for misfolded α-Synuclein (Syn506). Amygdala regions were also annotated on every 10th section through the length of the amygdala. A single analysis algorithm was then applied equally to all stained sections to quantify the percentage of area occupied by Syn506 staining. Specifically, the analysis included all DAB signal that was above a 0.157 optical density threshold, which was empirically determined to not include any background signal. This signal was then normalized to the total tissue area. A minimal tissue optical density of 0.02 was used to exclude any areas where tissue was split.
Antibody Sequencing
Total RNA was isolated from the hybridoma cells following the technical manual of TRIZOL® Reagent. Total RNA was then reverse-transcribed into cDNA using either isotype-specific anti-sense primers or universal primers following the technical manual of PRIMESCRIPT™ 1st Strand cDNA Synthesis Kit. Antibody fragments of heavy chain and light chain were amplified according to the standard operating procedure (SOP) of rapid amplification of cDNA ends (RACE) of GenScript. Amplified antibody fragments were cloned into a standard cloning vector separately. Colony PCR was performed to screen for clones with inserts of correct sizes. The consensus sequence was provided elsewhere herein. Statistical Analysis
All statistical analyses were done in GraphPad Prism 7. The analysis used for each data set is described in the figure legends. The number of samples (n) is noted in each figure legend. For primary neuron experiments, the n represents the number of independent wells assayed. For in vivo experiments, n represents the number of mice.
Example 1:
There is concern that pan-α-Synuclein antibodies may have liabilities as a therapeutic approach for PD. For example, there are conflicting data on whether reducing overall α- Synuclein levels in the brain would be deleterious to neuronal function. The abundance of α- Synuclein in red blood cells also raises the possibility that a pan-α-Synuclein antibody could cause on-target side effects in the blood, as antibody concentrations in the blood are approximately 1000-fold higher than in the brain. In addition, serum α-Synuclein could act as a sink for a pan-α-Synuclein antibodies, thereby reducing engagement with the intended target in the brain.
Thus, the present study related in part to the identification of e antibodies that are highly selective for pathogenic, misfolded α-Synuclein. In order to develop these antibodies, mice were first immunized with misfolded α-Synuclein pre-formed fibrils (PFFs) formed from recombinant human α-Synuclein (FIG. 1 A). Mice developed an immune response to the α-Synuclein PFF immunogen, and antibody-producing B cells were harvested and fused to myeloma cells to generate antibody-producing hybridoma cells (FIG. IB). Monoclonal hybridomas were isolated by limiting dilution, and antibody-containing supernatant from these clones was tested in several assays to determine which hybridoma clones were producing antibodies with preferred properties (FIG. 1C). Candidate antibodies were further subcloned to ensure monoclonality (FIG. ID), with antibody properties confirmed through a screen to ensure retention of properties (FIG. IE). Upon inspection of the results from the different screening assays, a non-limiting candidate antibody was selected for efficacy testing in an in vivo model of PD (FIG. IF), where it was compared to a previously characterized immunotherapy antibody.
Example 2: Immunohistochemistry Reveals Antibodies That Preferentially Bind LBs
In a non-limiting aspect, certain antibodies of interest have a high binding preference for misfolded LB α-Synuclein over monomeric α-Synuclein. In order to rapidly screen for antibody selectivity to pathological α-Synuclein, amygdala sections from PD patients with abundant LB pathology were immunostained. Hybridoma supernatants were used undiluted or at a 1:3 dilution on screening slides processed in parallel to allow direct comparison of immunostaining. Most antibodies tested showed a preference for binding to LB α-Synuclein over normal synaptic α-Synuclein in the neuropil (FIG. 2A). A LB discrimination index (optical density of LB/optical density of all tissue) was developed to better compare the relative binding of antibodies to LB over the neuropil pool (FIG. 2B). A value of 1 indicates no discrimination of LBs over normal synaptic neuropil staining. While most of the antibodies had a preference for LBs, a cutoff of 1.5 was established to remove antibodies that showed relatively non-selective staining of LBs from further consideration.
Example 3: Epitope Mapping Ensures that Preferred Antibodies Recognize Human and Mouse α-Synuclein
While selected immunotherapy antibodies can in principle be used in humans, the present study in certain non-limiting embodiments identified antibodies that can recognize both mouse and human α-Synuclein to allow further characterization in mouse primary neuron and wildtype mouse models of PD. Antibodies were assayed by Western blot to determine whether they bound to human and mouse α-Synuclein (FIGs. 3 A-3C). Multiple truncated forms of human α-Synuclein (FIG. 3 A) were also analyzed in parallel to determine the epitope within α-Synuclein that was recognized by each antibody. All antibodies recognized some portion of the immunogenic C-terminus of α-Synuclein, with a large proportion recognizing far C-terminal amino acids (120-140; FIG. 3B). Another large group of antibodies recognized a slightly more internal epitope (110-120), and only a few antibodies recognized a region closer to the aggregation-prone NAC (hoh-Ab component of Alzheimer's disease amyloid domain (residue 61-95) of α-Synuclein (FIG. 3C). The majority of antibodies recognized mouse as well as human α-Synuclein, although there were examples of antibodies in each epitope class that showed preferential binding to human α-Synuclein.
Only two antibodies showed evidence of cross-reactivity with b-Synuclein (FIG. 10).
Example 4: Sandwich ELISA Identifies Antibodies with a Preference for Misfolded α- Synuclein
Antibodies that showed selectivity for LBs in human tissue by immunohistochemistry and recognized both human and mouse α-Synuclein underwent a further testing of selectivity by assessing their ability to bind to monomeric human α-Synuclein and α-Synuclein PFFs in a sandwich ELISA format. This assay retains the conformation of α-Synuclein by allowing binding of α-Synuclein that is in solution to immobilized antibody, and allows a broad range of affinity detection. Antibodies of interest were coated on an ELISA plate and either α- Synuclein monomer or PFF were incubated with the antibodies at increasing α-Synuclein concentrations to determine relative affinity of the antibodies for each form of α-Synuclein. The previously characterized Syn211 antibody (Giasson, et al. , 2000, J. Neurosci. Res. 59:528-533) was also coated on each plate as a non-selective antibody control. Bound α- Synuclein was detected with a monoclonal antibody (MJF-R1, Abeam, Cat#138501) and a goat-anti-rabbit IgG-HRP conjugate.
Capture antibodies could be categorized almost evenly into three categories: 17 nonbinding (FIGs. 4A & 11), 18 non-selective (FIG. 4B & 12), 19 PFF-selective (FIG. 4C & 13). Without wishing to be limited by any theory, since nearly all of the non-binding antibodies bound to LB pathology and detected α-Synuclein by immunoblotting, the lack of activity in the sandwich ELISA can suggest that immobilization on ELISA plate wells affected their ability to capture α-Synuclein.
By fitting the absorbance values with a sigmoid dose curve, ECso values were calculated for each antibody. PFF preference values were then calculated for each antibody using the following equation, with Syn211 as a non-selective control:
Test Ab PFF EC50 / 211 PFF EC50
PFF Preference =
Test Ab Monomer EC50/ 211 Monomer EC50
Values are summarized in Table 1. To confirm that the apparent conformation selectivity was not due to shared epitopes between the capture and the detection antibody that would reduce detection of α-Synuclein monomers, four of the most selective antibodies were evaluated by sandwich ELISA using an alternate, polyclonal detection antibody, SNL4 (FIG. 14). This assay confirmed the conformation selectivity of the α-Synuclein antibodies.
Example 5: Primary Neuron Immunotherapy Assay Reveals Differential Potency of α- Synuclein Antibodies to Prevent LB-Like Pathology
While the intrinsic properties of antibodies are important, the ability of antibodies to prevent the induction of α-Synuclein pathology, a property which is critical for therapeutic success, was investigated. To accomplish this, a neuron immunotherapy assay was developed to allow co-treatment of antibodies with α-Synuclein PFFs in a high-content format. After 10 days in culture, neurons were treated with purified antibodies of interest. Thirty minutes later, neurons were treated with human α-Synuclein PFFs, which seed the recruitment of endogenous mouse α-Synuclein into LB- and LN-like inclusions. Neurons were fixed 7 days later and assayed for pathological pS129 α-Synuclein and neuron number (NeuN; FIG. 5 A). Antibodies showed a wide range of efficacy in this assay with 22 of the 41 antibodies causing over 75 percent reduction in pathology (FIG. 5B). The highest performing antibody, Syn9048, reduced pathology by a remarkable 97 percent.
The thorough characterization of α-Synuclein antibodies in multiple assays allowed one to compare antibodies quantitatively and select favored antibodies for subcloning and further screening (FIGs. 6A-6B). In certain embodiments, certain antibodies of interest recognize both mouse and human α-Synuclein, bind LBs preferentially in human tissue, show greater affinity for misfolded α-Synuclein than monomeric α-Synuclein, and reduce PFF- seeded α-Synuclein pathology in primary neurons. Based on these criteria, two antibodies (Syn9063 and Syn9048) were selected for subcloning, large-scale production and in vivo testing.
Example 6: Subclones Retain Properties of Parent Clones
One of the key features of the selected antibodies was their preference for misfolded α-Synuclein. Therefore, supernatants from clones derived during additional subcloning of Syn9063 and Syn9048 hybridomas were analyzed in the sandwich ELISA platform to identify clones producing the desired antibodies. All but one of the Syn9063 subclones showed a similar preference for α-Synuclein PFFs as the parental clone (FIG. 7A). However, upon clonal expansion, Syn9063 subclones had very low antibody yields, precluding their use in vivo , where greater antibody amounts are needed. All Syn9048 clones showed high selectivity for α-Synuclein PFFs (FIG. 7B) and clone #3 was used for further studies due to high yields of antibody obtained from roller cultures.
To gain a further understanding of the concentration of antibody necessary to effectively inhibit α-Synuclein pathology induction, purified Syn9048 was diluted over several log concentrations and assessed in the human α-Synuclein PFF-seeded primary hippocampal neuron assay as described above. Syn9048 reduced neuronal α-Synuclein pathology in a dose-dependent manner, with a molar antibody:α-Synuclein ratio IC50 of 0.006 (1:166) (FIGs. 7C-7D). Syn9048 showed almost complete inhibition of α-Synuclein pathology at a molar ratio of 0.03 or higher, suggesting that only one antibody per 33 α- Synuclein monomer units is sufficient to fully inhibit α-Synuclein seeding in neurons. Syn9048 was also capable of reducing α-Synuclein pathology induced by mouse α-Synuclein PFFs with a similar IC50 (FIG. 15), suggesting that it would be suitable for testing in a non- transgenic mouse model of PD.
Example 7: In Vivo Immunotherapy Is Well-Tolerated and Improves Dopaminergic Tone
Several α-Synuclein antibodies have been tested in animal models for their abilities to prevent PD-like pathology. However, in the absence of prodromal disease biomarkers, patients with neurodegenerative disorders are unlikely to be given immunotherapy treatments prior to the symptomatic stages of disease when brain pathology is already established.
Therefore, the efficacy of Syn9048 in reducing pathology and rescuing neuronal function after the initiation of pathology was tested. A previously established model of α- Synuclein pathology induction and transmission (Luk, et al. , 2012, Science 338:949-953) was employed in which non-transgenic mice were injected with 5 μg α-Synuclein PFFs in the dorsal striatum at 2-3 months of age. Mice were allowed 1 week for the BBB to recover and for pathogenic α-Synuclein to be taken up by neurons and induce pathology prior to treatment with antibody. The mice then received Syn9048 or isotype control antibody treatment (30 mg/kg intraperitoneally) weekly thereafter for 6 months (FIG. 8 A, 16 mice/group). An additional group of mice was treated with a comparator antibody, Syn303, which has previously been validated for in vivo immunotherapy models (Tran, et al. , 2014, Cell Reports 7:2054-2065). The one-week delay in antibody dosing after intrastriatal PFF injection was intended to minimize inhibition of initial PFF-seeding in neurons. In certain embodiments, sites of secondary α-Synuclein pathology formation that result from pathology transmission are most affected by antibody treatment. Mice in all three groups gained weight steadily over the course of the study, suggesting that the passive immunotherapy was well-tolerated (FIG. 8B).
Dopaminergic neuron loss in the substantia nigra (SN) is a primary feature of PD and is recapitulated in the PFF injection mouse model (Henderson, et al., 2019, Nature Neuroscience 22:1248-1257; Luk, etal., 2012, Science 338:949-953) (FIG. 8C). IgGl- treated mice have dramatic tyrosine hydroxylase (TH)-positive neuron loss ipsilateral to the injection site, and this neuron loss was not abrogated by either Syn303 or Syn9048 treatment (FIGs. 8D-8E). The dopaminergic neuron loss is consistent with these cells having direct connections to the injection site, such that antibody treatment one week after PFF injections would not be expected to block the initiation of pathology in these neurons. Dopaminergic tone is also reduced in the dorsal striatum in response to PFF injection (FIG. 8F). Somewhat surprisingly Syn9048, but not Syn303, was able to rescue the loss of striatal dopamine and DOPAC (FIGs. 8F-8G). Thus, while neurons are still lost, the function of remaining neurons may be improved by Syn9048 treatment, possibly due to reductions in α-Synuclein pathology. Example 8: Syn9048 Reduces α-Synuclein Pathology in the SN and Amygdala
To better understand how α-Synuclein pathology is changed in mice following passive immunotherapy, quantitative pathology for misfolded α-Synuclein (Syn506) in the SN (FIGs. 9A-9C) and amygdala (FIGs. 9D-9F) were performed. Syn303 and Syn9048 reduced mean pathology in the SN contralateral (FIG. 9B) and ipsilateral (FIG. 9C) to the injection site, although only the reduction by Syn9048 in the ipsilateral SN was statistically significant. A reduction in pathology was also more apparent in the contralateral amygdala (Fig. 9E) than in the ipsilateral amygdala (FIG. 9F), and was more substantial in Syn9048- treated animals than those treated with Syn303. Only the reduction by Syn9048 in the contralateral amygdala was statistically significant. The reduction in ipsilateral SN pathology by Syn9048, though modest may explain the improvement in striatal dopamine and DOPAC levels. Moreover, the greater effect of antibody treatment on contralateral α-Synuclein pathology suggests that efficacy is greater at sites where extracellular α-Synuclein spread is responsible for pathology induction. Table 1: Summary Measurements
Figure imgf000075_0001
Figure imgf000076_0001
Figure imgf000077_0001
NB=non-binding
Enumerated Embodiments
The following exemplary embodiments are provided, the numbering of which is not to be construed as designating levels of importance:
Embodiment 1 provides an isolated monoclonal antibody comprising a light chain variable region (VL) and a heavy chain variable region (VH), wherein the VL comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO:27, 46, 70, 114, 126, 185, 213, or 240; a CDR2 region comprising the amino acid sequence of SEQ ID NO:29, 72, 116, 214, or 242; and a CDR3 region comprising the amino acid sequence of SEQ ID NO:31, 85, 118, 129, 152, 205, 216, or 244; and wherein the VH comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO: 11, 58, 92, 101, 144, 160, or 226; a CDR2 region comprising the amino acid sequence of SEQ ID NO: 13, 40, 60, 93, 102, 134, 145, 161, 200, or 228; and a CDR3 region comprising the amino acid sequence of SEQ ID NO: 15, 62, 81, 147, 163, 194, 201, or 230.
Embodiment 2 provides the monoclonal antibody of Embodiment 1, wherein the VL comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO:27, 46, 70, 114, or
126; a CDR2 region comprising the amino acid sequence of SEQ ID NO:29, 72, or 116; and a CDR3 region comprising the amino acid sequence of SEQ ID NO:31, 85, 118, 129, or 152; and wherein the VH comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO: 11, 58, 92, 101, or 144; a CDR2 region comprising the amino acid sequence of SEQ ID NO: 13, 40, 60, 93, 102, 134, or 145; and a CDR3 region comprising the amino acid sequence of SEQ ID NO: 15, 62, 81, or 147. Embodiment 3 provides the monoclonal antibody of Embodiment 1, wherein the VL comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO:70, 185, 213, or 240; a CDR2 region comprising the amino acid sequence of SEQ ID NO:29, 72, 214, or 242; and a CDR3 region comprising the amino acid sequence of SEQ ID NO: 152, 129, 205, 216, or 244; and wherein the VH comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO: 160, 58, or 226; a CDR2 region comprising the amino acid sequence of SEQ ID NO: 161, 145, 200, or 228; and a CDR3 region comprising the amino acid sequence of SEQ ID NO: 163, 194, 201, or 230.
Embodiment 4 provides the monoclonal antibody of any one of Embodiments 1-3, wherein at least one applies:
(a) the VL comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO:27; a CDR2 region comprising the amino acid sequence of SEQ ID NO:29; and a CDR3 region comprising the amino acid sequence of SEQ ID NO:31; and the VH comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO: 11; a CDR2 region comprising the amino acid sequence of SEQ ID NO: 13; and a CDR3 region comprising the amino acid sequence of SEQ ID NO: 15;
(b) the VL comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO:46; a CDR2 region comprising the amino acid sequence of SEQ ID NO:29; and a CDR3 region comprising the amino acid sequence of SEQ ID NO:31; and the VH comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO: 11; a CDR2 region comprising the amino acid sequence of SEQ ID NO:40; and a CDR3 region comprising the amino acid sequence of SEQ ID NO: 15;
(c) the VL comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO:70; a CDR2 region comprising the amino acid sequence of SEQ ID NO:72; and a CDR3 region comprising the amino acid sequence of SEQ ID NO:85; and the VH comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO:58; a CDR2 region comprising the amino acid sequence of SEQ ID NO:60; and a CDR3 region comprising the amino acid sequence of SEQ ID NO:62;
(d) the VL comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO:70; a CDR2 region comprising the amino acid sequence of SEQ ID NO:72; and a CDR3 region comprising the amino acid sequence of SEQ ID NO:85; and the VH comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO:58; a CDR2 region comprising the amino acid sequence of SEQ ID NO:60; and a CDR3 region comprising the amino acid sequence of SEQ ID NO:81;
(e) the VL comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO:70; a CDR2 region comprising the amino acid sequence of SEQ ID NO:72; and a CDR3 region comprising the amino acid sequence of SEQ ID NO:85; and the VH comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO:92; a CDR2 region comprising the amino acid sequence of SEQ ID NO:93; and a CDR3 region comprising the amino acid sequence of SEQ ID NO:62;
(f) the VL comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO: 114; a CDR2 region comprising the amino acid sequence of SEQ ID NO: 116; and a CDR3 region comprising the amino acid sequence of SEQ ID NO: 118; and the VH comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO: 101; a CDR2 region comprising the amino acid sequence of SEQ ID NO: 102; and a CDR3 region comprising the amino acid sequence of SEQ ID NO:62;
(g) the VL comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO: 126; a CDR2 region comprising the amino acid sequence of SEQ ID NO:72; and a CDR3 region comprising the amino acid sequence of SEQ ID NO: 129; and the VH comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO: 101; a CDR2 region comprising the amino acid sequence of SEQ ID NO: 102; and a CDR3 region comprising the amino acid sequence of SEQ ID NO:62;
(h) the VL comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO:46; a CDR2 region comprising the amino acid sequence of SEQ ID NO:29; and a CDR3 region comprising the amino acid sequence of SEQ ID NO:31; and the VH comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO: 11; a CDR2 region comprising the amino acid sequence of SEQ ID NO: 134; and a CDR3 region comprising the amino acid sequence of SEQ ID NO: 15;
(i) the VL comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO:70; a CDR2 region comprising the amino acid sequence of SEQ ID NO:29; and a CDR3 region comprising the amino acid sequence of SEQ ID NO: 152; and the VH comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO: 144; a CDR2 region comprising the amino acid sequence of SEQ ID NO: 145; and a CDR3 region comprising the amino acid sequence of SEQ ID NO: 147;
(j) the VL comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO:70; a CDR2 region comprising the amino acid sequence of SEQ ID NO:29; and a CDR3 region comprising the amino acid sequence of SEQ ID NO: 152; and the VH comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO: 160; a CDR2 region comprising the amino acid sequence of SEQ ID NO: 161; and a CDR3 region comprising the amino acid sequence of SEQ ID NO: 163;
(k) the VL comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO: 185; a CDR2 region comprising the amino acid sequence of SEQ ID NO:29; and a CDR3 region comprising the amino acid sequence of SEQ ID NO: 129; and the VH comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO: 160; a CDR2 region comprising the amino acid sequence of SEQ ID NO: 145; and a CDR3 region comprising the amino acid sequence of SEQ ID NO: 163;
(l) the VL comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO:70; a CDR2 region comprising the amino acid sequence of SEQ ID NO:29; and a CDR3 region comprising the amino acid sequence of SEQ ID NO: 152; and the VH comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO: 160; a CDR2 region comprising the amino acid sequence of SEQ ID NO: 145; and a CDR3 region comprising the amino acid sequence of SEQ ID NO: 194;
(m) the VL comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO:70; a CDR2 region comprising the amino acid sequence of SEQ ID NO:72; and a CDR3 region comprising the amino acid sequence of SEQ ID NO:205; and the VH comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO:58; a CDR2 region comprising the amino acid sequence of SEQ ID NO:200; and a CDR3 region comprising the amino acid sequence of SEQ ID NO:201;
(n) the VL comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO:213; a CDR2 region comprising the amino acid sequence of SEQ ID NO:214; and a CDR3 region comprising the amino acid sequence of SEQ ID NO:216; and the VH comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO:58; a CDR2 region comprising the amino acid sequence of SEQ ID NO:200; and a CDR3 region comprising the amino acid sequence of SEQ ID NO:201; (o) the VL comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO:240; a CDR2 region comprising the amino acid sequence of SEQ ID NO:242; and a CDR3 region comprising the amino acid sequence of SEQ ID NO:244; and the VH comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO:226; a CDR2 region comprising the amino acid sequence of SEQ ID NO:228; and a CDR3 region comprising the amino acid sequence of SEQ ID NO:230.
Embodiment 5 provides the monoclonal antibody of any one of Embodiments 1-4, wherein the VL comprises the amino acid sequence of
SEQ ID NO:27-SEQ ID NO:28-SEQ ID NO:29-SEQ ID NO:30-SEQ ID NO:31,
SEQ ID NO:46-SEQ ID NO:28-SEQ ID NO:29-SEQ ID NO:30-SEQ ID NO:31,
SEQ ID NO:70-SEQ ID NO:71-SEQ ID NO:72-SEQ ID NO:73-SEQ ID NO:85,
SEQ ID NO:70-SEQ ID NO:127-SEQ ID NO:29-SEQ ID NO:151-SEQ ID NO: 152,
SEQ ID NO:70-SEQ ID NO:127-SEQ ID NO:29-SEQ ID NO:172-SEQ ID NO: 152,
SEQ ID NO:70-SEQ ID NO: 127-SEQ ID NO:72-SEQ ID NO:204-SEQ ID NO:205,
SEQ ID NO: 114-SEQ ID NO: 115-SEQ ID NO: 116-SEQ ID NO: 117-SEQ ID NO: 118, SEQ ID NO: 126-SEQ ID NO: 127-SEQ ID NO:72-SEQ ID NO: 128-SEQ ID NO: 129, SEQ ID NO:185-SEQ ID NO:186-SEQ ID NO:29-SEQ ID NO:187-SEQ ID NO: 129, SEQ ID NO:213-SEQ ID NO: 115-SEQ ID NO:214-SEQ ID NO:215-SEQ ID NO:216, or SEQ ID NO:240-SEQ ID NO:241-SEQ ID NO:242-SEQ ID NO:243-SEQ ID NO:244, and wherein the VH comprises the amino acid sequence of
SEQ ID NO: 11-SEQ ID NO: 12-SEQ ID NO: 13-SEQ ID NO: 14-SEQ ID NO: 15,
SEQ ID NO: 11-SEQ ID NO: 12-SEQ ID NO:40-SEQ ID NO:41-SEQ ID NO: 15,
SEQ ID NO: 11-SEQ ID NO: 12-SEQ ID NO:134-SEQ ID NO:135-SEQ ID NO: 15,
SEQ ID NO:58-SEQ ID NO:59-SEQ ID NO:60-SEQ ID NO:61-SEQ ID NO:62,
SEQ ID NO:58-SEQ ID NO:59-SEQ ID NO:60-SEQ ID NO:80-SEQ ID NO:81,
SEQ ID NO:58-SEQ ID NO:59-SEQ ID NO:200-SEQ ID NO:94-SEQ ID NO:201,
SEQ ID NO:92-SEQ ID NO:59-SEQ ID NO:93-SEQ ID NO:94-SEQ ID NO:62,
SEQ ID NO:101-SEQ ID NO:59-SEQ ID NO:102-SEQ ID NO:103-SEQ ID NO:62,
SEQ ID NO: 144-SEQ ID NO:59-SEQ ID NO: 145-SEQ ID NO: 146-SEQ ID NO: 147, SEQ ID NO:160-SEQ ID NO:59-SEQ ID NO: 145-SEQ ID NO:177-SEQ ID NO: 163, SEQ ID NO:160-SEQ ID NO:59-SEQ ID NO: 145-SEQ ID NO:193-SEQ ID NO: 194, SEQ ID NO:160-SEQ ID NO:59-SEQ ID NO:161-SEQ ID NO:162-SEQ ID NO: 163, or SEQ ID NO:226-SEQ ID NO:227-SEQ ID NO:228-SEQ ID NO:229-SEQ ID NO:230.
Embodiment 6 provides the monoclonal antibody of any one of Embodiments 1-5, wherein the VL comprises the amino acid sequence of:
SEQ ID NO:27-SEQ ID NO:28-SEQ ID NO:29-SEQ ID NO:30-SEQ ID NO:31,
SEQ ID NO:46-SEQ ID NO:28-SEQ ID NO:29-SEQ ID NO:30-SEQ ID NO:31,
SEQ ID NO:70-SEQ ID NO:71-SEQ ID NO:72-SEQ ID NO:73-SEQ ID NO:85,
SEQ ID NO:70-SEQ ID NO:127-SEQ ID NO:29-SEQ ID NO:151-SEQ ID NO: 152,
SEQ ID NO: 114-SEQ ID NO: 115-SEQ ID NO: 116-SEQ ID NO: 117-SEQ ID NO: 118, or SEQ ID NO: 126-SEQ ID NO: 127-SEQ ID NO:72-SEQ ID NO: 128-SEQ ID NO: 129; and wherein the VH comprises the amino acid sequence of:
SEQ ID NO: 11-SEQ ID NO: 12-SEQ ID NO: 13-SEQ ID NO: 14-SEQ ID NO: 15,
SEQ ID NO: 11-SEQ ID NO: 12-SEQ ID NO:40-SEQ ID NO:41-SEQ ID NO: 15,
SEQ ID NO: 11-SEQ ID NO: 12-SEQ ID NO:134-SEQ ID NO:135-SEQ ID NO: 15,
SEQ ID NO:58-SEQ ID NO:59-SEQ ID NO:60-SEQ ID NO:61-SEQ ID NO:62,
SEQ ID NO:58-SEQ ID NO:59-SEQ ID NO:60-SEQ ID NO:80-SEQ ID NO:81,
SEQ ID NO:92-SEQ ID NO:59-SEQ ID NO:93-SEQ ID NO:94-SEQ ID NO:62,
SEQ ID NO:101-SEQ ID NO:59-SEQ ID NO:102-SEQ ID NO:103-SEQ ID NO:62, or SEQ ID NO: 144-SEQ ID NO:59-SEQ ID NO: 145-SEQ ID NO: 146-SEQ ID NO: 147.
Embodiment 7 provides the monoclonal antibody of any one of Embodiments 1-5, wherein the VL comprises the amino acid sequence of:
SEQ ID NO:70-SEQ ID NO: 127-SEQ ID NO:29-SEQ ID NO:172-SEQ ID NO: 152,
SEQ ID NO:70-SEQ ID NO: 127-SEQ ID NO:72-SEQ ID NO:204-SEQ ID NO:205,
SEQ ID NO:185-SEQ ID NO:186-SEQ ID NO:29-SEQ ID NO:187-SEQ ID NO: 129, SEQ ID NO:213-SEQ ID NO: 115-SEQ ID NO:214-SEQ ID NO:215-SEQ ID NO:216, or SEQ ID NO:240-SEQ ID NO:241-SEQ ID NO:242-SEQ ID NO:243-SEQ ID NO:244. and wherein the VH comprises the amino acid sequence of:
SEQ ID NO:58-SEQ ID NO:59-SEQ ID NO:200-SEQ ID NO:94-SEQ ID NO:201,
SEQ ID NO:160-SEQ ID NO:59-SEQ ID NO: 145-SEQ ID NO:177-SEQ ID NO: 163, SEQ ID NO:160-SEQ ID NO:59-SEQ ID NO: 145-SEQ ID NO:193-SEQ ID NO: 194, SEQ ID NO:160-SEQ ID NO:59-SEQ ID NO:161-SEQ ID NO:162-SEQ ID NO: 163, or SEQ ID NO:226-SEQ ID NO:227-SEQ ID NO:228-SEQ ID NO:229-SEQ ID NO:230.
Embodiment 8 provides the monoclonal antibody of any one of Embodiments 1-7, which is humanized.
Embodiment 9 provides the monoclonal antibody of any one of Embodiments 1-8, which is labeled.
Embodiment 10 provides a pharmaceutical composition comprising the monoclonal antibody of any one of Embodiments 1-9 and at least one pharmaceutical excipient.
Embodiment 11 provides an isolated polynucleotide comprising at least one of the nucleic acid sequences of SEQ ID NOs:3, 5, 7, 19, 21, 23, 35, 43, 44, 50, 52, 54, 66, 68, 75, 77, 88, 89, 96, 97, 99, 106, 108, 110, 121, 132, 138, 139, 141, 148, 150, 155, 157, 167, 168, 170, 175, 180, 191, 195, 197, 198, 203, 207, 209, 211, 219, 221, 223, 233, 235, and 237.
Embodiment 12 provides the isolated polynucleotide of Embodiment 11, comprising: at least one nucleic acid sequence selected from the group consisting of SEQ ID NOs:3,
5, 7, 35, 50, 52, 54, 75, 77, 88, 89, 97, 99, 132, 138, 139, 141, 155, 157, 175, 191, 197, 198, 219, 221, and 223; and at least one nucleic acid sequence selected from the group consisting of SEQ ID NOs: 19, 21, 23, 43, 44, 66, 68, 96, 106, 108, 110, 121, 148, 150, 167, 168, 170, 180, 195, 203, 207, 209, 211, 233, 235, and 237.
Embodiment 13 provides the isolated polynucleotide of any of Embodiments 11-12, comprising: at least one nucleic acid sequence group selected from the group consisting of:
SEQ ID NOs:3, 5, 7; SEQ ID NOs:3, 35, 7; SEQ ID NOs:3, 132, 7; SEQ ID NOs:50, 52, 54; SEQ ID NOs:50, 75, 77; SEQ ID NOs:50, 139, 175; SEQ ID NOs:50, 139, 191;
SEQ ID NOs:50, 155, 157; SEQ ID NOs:50, 197, 198; SEQ ID NOs:88, 89, 54; SEQ ID NOs:97, 99, 54; SEQ ID NOs:138, 139, 141; and SEQ ID NOs:219, 221, 223; and at least one nucleic acid sequence group selected from the group consisting of:
SEQ ID NOs: 19, 21, 23; SEQ ID NOs: 19, 43, 44; SEQ ID NOs: 19, 66, 68; SEQ ID
', 66, 96; SEQ ID NOs: 19, 66, 203; SEQ ID NOs: 19, 148, 150; SEQ ID NOs:106,
108, 110; SEQ ID NOs: 121, 66, 68; SEQ ID NOs: 167, 168, 170; SEQ ID NOs: 167, 168, 195; SEQ ID NOs: 180, 168, 68; SEQ ID NOs:213, 214, 216; and SEQ ID NOs:233, 235, 237.
Embodiment 14 provides a method of treating, ameliorating, and/or preventing a synucleopathic disease in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of at least one isolated monoclonal antibody of any one of Embodiments 1-9.
Embodiment 15 provides the method of Embodiment 14, wherein the synucleopathic disease is at least one from the group consisting of Parkinson's disease, Parkinson's disease with dementia, dementia with Lewy bodies, Alzheimer's disease, Down's syndrome, multiple- system atrophy, prion diseases, and other α-Syn related neurodegenerative disorders.
Embodiment 16 provides the method of any one of Embodiments 14-15, wherein the antibody is provided to the subject as a pharmaceutical composition.
Embodiment 17 provides the method of any one of Embodiments 14-16, wherein the antibody is administered parenterally to the subject.
Embodiment 18 provides a method of detecting a synucleopathic disease in a subject, the method comprising administering to the subject at least one labeled isolated monoclonal antibody of any one of Embodiments 1-9, and detecting presence or absence of a complex of the labeled isolated monoclonal antibody with any α-Syn fibrils, oligomers, and/or other misfolded α-Syn species present in the subject, wherein, if the complex is detected, the subject has a synucleopathic disease.
Embodiment 19 provides a method of detecting total α-Syn, α-Syn fibrils and/or α- Syn oligomeric species in a sample, the method comprising contacting the sample with at least one labeled isolated monoclonal antibody of any one of Embodiments 1-9, and detecting presence or absence of a complex of the labeled isolated monoclonal antibody with total α- Syn, α-Syn monomer, α-Syn fibrils, and/or α-Syn oligomeric species present in the sample, wherein, if the complex is detected, total α-Syn, α-Syn monomers, α-Syn fibrils and/or α-Syn oligomeric species are present in the sample.
Embodiment 20 provides the method of Embodiment 19, wherein the sample comprises an in vitro and/or ex vivo sample.
Embodiment 21 provides an autonomously replicating or an integrative mammalian cell vector comprising a recombinant nucleic acid encoding an antibody comprising a light chain variable region (VL) and a heavy chain variable region (VH), wherein the VL comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO:27, 46, 70, 114, 126, 185, 213, or 240; a CDR2 region comprising the amino acid sequence of SEQ ID NO:29, 72, 116, 214, or 242; and a CDR3 region comprising the amino acid sequence of SEQ ID NO:31, 85, 118, 129, 152, 205, 216, or 244; and wherein the VH comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO: 11, 58, 92, 101, 144, 160, or 226; a CDR2 region comprising the amino acid sequence of SEQ ID NO: 13, 40, 60, 93, 102, 134, 145, 161, 200, or 228; and a CDR3 region comprising the amino acid sequence of SEQ ID NO: 15, 62, 81, 147, 163, 194, 201, or 230.
Embodiment 22 provides the cell vector of Embodiment 21, which comprises a plasmid or a virus.
Embodiment 23 provides the cell vector of any one of Embodiments 21-22, which comprises a mammalian cell expression vector.
Embodiment 24 provides the cell vector of any one of Embodiments 21-23, further comprising at least one nucleic acid sequence that directs and/or controls expression of the antibody.
Embodiment 25 provides an isolated host cell comprising at least one vector of any one of Embodiments 21-24.
Embodiment 26 provides the host cell of Embodiment 25, which is a non-human cell.
Embodiment 27 provides the cell vector of any one of Embodiments 25-26, which is mammalian.
The disclosures of each and every patent, patent application, and publication cited herein are hereby incorporated herein by reference in their entirety.
While this disclosure has been disclosed with reference to specific embodiments, it is apparent that other embodiments and variations of this disclosure may be devised by others skilled in the art without departing from the true spirit and scope of the disclosure. The appended claims are intended to be construed to include all such embodiments and equivalent variations.

Claims

CLAIMS What is claimed is:
1. An isolated monoclonal antibody comprising a light chain variable region (VL) and a heavy chain variable region (VH), wherein the VL comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO:27, 46, 70, 114, 126, 185, 213, or 240; a CDR2 region comprising the amino acid sequence of SEQ ID NO:29, 72, 116, 214, or 242; and a CDR3 region comprising the amino acid sequence of SEQ ID NO:31, 85, 118, 129, 152, 205, 216, or 244; and wherein the VH comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO: 11, 58, 92, 101, 144, 160, or 226; a CDR2 region comprising the amino acid sequence of SEQ ID NO: 13, 40, 60, 93, 102, 134, 145, 161, 200, or 228; and a CDR3 region comprising the amino acid sequence of SEQ ID NO: 15, 62, 81, 147, 163, 194, 201, or 230.
2. The monoclonal antibody of claim 1, wherein the VL comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO:27, 46, 70, 27, 27, 70, 70, 114, 126, 46, 46, 46, 70, or 46; a CDR2 region comprising the amino acid sequence of SEQ ID NO:29, 29, 72, 29, 29, 72, 72, 116, 72, 29, 29, 29, 29, or 29; and a CDR3 region comprising the amino acid sequence of SEQ ID NO:31, 31, 85, 31, 31, 85, 85, 118, 129, 31, 31, 31, 152, or 31; and wherein the VH comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO: 11, 58, 92, 101, or 144; a CDR2 region comprising the amino acid sequence of SEQ ID NO: 13, 40, 60, 93, 102, 134, or 145; and a CDR3 region comprising the amino acid sequence of SEQ ID NO: 15, 62, 81, or 147.
3. The monoclonal antibody of claim 1, wherein the VL comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO:70, 185, 213, or 240; a CDR2 region comprising the amino acid sequence of SEQ ID NO:29, 72, 214, or 242; and a CDR3 region comprising the amino acid sequence of SEQ ID NO: 152, 129, 205, 216, or 244; and wherein the VH comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO: 160, 58, or 226; a CDR2 region comprising the amino acid sequence of SEQ ID NO: 161, 145, 200, or 228; and a CDR3 region comprising the amino acid sequence of SEQ ID NO: 163, 194, 201, or 230.
4. The monoclonal antibody of claim 1, wherein at least one applies:
(a) the VL comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO:27; a CDR2 region comprising the amino acid sequence of SEQ ID NO:29; and a CDR3 region comprising the amino acid sequence of SEQ ID NO:31; and the VH comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO: 11; a CDR2 region comprising the amino acid sequence of SEQ ID NO: 13; and a CDR3 region comprising the amino acid sequence of SEQ ID NO: 15;
(b) the VL comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO:46; a CDR2 region comprising the amino acid sequence of SEQ ID NO:29; and a CDR3 region comprising the amino acid sequence of SEQ ID NO:31; and the VH comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO: 11; a CDR2 region comprising the amino acid sequence of SEQ ID NO:40; and a CDR3 region comprising the amino acid sequence of SEQ ID NO: 15;
(c) the VL comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO:70; a CDR2 region comprising the amino acid sequence of SEQ ID NO:72; and a CDR3 region comprising the amino acid sequence of SEQ ID NO:85; and the VH comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO:58; a CDR2 region comprising the amino acid sequence of SEQ ID NO:60; and a CDR3 region comprising the amino acid sequence of SEQ ID NO:62;
(d) the VL comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO:70; a CDR2 region comprising the amino acid sequence of SEQ ID NO:72; and a CDR3 region comprising the amino acid sequence of SEQ ID NO:85; and the VH comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO:58; a CDR2 region comprising the amino acid sequence of SEQ ID NO:60; and a CDR3 region comprising the amino acid sequence of SEQ ID NO:81;
(e) the VL comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO:70; a CDR2 region comprising the amino acid sequence of SEQ ID NO:72; and a CDR3 region comprising the amino acid sequence of SEQ ID NO:85; and the VH comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO:92; a CDR2 region comprising the amino acid sequence of SEQ ID NO:93; and a CDR3 region comprising the amino acid sequence of SEQ ID NO:62;
(f) the VL comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO: 114; a CDR2 region comprising the amino acid sequence of SEQ ID NO: 116; and a CDR3 region comprising the amino acid sequence of SEQ ID NO: 118; and the VH comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO: 101; a CDR2 region comprising the amino acid sequence of SEQ ID NO: 102; and a CDR3 region comprising the amino acid sequence of SEQ ID NO:62;
(g) the VL comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO: 126; a CDR2 region comprising the amino acid sequence of SEQ ID NO:72; and a CDR3 region comprising the amino acid sequence of SEQ ID NO: 129; and the VH comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO: 101; a CDR2 region comprising the amino acid sequence of SEQ ID NO: 102; and a CDR3 region comprising the amino acid sequence of SEQ ID NO:62;
(h) the VL comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO:46; a CDR2 region comprising the amino acid sequence of SEQ ID NO:29; and a CDR3 region comprising the amino acid sequence of SEQ ID NO:31; and the VH comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO: 11; a CDR2 region comprising the amino acid sequence of SEQ ID NO: 134; and a CDR3 region comprising the amino acid sequence of SEQ ID NO: 15;
(i) the VL comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO:70; a CDR2 region comprising the amino acid sequence of SEQ ID NO:29; and a CDR3 region comprising the amino acid sequence of SEQ ID NO: 152; and the VH comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO: 144; a CDR2 region comprising the amino acid sequence of SEQ ID NO: 145; and a CDR3 region comprising the amino acid sequence of SEQ ID NO: 147;
(j) the VL comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO:70; a CDR2 region comprising the amino acid sequence of SEQ ID NO:29; and a CDR3 region comprising the amino acid sequence of SEQ ID NO: 152; and the VH comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO: 160; a CDR2 region comprising the amino acid sequence of SEQ ID NO: 161; and a CDR3 region comprising the amino acid sequence of SEQ ID NO: 163;
(k) the VL comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO: 185; a CDR2 region comprising the amino acid sequence of SEQ ID NO:29; and a CDR3 region comprising the amino acid sequence of SEQ ID NO: 129; and the VH comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO: 160; a CDR2 region comprising the amino acid sequence of SEQ ID NO: 145; and a CDR3 region comprising the amino acid sequence of SEQ ID NO: 163;
(l) the VL comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO:70; a CDR2 region comprising the amino acid sequence of SEQ ID NO:29; and a CDR3 region comprising the amino acid sequence of SEQ ID NO: 152; and the VH comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO: 160; a CDR2 region comprising the amino acid sequence of SEQ ID NO: 145; and a CDR3 region comprising the amino acid sequence of SEQ ID NO: 194;
(m) the VL comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO:70; a CDR2 region comprising the amino acid sequence of SEQ ID NO:72; and a CDR3 region comprising the amino acid sequence of SEQ ID NO:205; and the VH comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO:58; a CDR2 region comprising the amino acid sequence of SEQ ID NO:200; and a CDR3 region comprising the amino acid sequence of SEQ ID NO:201;
(n) the VL comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO:213; a CDR2 region comprising the amino acid sequence of SEQ ID NO:214; and a CDR3 region comprising the amino acid sequence of SEQ ID NO:216; and the VH comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO:58; a CDR2 region comprising the amino acid sequence of SEQ ID NO:200; and a CDR3 region comprising the amino acid sequence of SEQ ID NO:201;
(o) the VL comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO:240; a CDR2 region comprising the amino acid sequence of SEQ ID NO:242; and a CDR3 region comprising the amino acid sequence of SEQ ID NO:244; and the VH comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO:226; a CDR2 region comprising the amino acid sequence of SEQ ID NO:228; and a CDR3 region comprising the amino acid sequence of SEQ ID NO:230.
5. The monoclonal antibody of claim 1, wherein the VL comprises the amino acid sequence of
SEQ ID NO:27-SEQ ID NO:28-SEQ ID NO:29-SEQ ID NO:30-SEQ ID NO:31,
SEQ ID NO:46-SEQ ID NO:28-SEQ ID NO:29-SEQ ID NO:30-SEQ ID NO:31,
SEQ ID NO:70-SEQ ID NO:71-SEQ ID NO:72-SEQ ID NO:73-SEQ ID NO:85,
SEQ ID NO:70-SEQ ID NO:127-SEQ ID NO:29-SEQ ID NO:151-SEQ ID NO: 152,
SEQ ID NO:70-SEQ ID NO:127-SEQ ID NO:29-SEQ ID NO:172-SEQ ID NO: 152,
SEQ ID NO:70-SEQ ID NO: 127-SEQ ID NO:72-SEQ ID NO:204-SEQ ID NO:205,
SEQ ID NO: 114-SEQ ID NO: 115-SEQ ID NO: 116-SEQ ID NO: 117-SEQ ID NO: 118, SEQ ID NO: 126-SEQ ID NO: 127-SEQ ID NO:72-SEQ ID NO: 128-SEQ ID NO: 129, SEQ ID NO:185-SEQ ID NO:186-SEQ ID NO:29-SEQ ID NO:187-SEQ ID NO: 129, SEQ ID NO:213-SEQ ID NO: 115-SEQ ID NO:214-SEQ ID NO:215-SEQ ID NO:216, or SEQ ID NO:240-SEQ ID NO:241-SEQ ID NO:242-SEQ ID NO:243-SEQ ID NO:244, and wherein the VH comprises the amino acid sequence of
SEQ ID NO: 11-SEQ ID NO: 12-SEQ ID NO: 13-SEQ ID NO: 14-SEQ ID NO: 15,
SEQ ID NO: 11-SEQ ID NO: 12-SEQ ID NO:40-SEQ ID NO:41-SEQ ID NO: 15,
SEQ ID NO: 11-SEQ ID NO: 12-SEQ ID NO:134-SEQ ID NO:135-SEQ ID NO: 15,
SEQ ID NO:58-SEQ ID NO:59-SEQ ID NO:60-SEQ ID NO:61-SEQ ID NO:62,
SEQ ID NO:58-SEQ ID NO:59-SEQ ID NO:60-SEQ ID NO:80-SEQ ID NO:81,
SEQ ID NO:58-SEQ ID NO:59-SEQ ID NO:200-SEQ ID NO:94-SEQ ID NO:201,
SEQ ID NO:92-SEQ ID NO:59-SEQ ID NO:93-SEQ ID NO:94-SEQ ID NO:62,
SEQ ID NO:101-SEQ ID NO:59-SEQ ID NO:102-SEQ ID NO:103-SEQ ID NO:62,
SEQ ID NO: 144-SEQ ID NO:59-SEQ ID NO: 145-SEQ ID NO: 146-SEQ ID NO: 147, SEQ ID NO:160-SEQ ID NO:59-SEQ ID NO: 145-SEQ ID NO:177-SEQ ID NO: 163, SEQ ID NO:160-SEQ ID NO:59-SEQ ID NO: 145-SEQ ID NO:193-SEQ ID NO: 194, SEQ ID NO:160-SEQ ID NO:59-SEQ ID NO:161-SEQ ID NO:162-SEQ ID NO: 163, or SEQ ID NO:226-SEQ ID NO:227-SEQ ID NO:228-SEQ ID NO:229-SEQ ID NO:230.
6. The monoclonal antibody of claim 1, wherein the VL comprises the amino acid sequence of:
SEQ ID NO:27-SEQ ID NO:28-SEQ ID NO:29-SEQ ID NO:30-SEQ ID NO:31, SEQ ID NO:46-SEQ ID NO:28-SEQ ID NO:29-SEQ ID NO:30-SEQ ID NO:31, SEQ ID NO:70-SEQ ID NO:71-SEQ ID NO:72-SEQ ID NO:73-SEQ ID NO:85, SEQ ID NO:70-SEQ ID NO: 127-SEQ ID NO:29-SEQ ID NO:151-SEQ ID NO: 152,
SEQ ID NO: 114-SEQ ID NO: 115-SEQ ID NO: 116-SEQ ID NO: 117-SEQ ID NO: 118, or SEQ ID NO: 126-SEQ ID NO: 127-SEQ ID NO:72-SEQ ID NO: 128-SEQ ID NO: 129; and wherein the VH comprises the amino acid sequence of:
SEQ ID NO: 11-SEQ ID NO: 12-SEQ ID NO: 13-SEQ ID NO: 14-SEQ ID NO: 15,
SEQ ID NO: 11-SEQ ID NO: 12-SEQ ID NO:40-SEQ ID NO:41-SEQ ID NO: 15,
SEQ ID NO: 11-SEQ ID NO: 12-SEQ ID NO:134-SEQ ID NO:135-SEQ ID NO: 15,
SEQ ID NO:58-SEQ ID NO:59-SEQ ID NO:60-SEQ ID NO:61-SEQ ID NO:62,
SEQ ID NO:58-SEQ ID NO:59-SEQ ID NO:60-SEQ ID NO:80-SEQ ID NO:81,
SEQ ID NO:92-SEQ ID NO:59-SEQ ID NO:93-SEQ ID NO:94-SEQ ID NO:62,
SEQ ID NO:101-SEQ ID NO:59-SEQ ID NO:102-SEQ ID NO:103-SEQ ID NO:62, or SEQ ID NO: 144-SEQ ID NO:59-SEQ ID NO: 145-SEQ ID NO: 146-SEQ ID NO: 147.
7. The monoclonal antibody of claim 1, wherein the VL comprises the amino acid sequence of:
SEQ ID NO:70-SEQ ID NO:127-SEQ ID NO:29-SEQ ID NO:172-SEQ ID NO: 152,
SEQ ID NO:70-SEQ ID NO: 127-SEQ ID NO:72-SEQ ID NO:204-SEQ ID NO:205,
SEQ ID NO:185-SEQ ID NO:186-SEQ ID NO:29-SEQ ID NO:187-SEQ ID NO: 129, SEQ ID NO:213-SEQ ID NO:l 15-SEQ ID NO:214-SEQ ID NO:215-SEQ ID NO:216, or SEQ ID NO:240-SEQ ID NO:241-SEQ ID NO:242-SEQ ID NO:243-SEQ ID NO:244. and wherein the VH comprises the amino acid sequence of:
SEQ ID NO:58-SEQ ID NO:59-SEQ ID NO:200-SEQ ID NO:94-SEQ ID NO:201,
SEQ ID NO:160-SEQ ID NO:59-SEQ ID NO:145-SEQ ID NO:177-SEQ ID NO: 163, SEQ ID NO:160-SEQ ID NO:59-SEQ ID NO:145-SEQ ID NO:193-SEQ ID NO: 194, SEQ ID NO:160-SEQ ID NO:59-SEQ ID NO:161-SEQ ID NO:162-SEQ ID NO: 163, or SEQ ID NO:226-SEQ ID NO:227-SEQ ID NO:228-SEQ ID NO:229-SEQ ID NO:230.
8 The monoclonal antibody of claim 1, which is humanized.
9. The monoclonal antibody of claim 1, which is labeled.
10. A pharmaceutical composition comprising the monoclonal antibody of claim 1 and at least one pharmaceutical excipient.
11. An isolated polynucleotide comprising at least one of the nucleic acid sequences of SEQ ID NOs:3, 5, 7, 19, 21, 23, 35, 43, 44, 50, 52, 54, 66, 68, 75, 77, 88, 89, 96, 97, 99, 106, 108, 110, 121, 132, 138, 139, 141, 148, 150, 155, 157, 167, 168, 170, 175, 180, 191, 195, 197, 198, 203, 207, 209, 211, 219, 221, 223, 233, 235, and 237.
12. The isolated polynucleotide of claim 11, comprising: at least one nucleic acid sequence selected from the group consisting of SEQ ID NOs:3, 5, 7, 35, 50, 52, 54, 75, 77, 88, 89, 97, 99, 132, 138, 139, 141, 155, 157, 175, 191, 197, 198, 219, 221, and 223; and at least one nucleic acid sequence selected from the group consisting of SEQ ID NOs: 19, 21, 23, 43, 44, 66, 68, 96, 106, 108, 110, 121, 148, 150, 167, 168, 170, 180, 195, 203, 207, 209, 211, 233, 235, and 237.
13. The isolated polynucleotide of claim 11, comprising: at least one nucleic acid sequence group selected from the group consisting of:
SEQ ID NOs:3, 5, 7; SEQ ID NOs:3, 35, 7; SEQ ID NOs:3, 132, 7; SEQ ID NOs:50, 52, 54; SEQ ID NOs:50, 75, 77; SEQ ID NOs:50, 139, 175; SEQ ID NOs:50, 139, 191;
SEQ ID NOs:50, 155, 157; SEQ ID NOs:50, 197, 198; SEQ ID NOs:88, 89, 54; SEQ ID NOs:97, 99, 54; SEQ ID NOs: 138, 139, 141; and SEQ ID NOs:219, 221, 223; and at least one nucleic acid sequence group selected from the group consisting of:
SEQ ID NOs: 19, 21, 23; SEQ ID NOs: 19, 43, 44; SEQ ID NOs: 19, 66, 68;
SEQ ID NOs: 19, 66, 96; SEQ ID NOs: 19, 66, 203; SEQ ID NOs: 19, 148, 150;
SEQ ID NOs: 106, 108, 110; SEQ ID NOs: 121, 66, 68; SEQ ID NOs: 167, 168, 170;
SEQ ID NOs: 167, 168, 195; SEQ ID NOs:180, 168, 68; SEQ ID NOs:213, 214, 216; and SEQ ID NOs:233, 235, 237.
14. A method of treating, ameliorating, and/or preventing a synucleopathic disease in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of at least one isolated monoclonal antibody of claim 1.
15. The method of claim 14, wherein the synucleopathic disease is at least one from the group consisting of Parkinson's disease, Parkinson's disease with dementia, dementia with Lewy bodies, Alzheimer's disease, Down's syndrome, multiple-system atrophy, prion diseases, and other α-Syn related neurodegenerative disorders.
16. The method of claim 14, wherein the antibody is provided to the subject as a pharmaceutical composition.
17. The method of claim 14, wherein the antibody is administered parenterally to the subject.
18. A method of detecting a synucleopathic disease in a subject, the method comprising administering to the subject at least one labeled isolated monoclonal antibody of claim 1, and detecting presence or absence of a complex of the labeled isolated monoclonal antibody with any α-Syn fibrils, oligomers, and/or other misfolded α-Syn species present in the subject, wherein, if the complex is detected, the subject has a synucleopathic disease.
19. A method of detecting total α-Syn, α-Syn fibrils and/or α-Syn oligomeric species in a sample, the method comprising contacting the sample with at least one labeled isolated monoclonal antibody of claim 1, and detecting presence or absence of a complex of the labeled isolated monoclonal antibody with total α-Syn, α-Syn monomer, α-Syn fibrils, and/or α-Syn oligomeric species present in the sample, wherein, if the complex is detected, total α-Syn, α-Syn monomers, α-Syn fibrils and/or α-Syn oligomeric species are present in the sample.
20. The method of claim 19, wherein the sample comprises an in vitro and/or ex vivo sample.
21. An autonomously replicating or an integrative mammalian cell vector comprising a recombinant nucleic acid encoding an antibody comprising a light chain variable region (VL) and a heavy chain variable region (VH), wherein the VL comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO:27, 46, 70, 114, 126, 185, 213, or 240; a CDR2 region comprising the amino acid sequence of SEQ ID NO:29, 72, 116, 214, or 242; and a CDR3 region comprising the amino acid sequence of SEQ ID NO:31, 85, 118, 129, 152,
205, 216, or 244; and wherein the VH comprises: a CDR1 region comprising the amino acid sequence of SEQ ID NO: 11, 58, 92, 101, 144, 160, or 226; a CDR2 region comprising the amino acid sequence of SEQ ID NO: 13, 40, 60, 93, 102, 134, 145, 161, 200, or 228; and a CDR3 region comprising the amino acid sequence of SEQ ID NO: 15, 62, 81, 147, 163, 194, 201, or 230.
22. The vector of claim 21, which comprises a plasmid or a virus.
23. The vector of claim 21, which comprises a mammalian cell expression vector.
24. The vector of claim 21, further comprising at least one nucleic acid sequence that directs and/or controls expression of the antibody.
25. An isolated host cell comprising at least one vector of claim 21.
26. The cell of claim 25, which is a non-human cell.
27. The cell of claim 25, which is mammalian.
PCT/US2020/061376 2019-11-19 2020-11-19 Anti-alpha-synuclein monoclonal antibodies, and methods using same Ceased WO2021102197A1 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
CN202080092715.8A CN114945592B (en) 2019-11-19 2020-11-19 Anti-alpha-synuclein monoclonal antibodies and methods of use thereof
AU2020386061A AU2020386061A1 (en) 2019-11-19 2020-11-19 Anti-alpha-synuclein monoclonal antibodies, and methods using same
CA3158364A CA3158364A1 (en) 2019-11-19 2020-11-19 Anti-alpha-synuclein monoclonal antibodies, and methods using same
JP2022528957A JP7777071B2 (en) 2019-11-19 2020-11-19 Anti-alpha-synuclein monoclonal antibodies and methods of use thereof
US17/778,061 US20230025707A1 (en) 2019-11-19 2020-11-19 Anti-Alpha-Synuclein Monoclonal Antibodies, and Methods Using Same
IL293108A IL293108A (en) 2019-11-19 2020-11-19 Anti-alpha-synuclein monoclonal antibodies, and methods using same
EP20889174.7A EP4061840A4 (en) 2019-11-19 2020-11-19 Anti-alpha-synuclein monoclonal antibodies, and methods using same
MX2022006026A MX2022006026A (en) 2019-11-19 2020-11-19 ANTI-ALPHA-SINUCLEIN MONOCLONAL ANTIBODIES AND METHODS THAT USE THEM.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962937636P 2019-11-19 2019-11-19
US62/937,636 2019-11-19

Publications (1)

Publication Number Publication Date
WO2021102197A1 true WO2021102197A1 (en) 2021-05-27

Family

ID=75981490

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2020/061376 Ceased WO2021102197A1 (en) 2019-11-19 2020-11-19 Anti-alpha-synuclein monoclonal antibodies, and methods using same

Country Status (9)

Country Link
US (1) US20230025707A1 (en)
EP (1) EP4061840A4 (en)
JP (1) JP7777071B2 (en)
CN (1) CN114945592B (en)
AU (1) AU2020386061A1 (en)
CA (1) CA3158364A1 (en)
IL (1) IL293108A (en)
MX (1) MX2022006026A (en)
WO (1) WO2021102197A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12162940B2 (en) 2021-05-05 2024-12-10 Immatics Biotechnologies Gmbh BMA031 antigen binding polypeptides

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4370154A4 (en) * 2021-07-15 2025-04-02 The Regents Of The University Of Michigan COMPOSITIONS AND METHODS FOR TREATING ALPHA-SYNUCLEINOPATHIES

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030079253A1 (en) * 2000-05-02 2003-04-24 Hiatt Andrew C. Immunoglobulin binding protein arrays in eukaryotic cells
US20090252683A1 (en) * 2005-10-11 2009-10-08 Micromet Ag Composition Comprising Cross-Species-Sepecific Antibodies and uses Thereof
CN103627676A (en) * 2013-05-10 2014-03-12 深圳大学 Physarum polycephalum 14-3-3 protein monoclonal antibodies and preparation method thereof
WO2018204352A1 (en) * 2017-05-01 2018-11-08 The Trustees Of The University Of Pennsylvania Monoclonal antibodies against alpha-synuclein fibrils

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101692092B (en) * 2009-09-24 2013-04-10 首都医科大学宣武医院 Method for quantitative detection of autologous α-synuclein antibody in human serum
NZ720769A (en) * 2013-12-09 2022-10-28 Allakos Inc Anti-siglec-8 antibodies and methods of use thereof
US10364286B2 (en) * 2016-12-22 2019-07-30 H. Lundbeck A/S Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation
EP3661961A4 (en) * 2017-08-02 2021-04-14 Stressmarq Biosciences Inc. ACTIVE ALPHA-SYNNUCLEIN BINDING ANTIBODIES
US11155608B2 (en) * 2017-08-23 2021-10-26 The Trustees Of The University Of Pennsylvania Monoclonal antibodies against pathological alpha-synuclein, and methods using same
CN110172098B (en) * 2019-05-27 2023-03-10 长春工业大学 Monoclonal antibody for resisting alpha-synuclein and application thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030079253A1 (en) * 2000-05-02 2003-04-24 Hiatt Andrew C. Immunoglobulin binding protein arrays in eukaryotic cells
US20090252683A1 (en) * 2005-10-11 2009-10-08 Micromet Ag Composition Comprising Cross-Species-Sepecific Antibodies and uses Thereof
CN103627676A (en) * 2013-05-10 2014-03-12 深圳大学 Physarum polycephalum 14-3-3 protein monoclonal antibodies and preparation method thereof
WO2018204352A1 (en) * 2017-05-01 2018-11-08 The Trustees Of The University Of Pennsylvania Monoclonal antibodies against alpha-synuclein fibrils

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP4061840A4 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12162940B2 (en) 2021-05-05 2024-12-10 Immatics Biotechnologies Gmbh BMA031 antigen binding polypeptides

Also Published As

Publication number Publication date
CN114945592A (en) 2022-08-26
CN114945592B (en) 2025-09-19
AU2020386061A1 (en) 2022-06-02
IL293108A (en) 2022-07-01
MX2022006026A (en) 2022-09-12
EP4061840A4 (en) 2024-05-15
EP4061840A1 (en) 2022-09-28
JP7777071B2 (en) 2025-11-27
JP2023502122A (en) 2023-01-20
US20230025707A1 (en) 2023-01-26
CA3158364A1 (en) 2021-05-27

Similar Documents

Publication Publication Date Title
RU2760875C1 (en) Antibodies specific to hyperphosphorylated tau-protein and their application methods
US12071474B2 (en) Monoclonal antibodies against alpha-synuclein fibrils
JP2022091948A (en) Its diagnostic and therapeutic use for the treatment of human antibodies and neurological disorders
JP2017522043A (en) FcRn-specific human antibody and autoimmune disease treatment composition containing the same
US20220041698A1 (en) Monoclonal Antibodies Against Pathological Alpha-Synuclein, and Methods Using Same
CN107531796A (en) Antibodies that recognize the T14 peptide of AChE
WO2016053610A1 (en) Antibodies against pathological forms of tdp-43 and uses thereof
US12459993B2 (en) Anti-alpha-synuclein antibodies and uses thereof
WO2023143425A1 (en) Method for improving cognitive disorders
JP7777071B2 (en) Anti-alpha-synuclein monoclonal antibodies and methods of use thereof
US9796778B1 (en) Antibodies against pathological forms of TDP-43 and uses thereof
US12553906B2 (en) Method for determining potency of therapeutic anti-clever-1 antibody
JP2025016653A (en) Musk Inhibition
EP4082574A1 (en) Agent for preventing or treating acute-phase neuromyelitis optica
US20230235034A1 (en) Monoclonal antibodies against pathological tau, and methods using same
KR20240112733A (en) Nanobodies for preventing or treating schizophrenia
WO2022060236A1 (en) ANTIBODY COMPOSITIONS TARGETING NON-PHOSPHORYLATED α-SYNUCLEIN AGGREGATES
EA041243B1 (en) ANTIBODIES TO N3PGLU BETA-AMYLOID PEPTIDE AND THEIR USE

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20889174

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3158364

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2022528957

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2020386061

Country of ref document: AU

Date of ref document: 20201119

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2020889174

Country of ref document: EP

Effective date: 20220620

WWG Wipo information: grant in national office

Ref document number: 202080092715.8

Country of ref document: CN